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Bone grafting is of significant clinical importance in orthopaedic, 
craniomaxillofacial, and dental reconstruction procedures.  Bone tissue engineering 
strategies are currently being developed as alternative mechanisms to address the clinical 
demand for bioactive and biomechanical graft material.  To date, these efforts have been 
largely restricted by inadequate supply of committed osteoprogenitor cells and loss of 
osteoblastic phenotype expression following in vitro culture and expansion. 
The objective of this thesis research was to address the cell sourcing limitations of 
tissue-engineered bone grafts by combining the fundamental principles of osteoblast 
biology and genetic and tissue engineering.  Specifically, the osteoblast-specific 
transcriptional activator Runx2/Cbfa1 was overexpressed in osteogenic target cells using 
retroviral gene delivery.  It was hypothesized that sustained overexpression of Runx2 in 
marrow-derived primary stromal cells would augment osteoblastic differentiation, 
including osteoblast-specific gene and protein expression and matrix mineralization, both 
in vitro and in vivo.  Following initial characterization of this Runx2 overexpression 
system in model non-osteoblastic and osteoblast-like cell lines, the global objective and 
hypothesis were tested through in vitro evaluation of Runx2-expressing marrow-derived 
stromal cells in monolayer culture and on three-dimensional (3-D) polymeric, 
biodegradable scaffolds, including both polylactide-co-glycolide (PLGA) foams and 
poly(ε-caprolactone) (PCL) fused deposition-modeled scaffolds.  Additionally, the in 
vivo performance of Runx2-expressing stromal cells was evaluated in two systems, 
subcutaneous and craniotomy defect syngeneic animal models.   
 
 xxii
Runx2 overexpression in marrow-derived stromal cells enhanced expression of 
multiple osteoblastic genes, including osteocalcin and collagen type I, as well as alkaline 
phosphatase biochemical activity.  More importantly, matrix mineralization was up-
regulated nearly two-fold following 2 and 3 weeks of in vitro culture.  To evaluate their 
performance in bone tissue engineering applications, Runx2-expressing cells were seeded 
onto PLGA and PCL polymeric scaffolds.  These two 3-D matrices possessed 
substantially different physical characteristics including pore size, strut architecture, and 
physical integrity.  Supporting flexibility of this genetic engineering system, Runx2-
transduced cells demonstrated significantly higher levels of 3-D mineralization when 
cultured on either scaffold compared to control cell-seeded scaffolds.   
To evaluate in vivo performance, Runx2-expressing cells were seeded onto PLGA 
scaffolds and subcutaneously implanted following various in vitro culture durations.  
Minimal quantifiable mineral was present on Runx2 or control constructs implanted 
following only 1 or 7 days of pre-culture, time points representing more immature 
scaffolds.  Notably, Runx2-transduced cell-seeded constructs pre-cultured to a 
mineralizing state in vitro (21 days) prior to implantation demonstrated a 10-fold increase 
in total mineral deposition and a 5-fold increase in the average daily mineral deposition 
rate upon subsequent in vivo implantation compared to similarly pre-cultured control 
cells, demonstrating a synergistic effect of Runx2 overexpression and in vitro construct 
development.   
Finally, Runx2 overexpression and in vitro construct maturation was examined in 
a critical size craniotomy defect model in syngeneic rats.  In this study, Runx2 
overexpressing and control cells were seeded on PCL fused deposition-modeled scaffolds 
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possessing a macroporous, fully interconnected architecture.  Defects treated with cell-
free PCL scaffolds demonstrated a significant healing response, suggesting that in this 
particular bone defect model, the open architecture and interconnected structural network 
of the fused deposition-modeled scaffolds provided a suitable osteoconductive scaffold 
capable of supporting significant new bone formation by infiltrating host cells.  Further 
supporting these observations, immature cell-seeded scaffolds implanted 1 day after cell 
seeding demonstrated healing comparable to cell-free scaffolds independent of treatment.  
In contrast to observations from the subcutaneous animal model, in vitro construct 
development for 21 days demonstrated an inhibitory effect on subsequent in vivo bone 
formation in defects receiving control bone marrow stromal cell-seeded constructs.  As 
observed in the subcutaneous model, however, defects receiving Runx2-modified cell-
seeded PCL constructs pre-cultured for 21 days demonstrated significantly more new 
bone formation than similarly pre-cultured control constructs.  The amount of new bone 
formation in Runx2-modified cell-seeded, 21 day pre-cultured constructs was comparable 
to cell-free scaffold and 1 day pre-culture construct groups, suggesting that Runx2 
overexpression in pre-cultured bone marrow stromal cells enhanced subsequent in vivo 
implant performance capable of overcoming the inhibitory effects on new bone formation 
observed in response to extended in vitro pre-culture of control cells. 
Collectively, these studies provided a thorough characterization regimen to 
observe the in vitro and in vivo performance of Runx2-expressing marrow-derived 
stromal cells and evaluated their potential as a candidate cell source for bone tissue 
engineering applications.  Furthermore, this series of analyses provided a novel 
combination of tissue and genetic engineering techniques toward the development of a 
 
 xxiv







Bone grafting is of significant clinical importance in orthopaedic, 
craniomaxillofacial, spine, and dental reconstruction procedures.  Although current 
clinical solutions, which include autologous and allogenic grafts, are successful in 
principle and function, these efforts are ultimately limited by the availability of donor 
bone, donor site morbidity, potential for immune rejection, processing-related reductions 
in biological activity, and risk of infection and disease transmission (Khan et al., 2000; 
Bucholz, 2002).  Bone tissue engineering strategies, developed by dispersing an 
osteogenic cell source in a 3-D scaffold or carrier matrix, have emerged as promising 
alternatives to address the clinical demand for bone grafting material.  To date, however, 
these efforts have been restricted by an inadequate supply of committed osteoprogenitor 
cells and loss of osteoblastic phenotype expression following in vitro expansion and 
culture (Bruder et al., 1997; Shi et al., 2002). 
The objective of this thesis research was to address current cell sourcing 
limitations associated with bone tissue engineering strategies through exogenous 
overexpression of the osteoblast-specific transcriptional activator Runx2/Cbfa1 in 
an osteogenic cell population to enhance osteoblastic phenotype expression in vitro 
and in vivo.  Specifically, this work focused on (i) the in vitro evaluation of primary bone 
marrow stromal cells genetically engineered to overexpress Runx2 in both monolayer and 
3-D culture and (ii) the in vivo characterization of Runx2-expressing stromal cells in both 
subcutaneous and critical size craniotomy defect animal models.  It was hypothesized 
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that sustained overexpression of Runx2 in osteogenic bone marrow stromal cells 
would augment osteoblastic differentiation, including osteoblast-specific gene and 
protein expression and matrix mineralization, both in vitro and in vivo, thereby 
providing an alternative cell source for the development of tissue-engineered bone 
graft substitutes.  Functional Runx2 expression is essential to embryonic bone formation 
(Otto et al., 1997; Komori et al., 1997) and postnatal, physiologic bone turnover (Ducy et 
al., 1999).  Additionally, forced expression of Runx2 in non-osteoblastic cells induces 
expression of other osteoblast-specific genes, including osteocalcin (Ducy et al., 1997; 
Xiao et al., 1999; Byers et al., 2002).  More importantly, overexpression of Runx2 in the 
MC3T3-E1 immature osteoblast-like cell line resulted in acceleration and robust up-
regulation of in vitro mineralized matrix production (Byers et al., 2002).  The global 
objective was addressed by the following specific aims:      
 
Aim 1:  To genetically engineer primary bone marrow stromal cells to overexpress 
the osteoblast-specific transcription factor Runx2/Cbfa1 to augment in vitro 
osteoblastic differentiation and enhance synthesis of mineralized matrix production 
in monolayer culture.  Transient overexpression (Ducy et al., 1997) and sustained, 
constitutive overexpression of Runx2 using a retroviral expression system (Byers et al., 
2002) in non-osteoblastic and osteoblast-like cells induced or up-regulated osteoblast-
specific gene expression, respectively.  Additionally, exogenous Runx2 expression 
accelerated and up-regulated in vitro matrix mineralization in the MC3T3-E1 immature 
osteoblast-like cell line (Byers et al., 2002).  Based on these initial studies, it was 
expected that the osteogenic subpopulation of the marrow stroma would be responsive to 
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Runx2 overexpression, resulting in robust up-regulation in osteoblast-specific gene 
expression and matrix mineralization in vitro. 
      
Aim 2:  To incorporate genetically engineered stromal cells into polymeric scaffolds 
to evaluate the effect of Runx2 overexpression on osteoblastic differentiation, 
specifically matrix maturation and mineralization, following 3-D in vitro culture.  
Runx2-expressing or unmodified stromal cells were seeded onto polymeric, 
biodegradable constructs for bone tissue engineering applications, namely polylactide-co-
glycolide (PLGA) foams and poly(ε-caprolactone) (PCL) fused deposition-modeled 
scaffolds.  It was hypothesized that in vitro cultured constructs containing Runx2-
modified stromal cells would demonstrate enhanced osteoblastic phenotype expression 
and up-regulated mineralized matrix production compared to scaffolds seeded with 
unmodified cells. 
 
Aim 3:  To implement fundamental tissue engineering principles to evaluate the 
performance of Runx2-modified cells in a both an ectopic site and a critical size 
craniotomy bone defect model through integration of Runx2-transduced primary 
bone marrow stromal cells into 3-D polymeric, biodegradable scaffolds.  Runx2-
modified or unmodified control cells were seeded onto polymeric scaffolds, cultured in 
vitro, and evaluated in two syngeneic animal models, a subcutaneous implant study and a 
critical size craniotomy defect model.  It was hypothesized that sustained Runx2 
overexpression in the osteogenic stromal cells would result in significantly more 
mineralized tissue formation in an ectopic site and enhance new bone formation in the 
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craniotomy defect compared to unmodified stromal cells, thereby enhancing defect 
healing. 
 
Collectively these analyses provided a broad-based characterization scheme to 
observe the in vitro and in vivo performance of Runx2-transduced bone marrow stromal 
cells and examined their potential as a cell source for bone tissue engineering therapies.  
Additionally, these results evaluated this combined tissue and genetic engineering 
strategy for the development of a Runx2-modified marrow stromal cell/polymeric 
scaffold composite for tissue-engineered bone graft substitutes.  Finally, this research 
established the foundation for future work and optimization experiments necessary to 




SIGNFICANCE OF RESEARCH 
 
A continuously increasing number of bone grafting procedures are performed to 
repair or treat damaged or diseased bone.  It is estimated that each year more than 
500,000 fracture non-unions require supplemental grafting to insight normal bone healing 
(Einhorn, 1999).  Although clinically successful, autologous and allogenic grafts face 
limitations, including minimal available donor bone, donor site morbidity, processing-
related reductions in biological activity and mechanical integrity, and risk of infection 
and disease transmission (Khan et al., 2000; Bucholz, 2002).     
Tissue engineering approaches to generate bone graft substitutes offer a promising 
alternative to address the current limitations associated with conventional grafting 
procedures.  The development of a successful tissue-engineered bone substitute requires 
the integration of three interrelated and significant components, including (i) an 
osteogenic cellular component capable of synthesizing a mature organic and mineralized 
extracellular matrix, (ii) biochemical factors, either soluble or matrix-associated, which 
direct and stimulate osteoblastic differentiation, and (iii) a synthetic scaffold with an 
interconnected pore structure that establishes the biomechanical characteristics of the 
construct and supports infiltration, proliferation, and differentiation of the cellular 
component (Reddi, 1994; Doll et al., 2001).  Therefore, depending upon the chemical 
identity of the scaffold, i.e. polymeric as opposed to bioceramic, the cellular component 
may provide the only osteogenic, osteoinductive, osteoconductive, and osteointegrative 
identity of the construct.  Notably, osteogenic cell sourcing remains the pivotal 
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component to the immediate and long term feasibility of bone tissue engineering 
endeavors, and, as a result, significant research has examined cell sourcing from osseous 
tissues, including marrow-derived and periosteal-derived cells as well as purified 
subpopulations of mesenchymal stem cells (Ishaug et al., 1997; Kadiyala et al., 1997; 
Vacanti and Bonassar, 1999).  Bone marrow-derived stromal cells have emerged as a 
popular model system of a clinically relevant cell source for bone tissue engineering 
applications due to their relative frequency, ease of isolation, and propensity for 
osteoblastic differentiation (Ohgushi et al., 1993; Ishaug-Riley et al., 1997).  The stroma 
is a heterogeneous cell population containing progenitors of several mesenchymal tissues, 
including bone, cartilage, fat, muscle, and tendon.  Although stromal cells exist at low 
frequencies in the marrow, they can be selectively isolated from more prevalent 
hematopoeitic cells in bone marrow aspirates through adhesion-dependent in vitro culture 
(Maniatopoulos et al., 1988).  In vitro and in vivo studies have clearly demonstrated the 
capacity of an osteogenic subpopulation of these adhesion-selected stromal cells to form 
bone-like mineralized nodules in response to osteoinductive stimulation (Maniatopoulos 
et al., 1988; Leboy et al., 1991; Aubin, 1999).  While bone marrow-derived and purified 
mesenchymal stem cells exhibit adequate mineralization capacity in model systems 
(Ohgushi et al., 1989; Bruder et al., 1994; Breitbart et al., 1999; Quarto et al., 2001; 
Horwitz et al., 2002), the effectiveness of these cell-based therapies to generate 
mechanically robust grafts to repair large non-healing osseous defects is hampered by the 
low frequency and age-related decrease of committed osteoprogenitor cells, extensive 
precursor cell death resulting from bone trauma or disease, and extended in vitro 
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expansion time necessary to obtain sufficient cell numbers for scaffold population, often 
with a concomitant loss in differentiation potential (Bruder and Fox, 1999). 
The objective of the proposed research was to address these cell sourcing 
limitations using genetic engineering principles to exogenously overexpress an 
osteoblast-specific transcription factor which is essential to normal bone formation and 
maintenance, thereby enhancing the osteogenic capacity of the target cells.  To date, a 
variety of strategies have been examined to overcome the differentiation limitations 
associated with isolated primary cells, principally through the delivery of osteoinductive 
bone morphogenetic proteins (BMPs) or other soluble growth and differentiation factors.  
BMPs have been delivered into ectopic sites or craniotomy and orthotopic defects in their 
recombinant protein form (Kenley et al., 1994; Whang et al., 1998) and more recently 
using viral gene therapy techniques to exogenously express the morphogens in osteogenic 
(Lieberman et al., 1998; Lieberman et al., 1999; Partridge et al., 2002) and even non-
osteogenic target cells, including skin fibroblasts (Krebsbach et al., 2000; Yang et al., 
2003) and muscle-derived stem cells (Lee et al., 2002).  Regardless of whether the 
genetically modified cells are themselves induced to form bone or serve as delivery 
vehicles to facilitate osteoblastic differentiation of infiltrating host cells, these strategies 
have shown success in healing of critical size defects in a variety of animal models.  
Nonetheless, inadequate delivery carriers, complex release kinetics, aphysiologic dosage 
and potency, insufficient expression duration and efficiency, immunogenicity, and long-
term safety restrict the wide-spread efficacy of these treatments (Boden, 1999; Doll et al., 
2001).   
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The research conducted herein addresses these issues by directly delivering and 
stably expressing Runx2/Cbfa1, a bone cell-specific transcription factor involved in the 
expression of multiple osteoblastic genes.  Alternatively to strategies which deliver 
soluble factors that ultimately initiate secondary signaling cascades, exogenous 
overexpression of a tissue-specific transcription factor in a heterogeneous cell population, 
such as bone marrow stromal cells, is a more robust mechanism to direct and potentially 
synchronize the osteoblastic differentiation cascade of target cells.  It is this direct nuclear 
manipulation of target cells which may provide more reproducible, consistent osteogenic 
differentiation than approaches which utilize soluble molecule delivery requiring 
secondary signaling molecules which may or not be simultaneously expressed within the 
target cell population. 
Initial studies in model cell lines indicated that Runx2 overexpression enhances 
osteoblast-specific gene expression and up-regulates matrix mineralization in monolayer 
(Chapter 4).  These results are significant in addressing cell sourcing limitations 
associated with bone tissue engineering, and the rigorous experimental scheme further 
examined in this research enabled more complete characterization of cellular phenotype 
as well as the organic and mineral components of the matrix deposited by these 
genetically modified stromal cells both in vitro and in vivo.  Ultimately, it will be 
essential to optimize in vitro culture parameters and properties of the 3-D scaffolds in 
which Runx2-modified cells are incorporated to ensure the long term efficacy of this 
genetic and tissue engineering approach.  Additionally, it was of significant importance to 
conduct the implantation studies presently detailed in order to evaluate the in vivo 
performance of Runx2-modified cells.  The outcome of implantation in these animal 
 
 9
models was necessary to justify both extensive in vitro optimization experiments and 
higher order in vivo models. 
The genetic engineering techniques involved in this approach are flexible and 
robust, promoting the examination of Runx2 overexpression in a broad array of cell types 
from a variety of species.  Furthermore, the incorporation of Runx2-modified primary 
bone marrow stromal cells into candidate 3-D biodegradable, polymeric scaffolds and 
subsequent implantation in both subcutaneous and craniotomy defect animal models 
demonstrates the feasibility of this integrated genetic and tissue engineering approach and 
establishes a foundation for examination of additional bone defect models requiring 






Bone and the Osteoblast 
The varied and dynamic functions of bone include its role as the primary reservoir 
of calcium and other minerals, a storage facility and factory for hematopoeisis, the 
mechanical framework to support the soft tissues of the body as well as attachment for 
tendons and ligaments to facilitate locomotion (Yaszemski et al., 1996).  As a structure, 
bone is composed of an organically synthesized matrix comprised primarily of type I 
collagen (95%) and multiple noncollagenous proteins, including osteopontin, bone 
sialoprotein, osteocalcin, and proteoglycans.  This organic matrix is embedded with 
crystalline salts, primarily calcium and phosphate, in a lattice structure known as 
hydroxyapatite (Marks and Hermey, 1996).  Four cell types execute the functional 
responsibilities required for normal bone physiology, including osteoblasts, bone lining 
cells, osteocytes, and osteoclasts.  Osteoblasts, bone lining cells, and osteocytes primarily 
serve an anabolic activity to regulate synthesis and maintenance of mineralized bone 
matrix, although osteocytes are capable of localized resorption activity.  These cell types 
arise from mesenchymal osteoprogenitor cells residing in the marrow cavity, periosteum, 
and endosteum.  Osteoclasts, on the other hand, initiate from the fusion of circulating 
mononuclear cells of hematopoeitic origin to form multinucleated cells which serve as 
the primary resorptive cell type for bone remodeling (Marks and Hermey, 1996). 
The bone marrow stroma is heterogeneous in nature, containing primitive, 
uncommitted stem cells as well as more developed progenitors committed to a variety of 
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mesenchymal tissue types, including osteoblastic, fibroblastic, adipogenic, myoblastic, 
and chondrogenic lineages (Bruder et al., 1994; Bianco et al., 2001).  Identification of an 
osteoprogenitor subpopulation of stem cells present in the proliferative fibroblast 
component of the bone marrow stroma by Friedenstein (Friedenstein, 1976) and others 
elicited significant in vitro and in vivo studies to determine the origin and cues giving rise 
to fully differentiated osteoblasts.  The progressive cascade of osteoblastic differentiation 
has been primarily characterized by in vitro systems to define a developmental sequence 
with three primary components, including (i) proliferation, (ii) organic matrix synthesis 
and maturation, and (iii) matrix mineralization (Stein et al., 1990). 
A definitive pathway defining the interplay between stromal cell proliferation and 
differentiation, specifically for the osteoprogenitor subfraction, has yet to be completely 
elucidated; however, an extensive number of soluble growth factors and hormones have 
been shown to play a role in this complex and dynamic cascade.  Mitogenic growth 
factors including platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
basic fibroblast growth factor (bFGF), and transforming growth factor β (TGFβ) have 
been shown to induce stem and progenitor cell proliferation in multiple studies (Gronthos 
and Simmons, 1995; Locklin et al., 1995).  In vitro experiments have demonstrated that 
actively proliferating pre-osteoblastic cells express high levels of genes required for cell 
cycling, such as histone proteins, and regulatory factors responsible for cell growth and 
cell cycle progression, including c-myc and c-fos (Owen et al., 1990a; Choi et al., 1996).     
Although osteoprogenitor cells of the stroma and bone surface regions, including 
the periosteum and endosteum, have a predisposition toward osteoblastic differentiation, 
this process is facilitated physiologically by local osteoinductive factors, systemic steroid 
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hormones, tissue-specific transcription factors, as well as cell-ECM and cell-cell 
interactions (Stein et al., 1990; Moursi et al., 1996; Robey and Boskey, 1996; Boyan et 
al., 1996; Lecanda et al., 1998; Xiao et al., 1998a).  The induction of osteoblastic 
differentiation by soluble components isolated from demineralized bone matrix, later 
characterized as bone morphogenetic proteins (BMPs), was originally demonstrated by 
Urist (Urist, 1965).  Related in structure and function, multiple homodimeric BMPs have 
been shown to be osteoinductive, including BMP-2, -4, -7, and -9, acting through a 
serine/threonine cell surface receptor signaling cascade to induce endochondral bone 
formation (Wozney, 2002).  As stated, a variety of systemic and local proteins and 
steroids also have a pronounced impact on bone physiology, including parathyroid 
hormone, parathyroid hormone-related protein, vitamin D3, estrogen, and glucocorticoids 
(Aubin and Liu, 1996).  
Osteoblasts are postproliferative cells of mesenchymal origin responsible for the 
formation of the mineralized matrix composing both endochondral and intramembranous 
bone.  Throughout the maturation process, osteoblasts express characteristic and 
identifiable, phenotype-specific markers including the components of the extracellular 
matrix, as well as growth factors, cytokines, and hormone receptors.  Although 
differentiated osteoblasts may express only a subset of the complete repertoire of 
osteoblast-specific genes, the matrix-associated markers consist of alkaline phosphatase, 
type I collagen, osteocalcin, osteopontin, bone sialoprotein, proteoglycans, and 
fibronectin (Aubin and Liu, 1996).  The time-dependent expression of osteoblastic genes 
has been largely elucidated by in vitro studies and corroborated by in situ hybridization 
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and immunohistochemical analyses of bone specimens (Stein et al., 1990; Weinreb et al., 
1990; Owen et al., 1990b; Quarles et al., 1992).   
While still in the first, proliferative phase of the maturation process, 
preosteoblasts initiate and actively synthesize elements comprising the structural 
components of the extracellular matrix (ECM), principally type I collagen (Stein et al., 
1990).  Type I collagen synthesis during this phase is consistent with the expression and 
role of TGFβ in regulating ECM biosynthesis (Bortell et al., 1990).  At the conclusion of 
the proliferative phase, DNA synthesis and histone production decline.  One of the 
earliest markers indicating the initiation of osteoblastic differentiation and concomitant 
cessation of proliferation is alkaline phosphatase (ALP), a membrane bound glycosyl-
phosphatidylinositol protein.  The onset of ALP expression has been shown in early pre-
osteoblastic cells and an increase in transcript levels has been associated with progression 
to a more fully differentiated state (Stein et al., 1990).  Two other bone-related proteins 
commonly examined during the progressive differentiation cascade are osteopontin and 
osteocalcin.  Osteopontin expression is biphasic, appearing both at end of the first stage 
and toward the beginning of the final mineralization phase.  Osteocalcin, on the other 
hand, is typically characterized as the latest functional osteoblast-specific marker, 
appearing only slightly before the onset of mineralization (Owen et al., 1990b).  The 
culmination of this maturational process occurs through mineralization of the 
extracellular matrix.  The crystalline structure found in bone, termed hydroxyapatite 
(Ca10(PO4)6(OH)2), contains a variety of ionic substitutions, most commonly carbonate, 
and is arranged in an oriented manner embedded within the fibrillar collagen matrix 
(Robey and Boskey, 1996). 
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Although significant work has led to the identification of numerous pathways that 
contribute to osteoblastic maturation, a great deal of uncertainty remains toward 
assimilating these signaling cascades, including those of biochemical and mechanical 
origins, in the complete elucidation of the developmental process beginning with a 
relatively immature multipotential stem cell and culminating in a quiescent, matrix 
embedded osteocyte.  In particular, identifying the interactions of transcriptional 
pathways, whether linear or circular in nature that give rise to the natural progression of a 
developing osteoblast are currently receiving significant scientific research and exposure.  
A primary, if not the most central, transcription factor under investigation for its 
regulatory involvement in bone formation and skeletal maturity is Runx2, a 
transcriptional activator of osteoblastic differentiation.           
   
Runx2 and Osteoblastic Differentiation 
Runx2, also termed Cbfa1 (Banerjee et al., 1997; Ducy et al., 1997)/PEBP2αA 
(Ogawa et al., 1993)/AML3 (Levanon et al., 1994), has been characterized as an 
osteoblast-specific transcriptional activator (Ducy et al., 1997).  Runx2 was identified as 
a trans-acting factor binding OSE2, a cis-acting element in the promoter of the 
osteocalcin (OCN) gene having the conserved sequence 5′-AACCACA-3′ (Ducy and 
Karsenty, 1995).  Analysis of OSE2 (Geoffroy et al., 1995; Merriman et al., 1995) 
showed similarity to the DNA sequence targeted by Drosophila runt transcription factors 
(Gergen and Wieschaus, 1985; Daga et al., 1992).  This transcription factor family is 
distinguished by a highly conserved 128 amino acid-long DNA-binding runt homology 
domain (Kagoshima et al., 1993) and contains three known isoforms, Runx1, Runx2, and 
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Runx3, expressed in a cell-type and tissue specific manner (Miyoshi et al., 1991; Wang 
and Speck, 1992; Bae et al., 1993; Bae et al., 1995; Meyers et al., 1995; Wijmenga et al., 
1995; Meyers et al., 1996). 
At least eight exons have been identified in the genomic code of the endogenous 
Runx2 gene (Geoffroy et al., 1998; Drissi et al., 2000), and the mature mRNA is highly 
conserved across multiple species, including human, rat, and mouse (Xiao et al., 1998b).  
The presence of two separate promoters and multiple splice donor and acceptor 
sequences primarily at the 5’ end result in the utilization of two unique start codon 
translation sites that give rise to two Runx2 isoforms with different amino termini, 
spatiotemporal expression patterns, and physiologic functions (Drissi et al., 2000).  The 
type I isoform begins with the MRIPVD amino terminus (Mundlos et al., 1997) and has 
been well characterized for its role in transcriptional activation of T-cell-specific gene 
expression (Ogawa et al., 1993).  Furthermore, type I Runx2 appears ubiquitously in 
nonosseous mesenchymal tissues, including skin and muscle, and other nonmesenchymal 
sources, such as liver and lung (Sudhakar et al., 2001; Banerjee et al., 2001).  
Transcription from the P1 promoter encodes the second isoform, commonly referred to as 
the type II isoform (Thirunavukkarasu et al., 1998; Xiao et al., 1998b; Harada et al., 
1999), which begins with the MASNSLF amino acid sequence.  Transcripts of both 
isoforms have been detected in developing mesenchymal condensations, osteoblast 
progenitors, and mature osteoblasts (Ducy et al., 1997; Harada et al., 1999; Banerjee et 
al., 2001).  Although in vitro exogenous transfection experiments have indicated the two 
isoforms have nearly equivalent transcriptional activation potential for the regulation of 
osteoblast-specific genes (Harada et al., 1999; Banerjee et al., 2001), analyses indicate 
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that only transcript mRNA splicing activity, protein levels, and DNA binding activity of 
the type II isoform are physiologically altered/up-regulated in response to osteoinductive 
stimulation and osteoblastic maturation (Banerjee et al., 2001).  The type II Runx2 
isoform was evaluated in the ensuing in vitro and in vivo analyses of this dissertation, 
therefore any generalized reference to Runx2 in subsequent reading refers specifically to 
the type II (MASNSLF) isoform unless otherwise stated. 
To date, the mechanisms of tissue and cell-type-specific activity and modulation 
of Runx2 expression through transcriptional, post-transcriptional/translational, and post-
translational regulation and/or modification have yet to be completely elucidated.  
However, each of these regulatory checkpoints is currently under examination.  Current 
evidence indicates that each of these mechanism may play an integral and coordinated 
role in regulation and function of Runx2, including its participation in cell cycle 
progression and ultimately osteoblastic differentiation.  For example, Banerjee et al. have 
demonstrated Runx2 transcript levels in rat osteoblasts were lower during the 
proliferative phase and increased to higher levels throughout later stages of 
differentiation.  Furthermore, Runx2 protein levels dramatically increased between the 
proliferation (day 2) and differentiation (day 14) phases of primary rat calvarial 
osteoblasts in vitro, and expression levels remained at similar elevated levels even at late 
stages of differentiation (day 21).  Interestingly, however, the DNA binding activity of 
Runx2 dramatically increased from day 14 to day 21, suggesting additional post-
translational modifications facilitate transcriptional complex formation and enhance DNA 
binding (Banerjee et al., 2001).  Contrary to these observations in rodent stromal cells 
and osteoblasts, temporal alterations in Runx2 mRNA expression were not observed in 
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immortalized human marrow stromal cell lines and osteoblasts (Satomura et al., 2000; 
Prince et al., 2001; Shui et al., 2003).  Although Runx2 mRNA message levels were 
essentially constant, Runx2 protein levels increased with progressive osteoblastic 
differentiation (Prince et al., 2001), and activity was also up-regulated in a temporal 
manner, possibly due to interactions with other proteins and transcription factors and/or 
phosphorylation of the Runx2 protein, including tyrosine, threonine, and serine residues 
(Xiao et al., 2000; Prince et al., 2001; Shui et al., 2003). 
Currently, the biological signals eliciting Runx2 transcription are not well 
understood.  Several key developmental and regulatory transcription factors have been 
shown to regulate Runx2 expression, including MSX-2, AP-1, Bapx1, Hoxa-2, and Dlx-5 
(Otto et al., 2003; Lee et al., 2003).  The signaling pathways eliciting this regulatory 
control are only now being identified, and multiple growth factors and steroid hormones 
have been implicated in controlling Runx2 message and protein levels, such as BMP-2 
(Banerjee et al., 2001) and BMP-4/7 (Tsuji et al., 1998) and the glucocorticoid family of 
steroid hormones (Prince et al., 2001).  Furthermore, it has been demonstrated that Runx2 
possesses autoregulatory capability.  Specifically, the proximal “bone-related” P1 
promoter that regulates expression of the type II Runx2 isoform contains at least five 
Runx2 binding domains, three of which are located within the 5’ untranslated region of 
the mRNA (Xiao et al., 1998b; Fujiwara et al., 1999; Drissi et al., 2000).  Co-transfection 
experiments of Runx2 and a reporter plasmid containing this promoter region revealed 
that Runx2 binding to only one of these three sites is sufficient to regulate 
autosuppression of Runx2 transcription (Drissi et al., 2000). 
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The potential for a post-transcriptional regulatory mechanism in Runx2 protein 
expression levels has also been detailed (Sudhakar et al., 2001; Xiao et al., 2001).  In 
these studies, a basal level of splice variant Runx2 mRNA transcripts were detected by 
RNase protection analysis in a variety of osseous and non-osseous cell lines, including 
MC3T3-E1 osteoblast-like cells, ROS17/2.8 osteoblasts, C3H10T1/2 pluripotent 
fibroblasts, C2C12 myoblasts, and L929 skin fibroblasts.  A common splice variant 
detected included an isoform containing a ‘mini-intron’ embedded within the 5’ 
untranslated region (UTR) of exon 1.  Present in C2C12 cells, this immature transcript 
underwent a micro-splicing event in response to BMP-2 treatment, and only the fully 
processed Runx2 mRNA was subsequently detected.  The authors proposed that post-
transcriptional processing may therefore be involved in tissue-specific expression of 
mature Runx2 protein.  Specifically, basal levels of unprocessed Runx2 transcripts may 
exist in a variety of tissues, including those nonosseous in nature, but only following 
osteoblast-specific signaling or induction is the post-transcriptional processing necessary 
for production of mature Runx2 mRNA and protein initiated. 
  The involvement of Runx2 in skeletal development has been extensively 
investigated (Ducy et al., 1997; Otto et al., 1997; Komori et al., 1997; Mundlos et al., 
1997; Kim et al., 1999; Inada et al., 1999; Enomoto et al., 2000; Takeda et al., 2001; Ueta 
et al., 2001).  OSE2 sequences have been discovered in the promoters of genes expressed 
only (OCN (Ducy and Karsenty, 1995)) or highly (α1(I) and α2(I) collagen (Kern et al., 
2001), bone sialoprotein (BSP) (Benson et al., 1999), osteopontin (OPN) (Sato et al., 
1998), and CCAAT/enhancer–binding protein δ (C/EBPδ) (McCarthy et al., 2000)) in 
osteoblasts.  Additional genes involved in bone development and turnover have also been 
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shown to be positively regulated by Runx2 expression, including vascular endothelial 
growth factor (VEGF) (Zelzer et al., 2001), collagenase III (Jimenez et al., 2001), and 
osteoprotegerin (Thirunavukkarasu et al., 2000).  Transient forced expression of Runx2 in 
non-osteoblastic cells induces expression of several osteoblast-specific genes, including 
OCN and BSP (Ducy et al., 1997).  In addition to its role as regulatory factor in 
osteoblastic differentiation, Runx2 is expressed in high levels in proliferating osteoblasts 
and mediates cell cycle progression toward a more differentiated state (Pratap et al., 
2003).   
Runx2 transactivational and repressor functions are mediated through complexes 
involving numerous cofactors existing both ubiquitously and temporally throughout the 
osteoblastic differentiation cascade.  Cbfβ, is a non-DNA binding, runt homology 
domain-associating co-factor similarly essential to normal bone formation (Miller et al., 
2002; Kundu et al., 2002).  CCAAT/enhancer–binding protein (C/EBP) family members, 
specifically β and δ, have been implicated in osteoblastic differentiation and 
synergistically interact with Runx2 to enhance expression of osteoblast-specific genes, 
including osteocalcin (Gutierrez et al., 2002).  Additionally, autophosphorylation of 
cytoplasmic components of the TGFβ or BMP receptors in response to morphogen 
binding elicits a signaling cascade which propagates to the nucleus via Smads, small 
accessory transcription factors which among other targets, co-localize with Runx2 to 
regulate gene transcription both positively and negatively (Li et al., 1998; Zaidi et al., 
2002).  Runx2 also functions as a repressor of gene expression largely in combination 
with members of the Groucho/TLE/R-esp transcription factor family (Javed et al., 2000). 
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  Functional expression of Runx2 is essential to normal bone formation.  
Specifically, Runx2-deficient mice have normally patterned cartilaginous skeletons but 
display a complete lack of endochondral and intramembranous bone formation, while 
heterozygous mutants (Runx2+/-) have hypoplastic clavicles among other deformations 
arising from delayed development of intramembranous bones (Otto et al., 1997; Komori 
et al., 1997).  The human autosomally dominant disorder cleidocranial dysplasia (CCD) 
demonstrates a phenotype consistent with Runx2+/- mutant mice (Mundlos et al., 1997; 
Lee et al., 1997).  Nearly 75% of all CCD cases are attributable to haploinsufficiency 
resulting from genomic alteration of the Runx2 sequence (Mundlos, 1999).  Additionally, 
transgenic mice engineered to postnatally overexpress a nontransactivating Runx2 DNA-
binding domain competitor protein have normal skeletons at birth but develop an 
osteopenic phenotype thereafter (Ducy et al., 1999), indicating that expression of 
functional Runx2 protein is essential to normal physiologic bone turnover.  Runx2 
expression is also involved in chondrocyte maturation, specifically in hypertrophic 
chondrocytes participating in calcification of the growth plate (Kim et al., 1999; Inada et 
al., 1999; Enomoto et al., 2000; Ueta et al., 2001). 
Collectively, these findings demonstrate the essential role of functional Runx2 
expression in embryonic bone formation as well as regulation of bone matrix deposition 
by differentiated osteoblasts throughout adult life. 
 
Bone Graft Technology Overview 
In excess of 500,000 clinical procedures are performed annually (Einhorn, 1999) 
in which bone grafting plays an integral role in native tissue repair, including diseases, 
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such as osteoimperfecta, malignant or benign tumors, and osteoporosis, and in fracture 
nonunions occurring in orthopaedic, craniomaxillofacial, spinal, and dental areas (Boden, 
1999; Einhorn, 1999).  Even though many bone injuries are self-healing, there exists a 
high frequency of clinical applications which require healing enhancement/engraftment 
due to terminal compromise of native tissue.  Currently, there is a lack of effective bone 
repair and regeneration solutions, especially for large segmental defects.  As a result, 
alternative healing mechanisms are being investigated, most notably bone tissue 
engineering strategies.  In accordance with innate regenerative capacity of bone, the 
requirements of a clinically successful bone graft substitute are defined by its capacity to 
be: (i) osteointegrative, supporting chemical bonding with the surface of bone; (ii) 
osteoconductive, promoting the growth of bone over its surface; (iii) osteoinductive, 
inducing the differentiation of cells adjacent to the implantation site down the 
osteoblastic lineage; (iv) osteogenic, forming new bone within the graft through a cellular 
component present within the graft (Yaszemski et al., 1996; Moore et al., 2001); (v) 
mechanically accommodative, providing sufficient localized mechanical integrity 
essential for immediate and permanent restitution of mechano-continuity in load bearing 
applications while minimizing detrimental stress-shielding of native tissue (Athanasiou et 
al., 2000).    
 
Biological Bone Grafts 
Currently, the clinical gold standard of bone grafting is the autogenous cancellous 
bone graft (Yaszemski et al., 1996), which is the only solution capable of satisfying all of 
the biological requirements of a graft material, provided sufficient precursors cells 
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survive the implantation procedure.  These efforts are, however, limited by the supply of 
autograft tissue, donor site morbidity, chronic pain (Crane et al., 1995; Perry, 1999; 
Moore et al., 2001), as well as insufficient biomechanical properties.   Although lacking a 
cellular component to provide osteogenic characteristics, allograft material from 
cadaveric bone is more abundant, addressing the supply and donor site morbidity 
complications associated with autografts.  However, graft resorption, risk of pathogen 
transfer, as well as minor immuno-acceptance issues complicate these efforts (Crane et 
al., 1995).  Furthermore, excessive donor variability (Heiple et al., 1987) and processing-
related reduction of bioactivity and mechanical properties result in significant variability 
in osteoinductivity and heightened risk of fracture, complications which limit the overall 
effectiveness of these techniques. 
 
Synthetic Materials 
In addition to biocompatibility, the physical attributes essential to synthetic 
materials include a similar level of strength, modulus of elasicity, and fracture toughness 
to minimize stress shielding of native tissue and fatigue under cyclic loading (Moore et 
al., 2001).  A variety of synthetic materials have been investigated in bone grafting or 
implant applications including ceramics, polymers, metals, and hybrid composites.  These 
biomaterials pose a variety of limitations including an obvious lack of osteogenic or 
osteoinductive component and elicitation of detrimental inflammatory responses and 
adverse host tissue necrosis or resorption due to relatively poor biomechanical 
compatibility, e.g. stress-shielding of native tissue, or generation of wear debris 
(Yaszemski et al., 1996; Bauer and Muschler, 2000).  Calcium phosphate ceramics, 
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including bioactive glasses (el Ghannam et al., 1997), β-tricalcium phosphates (TCP) 
(Dong et al., 2002), and synthetic or coralline hydroxyapatites (Ohgushi et al., 1993; 
Shors, 1999), have been extensively investigated for their osteoconductive properties.  
Unfortunately, bioactive glasses and ceramics possess poor fracture toughness and are 
incapable of adequately filling cyclically loaded bone defects.  Hydroxyapatites and β-
TCP are also brittle under tension and shear, which compromises their in vivo 
functionality and complicates manufacturing and processing techniques.  Additionally, 
these ceramics have variable bioresorptive properties in which either complete or 
minimal resorption occurs, thereby restricting timely integration and remodeling. 
 
Bone Tissue Engineering Strategies 
Overview 
Tissue engineering has been described as an interdisciplinary field in which the 
principles of engineering and the life sciences are applied toward the generation of 
biologic substitutes aimed at the creation, preservation, or restoration of lost organ 
function (Vacanti and Bonassar, 1999; Laurencin et al., 1999; Goldstein, 2002).  The 
well-established regenerative capacity of bone, whether from injury or normal biological 
turnover, can be advantageously utilized in bone tissue engineering strategies through the 
isolation and incorporation of committed osteogenic cells into biocompatible three-
dimensional (3-D) matrices.  The maturation of these osteoprogenitor cells within the 
construct, namely through migration and proliferation and ultimately guided 
differentiation toward the osteoblastic lineage, recapitulates the intramembranous bone 
formation cascade.  Introduction of this biological component promotes the critical 
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osteogenic and even osteoinductive characteristics required for successful grafting, 
providing a viable alternative to address the clinical demand for bioactive bone graft 
material.      
Ultimately, three principle components essential to the development of successful 
tissue-engineered constructs include (i) an osteogenic cells source, (ii) a 3-D matrix or 
scaffold designed to promote cellular growth and differentiation, and (iii) 
regulatory/inductive/stimulatory signals to direct osteoblastic differentiation (Reddi, 
1994; Bruder and Fox, 1999). 
 
Cell Sourcing Strategies for Bone Tissue Engineering 
The principle of cell-based bone tissue engineering focuses on the isolation of 
cells, commonly osteogenic in nature, from a relatively small tissue specimen, expansion 
typically under adhesion-dependent in vitro culture, and delivery to a defect site within a 
carrier material or configuration that will generate a new functional tissue (Vacanti and 
Bonassar, 1999).  To address this principle, multiple cell sources from osseous and 
nonosseous tissues in a variety of animal models have been examined for their osteogenic 
differentiation capacity either endogenously or following osteoinductive stimulation, 
including bone marrow stroma (Maniatopoulos et al., 1988; Ishaug-Riley et al., 1997), 
purified marrow-derived, mesenchymal stem cells (Bruder et al., 1997), osteoprogenitors 
from fetal calvaria (Ishaug-Riley et al., 1998; Malaval et al., 1999), periosteal cells 
(Breitbart et al., 1999; Vacanti and Bonassar, 1999), vascular-derived pericytes (Doherty 
et al., 1998), muscle-derived stem cells (Deasy et al., 2001; Jankowski et al., 2002), and 
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even adipose-derived cells and human marrow-derived adipocytes (Park et al., 1999; 
Halvorsen et al., 2001). 
Based on their relative ease of harvest and traditionally simplistic in vitro 
isolation and expansion techniques, bone marrow-derived stromal cells provide one of the 
most accessible and viable sources of multipotent cells available for therapeutic 
applications (Bianco et al., 2001).  The endogenous in vitro osteogenic capacity of 
marrow-derived stromal cells has been extensively investigated (Maniatopoulos et al., 
1988; Leboy et al., 1991; Aubin, 1999; Calvert et al., 2000), and their candidacy as an 
osteogenic cell source for bone tissue engineering applications has been demonstrated in 
both in vitro and in vivo model systems (Ohgushi et al., 1989; Ohgushi et al., 1993; 
Bruder et al., 1994; Ishaug et al., 1997; Kadiyala et al., 1997; Breitbart et al., 1999; 
Quarto et al., 2001; Horwitz et al., 2002; Holy et al., 2003).  However, the effectiveness 
of these stromal cell-based therapies is hampered by the low frequency of committed 
osteoprogenitor cells (0.001% of total viable nucleated marrow cells) (Bruder et al., 
1997) and further complicated by the observed decrease in osteoprogenitor frequency in 
the marrow of aged patients, who find themselves at the greatest risk of catastrophic bone 
fracture (Quarto et al., 1995; Glowacki, 1995).  Additionally, extensive precursor cell 
death resulting from bone trauma or disease and extended in vitro expansion time 
necessary to obtain sufficient cell numbers for scaffold population (Bruder and Fox, 
1999) limit these approaches.  Furthermore, adhesion-dependent in vitro expansion of 
bone marrow stromal cells results in a loss of osteoblastic differentiation capacity (Ter 




Scaffold Technology in Bone Tissue Engineering 
Primary qualifications of synthetic scaffolds for bone tissue engineering 
applications include biocompatibility, osteoconductivity, sterilizability, and 
biodegradability over a reasonable and appropriate time-scale (Crane et al., 1995).  
Furthermore, secondary parameters which will ultimately enhance bone tissue 
engineering successes consist of high porosity for cell loading and surface characteristics 
which support protein adsorption and cell attachment, growth, and differentiation (Crane 
et al., 1995; Boyan et al., 1996).   
Osteogenic cells, primarily bone marrow stromal cells, have been used in 
conjunction with osteoconductive hydroxyapatites and other calcium phosphate ceramics 
(Ohgushi et al., 1993; Yoshikawa et al., 1998; Bareille et al., 2000) (Livingston et al., 
2002; Dong et al., 2002) to demonstrate ectopic bone formation in a subcutaneous site 
and healing in bone defect models.  However, suboptimal in vivo degradation properties, 
poor fracture toughness, and lack of a complete interconnected pore structure complicate 
efforts to identify a suitable bioceramic for bone tissue engineering applications.  
Incorporation of osteogenic cells into polymer-based scaffolds, including poly (α-
hydroxy) esters, including copolymers of polylactide and polyglycolide (PLGA) 
(Hollinger, 1983; Athanasiou et al., 1996; Ishaug et al., 1997; Ishaug-Riley et al., 1998; 
Calvert et al., 2000; Holy et al., 2000; Lin et al., 2003) and polycaprolactones 
(Hutmacher et al., 2001; Zein et al., 2002), have also received significant attention 
because of their biodegradability and status as FDA-approved biomaterials.  These 
osteogenic cell-polymeric composite scaffolds have been evaluated through in vitro 
characterization and subcutaneous implantation or non-load bearing bone defect repair 
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models.  Importantly, these solutions are often incapable of providing long term success 
in large critical size defects due to poor mechanical properties, discontinuity of 
degradation rates, and minimal osteoconductive and osteointegrative properties.   
 
Osteoinductive Bioactive Factors in Bone Tissue Engineering 
Examination of soluble molecules which initiate signaling cascades that promote 
osteogenesis have primarily focused on bone morphogenetic proteins (BMPs) (Hollinger 
et al., 1998), since the early discovery of an osteoinductive component present in 
demineralized bone matrix (Urist, 1965) and subsequent isolation and cloning of specific 
osteoinductive isoforms including BMP-2, 4, and 7 (Ebara and Nakayama, 2002).  
Additional growth factors have also been examined in the healing of bone defects, 
including PDGF (Park et al., 2000), TGFβ (Mehrara et al., 1999), FGF (Nakamura et al., 
1997), and IGF (Busch et al., 1996).   
Although successful in principle, delivery of soluble purified or recombinant 
BMPs or growth factors to a wound site often proves ineffective for several reasons (Doll 
et al., 2001), including insufficient dosing and temporal inconsistencies largely due to 
ineffective delivery vehicles (Marshall, 1995), asynchrony between growth factor 
availability and the kinetics of signaling receptor expression (Howell et al., 1997), 
transient active half-life of growth factors (Centrella et al., 1994), inappropriate target 
cell populations, and excessive diffusion, sequestering by plasma membranes, and 
proteolytic degradation in the wound healing environment (Bonadio et al., 1999). 
These limitations have resulted in the implementation of genetic engineering 
strategies, including both in vivo and ex vivo gene transfer to appropriate target cells in 
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order to elicit a more stable and constant delivery or expression of a therapeutic gene to 
enhance bone tissue engineering initiatives. 
 
Genetic Engineering in Bone Tissue Engineering   
Gene delivery techniques are gaining popularity and significance in the treatment 
of diseased or damaged tissue because of the functionality and flexibility associated with 
the varied genetic engineering strategies currently available.  These consist of non-viral 
transient transfection methods as well as techniques which utilize viral machinery and 
cell surface adhesion mechanisms to introduce therapeutic genetic information into target 
cell populations.  Although delivery of naked or liposome-complexed osteogenic plasmid 
DNA has been investigated (Fang et al., 1996), transfection efficiencies are often quite 
low and transgene expression duration typically lasts for a very limited timeframe.  The 
most common gene therapy strategies for the stringent bone tissue engineering 
applications involve either adeno- or retroviral-mediated transgene delivery.  Briefly, 
adenoviruses (Ad) enter a cell via a capsid protein ligand-cell surface receptor 
interaction, introduce genetic information as temporary episomal elements, and infect 
either dividing or non-dividing target cells.  Adenoviruses can be used for either ex vivo 
or in vivo gene therapy as they possess a relatively high multiplicity of infection.  
However, adenoviruses also elicit an undesirable and perhaps antagonsitic immunogenic 
response in vivo.  Alternatively, retroviruses are more suited to ex vivo gene delivery 
applications due to their lower titers and inability to transduce non-dividing cells.  These 
enveloped viruses, which enter the cell through receptor-ligand and membrane fusion 
events, deliver viral RNA which is reverse transcribed and ultimately stably integrated 
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into the genome of a proliferating target cell population by companion viral polymerases 
and other enzymes.  This stable integration promotes sustained and theoretically 
permanent transgene expression, as the therapeutic message is maintained in daughter 
cells. 
To date, the primary strategies of genetic engineering in bone regeneration 
applications have been the incorporation of AdBMP(-2 and -7)-transduced target cells 
into carrier matrices for implantation into a defect (Lieberman et al., 1999) or through 
direct injection of AdBMP supernatant to demonstrate heterotopic bone formation 
(Musgrave et al., 1999; Okubo et al., 2000).  The target cells are either osteogenic in 
nature, such as primary stromal cells (Lieberman et al., 1999; Partridge et al., 2002), or 
nonosseous cells (Krebsbach et al., 2000), which are themselves induced to form bone or 
function as a delivery vehicle for the osteoinductive soluble factor in order to stimulate 
native osteogenic cells surrounding or infiltrating into the defect site.  These techniques 
have been investigated in subcutaneous implantation models (Musgrave et al., 1999) as 
well as cranial (Krebsbach et al., 2000) and segmental (Lieberman et al., 1999) critical 
size defects.  Although less prevalent than adenoviral vectors, ex vivo retroviral 
expression systems for BMP-2 (Laurencin et al., 2001), -4 (Gysin et al., 2002), and -7 
(Breitbart et al., 1999) have also been investigated.  These analyses demonstrated 
sustained BMP expression as well as healing of critical size cranial defects. 
 
SUMMARY 
Although genetic modification of cells to overexpress BMPs and other soluble 
growth factors have successfully repaired critical size defects in model systems, 
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diffusional limitations, safety concerns involving the inadvertent targeting and 
morphogenesis of neighboring nonosseous tissues, requisite accessory receptors and 
cofactors which functionalize the signal into a transcriptional message, and the adverse 
tissue environment present in large critical size and segmental defects may ultimately 
reduce the effectiveness of these techniques.  An alternative approach to the delivery of a 
soluble osteoinductive factor that elicits directed differentiation through secondary 
signaling mechanisms is to genetically engineer isolated osteoprogenitor cells to 
overexpress an osteogenic transcription factor, such as Runx2.  In principle, this approach 
serves to directly overexpress a primary transcriptional activator which is a prominent 
and characteristic downstream target of many osteoinductive BMPs.  Additionally, 
Runx2 is a robust selection for exogenous overexpression in osteoprogenitor cells due to 
its regulatory involvement in the expression of numerous osteoblastic genes/proteins that 
comprise a significant portion of the organic matrix of bone and essentiality for normal 







RUNX2 OVEREXPRESSION IN MODEL CELL LINES*
                                                          
* Modified from Byers BA, Pavlath GK, Murphy TJ, Karsenty G and Garcia AJ (2002) 
Cell-type-dependent up-regulation of in vitro mineralization after overexpression of the 
osteoblast-specific transcription factor Runx2/Cbfal. J Bone Miner Res 17: 1931-1944. 
 
INTRODUCTION 
Functional expression of the transcriptional activator Runx2/Cbfa1 is essential for 
osteoblastic differentiation and bone formation and maintenance (Ducy et al., 1997; Otto 
et al., 1997; Komori et al., 1997; Ducy et al., 1999).  Forced expression of Runx2 in non-
osteoblastic cells induces expression of osteoblast-specific genes (Ducy et al., 1997; Xiao 
et al., 1999), but the effects of Runx2 overexpression on in vitro matrix mineralization 
had not previously been examined.  In order to determine whether exogenous Runx2 
expression was sufficient to direct in vitro mineralization, sustained expression of Runx2 
expression was investigated in non-osteoblastic and osteoblast-like cell lines using 
retroviral gene delivery.  As expected, forced expression of Runx2 induced several 
osteoblast-specific genes in NIH3T3 and C3H10T1/2 fibroblasts and up-regulated 
expression in MC3T3-E1 immature osteoblast-like cells.  However, Runx2 expression 
enhanced matrix mineralization in a cell-type dependent manner.  NIH3T3 and IMR-90 
fibroblasts transduced with Runx2 did not produce a mineralized matrix, indicating that 
forced expression of Runx2 in these non-osteogenic cell lines was not sufficient to direct 
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in vitro mineralization.  Consistent with the pluripotent nature of the cell line, a fraction 
(25%) of Runx2-expressing C3H10T1/2 fibroblast cultures produced mineralized nodules 
in a viral supernatant-dependent manner.  Notably, bone sialoprotein gene expression was 
detected at significantly higher levels in mineralizing Runx2-modified C3H10T1/2 cells 
compared to Runx2-expressing cultures which did not mineralize.  Treatment of Runx2-
transduced C3H10T1/2 cultures with dexamethasone enhanced osteoblastic phenotype 
expression, inducing low levels of mineralization independent of viral supernatant.  
Finally, Runx2 overexpression in immature osteoblast-like MC3T3-E1 cells resulted in 
acceleration and robust up-regulation of matrix mineralization compared to controls.  
These results suggested that, although functional Runx2 is essential to multiple 
osteoblast-specific activities, in vitro matrix mineralization requires additional tissue-
specific cofactors which supplement Runx2 activity.   
 
MATERIALS AND METHODS 
Cells and Reagents 
 Characterization of forced Runx2 expression was investigated in well-established 
model cell lines.  NIH3T3 murine fibroblasts (CRL-1658) obtained from American Type 
Culture Collection (Manassas, VA) served as model non-osteoblastic cells, as this cell 
line does not express osteoblast-specific genes nor mineralize the ECM in vitro.  
C3H10T1/2 murine pluripotent fibroblasts (ATCC, CCL-226) were chosen as a 
potentially more responsive fibroblastic cell line.  This multipotential cell line does not 
endogenously express osteoblast-specific markers, but Runx2 and other markers of 
osteoblastic differentiation are induced following exposure to BMP-2 (Katagiri et al., 
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1990) and BMP-7 (Ducy et al., 1997).  MC3T3-E1 murine immature osteoblast-like cells 
(RCB1126) were purchased from the Riken Cell Bank (Hirosawa, Japan) and used as a 
model for osteoblastic differentiation.  Under specific in vitro culture conditions, this 
established cell line expresses osteoblast-specific genes and produces mineralized 
nodules, undergoing the developmental stages associated with differentiating osteogenic 
cells (Sudo et al., 1983). 
Fetal bovine serum (FBS) and newborn calf serum (NCS) were obtained from 
Hyclone Laboratories (Logan, UT) and Mediatech (Herndon, VA), respectively.  
Recombinant human BMP-2 was purchased from Kamiya Biomedical Co. (Seattle, WA).   
Remaining cell culture supplies were obtained from Invitrogen (Carlsbad, CA), while 
chemical reagents were purchased from Sigma Chemical Co. (St. Louis, MO).  RNA 
isolation and DNA purification reagents were acquired from Qiagen (Valencia, CA).  
Molecular biology reagents for reverse transcription (RT) and conventional polymerase 
chain reaction (PCR) were purchased from Invitrogen, reagents for real-time PCR were 
acquired from Applied Biosystems (Foster City, CA), and PCR oligos were obtained 
from Integrated DNA Technologies (Coralville, IA). 
 
Cell Culture 
NIH3T3 fibroblasts were grown in Dulbecco’s modified Eagle’s medium 
(DMEM), 10% NCS, and 1% penicillin-streptomycin.  C3H10T1/2 fibroblasts were 
cultured in Basal Medium Eagle, 10% FBS, and 1% pen-strep.  The MC3T3-E1 cell line 
was maintained in α-minimum essential medium (α-MEM), 10% FBS, and 1% pen-strep.  
All cell lines were subcultured using standard techniques.  Primary skin fibroblasts were 
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isolated from murine skin explants digested in collagenase/trypsin and maintained in 
DMEM, 10% FBS, and 1% pen-strep. 
 
Runx2 Retroviral Vector and Retroviral Transductions 
Murine cDNA for the MASNSLF Runx2 isoform was amplified from the 
originally reported pCMV-Osf2/Cbfa1 expression plasmid (Ducy et al., 1997) using the 
Advantage®-GC 2 high fidelity PCR system (Clontech Laboratories, Palo Alto, CA) and 
primers: 5'-CGAGGGCGTTTAAATGGTTAA-3' and 5'-
GCCATGGTTGACGAATTTCAA-3'.  Following fragment purification and blunt-
ending, SfiI adapters (formed with oligonucleotides 5'-CTAGGCCTACA-3' and 5'-
AGGCCTAG-3') were ligated onto the PCR fragment.  The gel-purified fragment was 
then ligated into the SfiI universal cloning site of the pTJ66 retroviral expression vector 
(Abbott et al., 2000) (See Appendix A for detailed description of vector cloning).  The 
Runx2 isoform investigated in this study contains the N-terminal 19 residue 
transcriptional activation domain (AD1) (Thirunavukkarasu et al., 1998).  The pTJ66 
vector utilizes a retroviral long terminal repeat promoter to express a single, bicistronic 
mRNA that produces a therapeutic protein through cap-dependent translation and a 
zeocin resistance-eGFP fusion protein by internal ribosomal entry site (IRES) translation.  
The resulting Runx2 retroviral expression plasmid (Figure 4-1) was confirmed by DNA 





Retroviruses were packaged by transient transfection of helper-virus free ΦNX 
amphotropic producer cells (Pear et al., 1993) with plasmid DNA as previously described 
(Abbott et al., 1998).  Briefly, ΦNX producer cells were plated at 9×104 cells/cm2 the day 
prior to transfection and maintained in DMEM supplemented with 10% FBS and 1% pen-
strep in a humidified 5% CO2 atmosphere at 37°C.  Cultured cells at 50-80% confluence 
were transfected with plasmid DNA, either Runx2 or control vector (no Runx2 insert), by 
calcium phosphate coprecipitation (Pear et al., 1993) and 25 µM chloroquine for 8-12 
hours prior to refeeding with fresh growth media.  Twenty-four hours after the start of the 
transfection, media was replaced and dishes were transferred to a humidified 5% CO2 
atmosphere at 32°C to enhance retroviral titer (Kotani et al., 1994).  Retrovirus-
containing supernatants were collected at 48, 60, and 72 hours after transfection, filtered 
through a 0.45 µm cellulose acetate filter, aliquoted, snap frozen, and stored at -80°C 
until use. 
Prior to retroviral transduction, target mammalian cells were plated on 0.1% type 
I collagen-coated (Vitrogen-100; Cohesion, Palo Alto, CA) 6 well plates at a density of 
1×104 cells/cm2 and incubated in growth media overnight at 37°C.  Cells at 50-80% 
Figure 4-1. Linear representation of the Runx2 retroviral expression 
plasmid. (8544 bp)  Constitutive transcription of the MASNSLF Runx2 isoform is 
regulated by the viral promoter in the long terminal repeat (LTR), a Zeo:eGFP
selectable marker is translated from an IRES, and ampicillin resistance (Amp) is 
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confluence were transduced by adding 0.2 ml/cm2 of retroviral supernatant supplemented 
with 4 µg/ml hexadimethrine bromide (Polybrene) and spinning at 2500 rpm (1200 g) for 
30 minutes at 32°C in a Beckman model GS-6R centrifuge with swinging bucket rotor 
(Springer and Blau, 1997).  Transductions and endpoint assays were performed in parallel 
on all target cell types, and empty vector served as a control for all transductions.  After 
transduction, growth media was reapplied, and the cells were returned to incubation at 
37°C.  To increase transduction efficiency, an additional transduction was performed 10-
12 hours later.  After this final transduction, media was supplemented with 50 µg/ml L-
ascorbic acid and 3 mM sodium β-glycerophosphate to support osteoblastic 
differentiation and mineralization.  In addition to their respective supplemented growth 
media, NIH3T3 and C3H10T1/2 fibroblasts were also cultured in α-MEM supplemented 
with 10% FBS, the same differentiation media shown to support endogenous 
mineralization in the MC3T3-E1 cells.  Media was replaced every 48 hours.  The 
combined effect of forced Runx2 expression and additional osteoinductive factors in 
C3H10T1/2 cells was also examined.  These factors, including rhBMP-2 (300 ng/ml) 
(Katagiri et al., 1990; Lee et al., 1999) and the synthetic glucocorticoid dexamethasone 
(10 nM) (Bellows et al., 1987), were added to the culture medium following the final 
transduction and maintained with fresh media changes for the duration of the 
experiments. 
No significant differences in viral titer or gene transduction efficiency were 
observed among independent viral supernatant stocks.  Retroviral titer, determined 
similarly to Galipeau et al. (Galipeau et al., 1999), of Runx2 viral supernatants were in 
the range of 1-2×105 cfu/ml.  During experimental transductions, retrovirally transduced 
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cells were noninvasively analyzed for eGFP expression by fluorescence microscopy 
(Figure 4-2A) and flow cytometry (Figure 4-2C), using a Becton-Dickinson FACS 
Vantage SE Cell Sorter.  After two rounds of retroviral transduction, cytometric analyses 
indicated a transduction efficiency >95% in NIH3T3 cells (Figure 4-1D), >90% in 
C3H10T1/2 cells, and >85% in MC3T3-E1 cells. 
 
Figure 4-2. Observation of transduction efficiency and Runx2 gene 
expression in Runx2-transduced and control NIH3T3 fibroblasts. (A) 
Noninvasive detection of eGFP expression by fluorescence (left) and phase 
contrast (right) micrographs of Runx2-expressing NIH3T3 fibroblasts, indicating 
high and uniform transduction efficiency. (B) Runx2 and OCN transcripts detected 
by PCR at 1 and 28 days post transduction in NIH3T3 Runx2-expressing (+) and 
control cultures (-), demonstrating immediate and sustained gene expression and 
functional protein expression of Runx2.  (C) Flow cytometry histograms of 
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Osteoblast-Specific Gene Expression 
Total RNA was isolated at 1, 3, and 7 days post transduction using the RNeasy 
RNA isolation kit.  cDNA synthesis was performed on DNaseI-treated (27 Kunitz 
units/sample) total RNA (1 µg) by oligo(dT) priming using the Superscript II™ 
Preamplification System.  Conventional PCR was performed using recombinant Taq 
DNA polymerase and the Perkin Elmer GeneAmp® System 9700 thermal cycler (35 
cycles, melting: 30 sec at 94ºC, annealing: 60 sec at 57ºC, extension: 90 sec at 72ºC).  
Conventional PCR oligonucleotide primers (Table 4-1) for Runx2 were designed using 
Primer Premier (Premier Biosoft International, Palo Alto, CA), those for BSP and OCN 
were previously reported (Tintut et al., 1999), and β-actin was obtained from Clontech.  
Gene expression was normalized to cytoskeletal β-actin using agarose gel electrophoresis 
and the Kodak Digital Science 1D image analysis software (Eastman Kodak Co., 
Rochester NY).  Real-time PCR oligonucleotide primers (Table 4-1) were designed using 
Primer Express software (Applied Biosystems).  Real-time products were analyzed on 
2.2% agarose gels to confirm primer specificity. Real-time PCR using Sybr Green 
intercalating dye was performed with the ABI Prism 7700 Sequence Detection System 
(Applied Biosystems) (40 cycles, melting: 15 sec at 95ºC, annealing and extension: 60 
sec at 60ºC).  Gene transcript concentration in template cDNA solutions was quantified 
by generating a linear standard curve from a decade-dilution of an absolute standard for 
each gene and plotting the log of concentration vs. the CT value, which is the cycle 
number at which the observed fluorescence reaches a threshold level.  Standards for each 
gene were amplified from template cDNA using real-time oligonucleotides, purified 
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using a Qiagen agarose gel extraction kit, and diluted over a functional range of 
concentrations.   
 
 
Alkaline Phosphatase Biochemical Activity 
As an early marker of osteoblastic differentiation (Aubin and Liu, 1996), alkaline 
phosphatase (ALP) activity was quantified at 3, 7, and 14 days post transduction using a 
modification of the method of Sodek and Berkman (Sodek and Berkman, 1987).  Briefly, 
cells were rinsed and scraped in ice-cold 50 mM Tris⋅HCl.  Following sonication and 
centrifugation, total soluble protein concentration was quantified using the MicroBCA 
Protein Assay Kit (Pierce, Rockford, IL).  Equal amounts of protein (2.5 µg) were added 
to 60 µg/mL 4-methyl-umbelliferyl-phosphate fluorescent substrate in diethanolamine 
buffer (pH 9.5).  Following incubation for 60 minutes at room temperature, the 
fluorescence was read at 365 nm excitation/450 nm emission on an HTS 7000 Plus 
Table 4-1. PCR oligonucleotides for murine osteoblastic genes
Gene Type Forward Primer Reverse Primer Size (bp) 
Runx2 C mRunx2-490.F  5'-GCAGTGCCCCGATTGAGG-3' 
mRunx2-976.R  
5'-CATACTGGGATGAGGAATGCG-3' 487 
  AF010284¥ R-T mRunx2-217.F RT  5'-AGCCTCTTCAGCGCAGTGAC-3' 
mRunx2-275.R RT  
5'-CTGGTGCTCGGATCCCAA-3' 59 
BSP C mBSP-402.F 5'-CTCGGGTGTAACAGCTAGCTAC-3' 
mBSP-785.R 
5'-CGTTCAGAAGGACAGCTGTCTG-3' 384 
  L20232 R-T mBSP-219.F RT   5'-TCCTCCTCTGAAACGGTTTCC-3' 
mBSP-291.R RT   
5'-GGAACTATCGCCGTCTCCATT-3' 73 
OCN C mOCN-91.F 5'-CTCTGTCTCTCTGACCTCACAG-3' 
mOCN-450.R  
5'-GGAGCTGCTGTGACATCCATAC-3' 360 
  X04142 R-T mOCN-126.F RT   5'-CGGCCCTGAGTCTGACAAA-3' 
mOCN-193.R RT   
5'-GCCGGAGTCTGTTCACTACCTT-3' 68 
COLα1(I) R-T mCOLα1(Ι)-3963.F RT 5'-TGG ATT CCC GTT CGA GTA CG -3' 
mCOLα1(Ι)-4024.R RT 
5'-TCA GCT GGA TAG CGA CAT CG-3' 62 
  U08020  
  
 
β-actin C β-actin-25.F  5'-GTGGGCCGCTCTAGGCACCAA-3' 
β-actin-564.R  
5'-CTCTTTGATGTCACGCACGATTTC-3' 540 
  X03672 R-T mβ-actin-459.F RT   5'-TTCAACACCCCAGCCATGT-3' 
mβ-actin-527.R RT   
5'-TGTGGTACGACCAGAGGCATAC-3' 69 
¥: GenBank accession number; m, murine; C, conventional PCR; R-T, real-time PCR.
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BioAssay Reader (Perkin Elmer, Norwalk, CT).  Enzymatic activity was standardized 




Cultures were fixed in 70% ethanol at 14 and 21 days and examined 
histochemically for mineralized matrix formation by von Kossa staining.  Following 
addition of 5% AgNO3, plates were incubated under uniform light exposure for 30 
minutes.  The stain was then fixed in 5% Na2SO3 for 2 min and cultures were air-dried.  
Mineralized surface area was quantified by capturing and averaging sixteen 
representative 1.8× images using Image Pro image analysis software (Media Cybernetics, 
Silver Springs, MD).  For further characterization of the mineral phase, chemical 
composition analyses were performed on acetone-fixed cultures by Fourier Transform 
Infrared (FT-IR) microscopy (Nicolet Magna 550, ThermoNicolet, Madison, WI) 
(Boskey et al., 1996). 
A calcium dissolution assay was performed to determine the onset of matrix 
mineralization in Runx2-modified and control MC3T3-E1 cultures.  Beginning at 6 and 
continuing to 12 days post transduction, cultures were rinsed twice in calcium-free PBS, 
lysed and homogenized in equal volumes of 0.5 N HCl, and shaken for 4 hrs at 4ºC.  Cell 
lysates were sonicated and centrifuged (8000 g) for 10 minutes, and total soluble calcium 
was quantified using a colorimetric assay kit and calcium/phosphorous standards (Sigma) 
according to the manufacturer’s instructions.  NIH3T3 cells, which do not mineralize, 




 All analyses were performed on assays conducted at least three times, each with 
unique Runx2 retroviral supernatant preparations.  Data are reported as mean ± SEM, and 
statistical comparisons using SYSTAT 8.0 were based on an analysis of variance 
(ANOVA) and Tukey’s test for pairwise comparisons with a p-value < 0.05 considered 
significant.  In order to make the variance independent of the mean, statistical analysis of 




Runx2 induces/up-regulates osteoblast-specific gene expression 
Osteoblast-specific gene expression, including Runx2, OCN, BSP, and COLα1(I), 
was investigated at multiple time points after Runx2 transduction by conventional (Figure 
4-3A) and real-time PCR (Figure 4-3B).  Runx2 expression was detected in Runx2-
expressing target cells as early as 24 hours and remained at an up-regulated level at 28 
days (Figures 4-2B and 4-3).  Runx2 transcripts in Runx2-transduced NIH3T3 cultures 
were 4-fold higher than in C3H10T1/2 cells and 6-fold higher than in MC3T3-E1 
cultures as determined by real-time PCR at 1 day.  Runx2 transcripts were absent from 
NIH3T3 and C3H10T1/2 fibroblasts with control vector at all time points as shown by 
conventional PCR (Figure 4-3A), and real-time data indicated that signal was 2 to 3 
orders of magnitude lower than Runx2-expressing cultures (Figure 4-3B).  In comparison 
to endogenous expression in MC3T3-E1 controls, Runx2 expression in Runx2-treated 
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MC3T3-E1 cultures was nearly 10-fold greater at 1 day, 5-fold higher at 3 days, and 2-
fold greater at 7 days. 
OCN provides a primary marker for Runx2 overexpression, as it is expressed only 
in mature osteoblasts (Hauschka et al., 1989; Weinreb et al., 1990) and is 
transcriptionally regulated by a Runx2-binding cis-acting element (Ducy and Karsenty, 
1995).  In non-osteoblastic cells, Runx2 induced OCN expression at all time points 
examined, whereas control cultures lacked detectable OCN expression (Figure 4-3).  
Sustained expression of OCN in Runx2-treated non-osteoblastic cells at 28 days (Figure 
4-2B) indicated stable integration of the Runx2 sequence into the host genome and 
constitutively active translation of a functional Runx2 protein.  Additionally, OCN 
expression was accelerated and enhanced in Runx2-expressing MC3T3-E1 cells.  OCN 
transcripts were detected as early as 1 day post Runx2-treatment, whereas endogenous 
expression was not detected in control cultures until day 7 by conventional PCR.  Real-
time PCR displayed 5 to 8-fold up-regulated OCN expression at various time points 
(Figure 4-3B). 
BSP transcripts were not detected in Runx2-expressing NIH3T3 fibroblasts in 
four separate retroviral transductions (Figures 4-3A and 4-3B).  Runx2-expressing 
C3H10T1/2 fibroblasts typically did not produce BSP levels detectable by conventional 
PCR (Figure 4-3A).  Using the enhanced sensitivity of real-time PCR, BSP transcripts 
were detected at 3 and 7 days in Runx2-treated cultures, yet the relative expression was 
more than 50-fold less than that detected in parallel MC3T3-E1 cultures (Figure 4-3B).  
In one C3H10T1/2 transduction, which is further detailed later, BSP transcripts were 
detected at levels comparable to Runx2-treated MC3T3-E1 cultures.  Finally, BSP 
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expression was up-regulated nearly 10-fold in Runx2-expressing MC3T3-E1 cultures at 
later time points.  As with OCN, endogenous BSP expression in control MC3T3-E1 
increased over time, in accordance with the progressive differentiation program of this 
immature osteoblast-like cell line. 
Runx2 overexpression resulted in no differences in COLα1(I) gene expression 
when examined by conventional PCR in any of the three cell types (data not shown).  
Corroborating these results, no significant differences in COLα1(I) transcript levels were 




Figure 4-3.  Osteoblast-specific gene expression in Runx2-modified and 
control fibroblastic and osteoblast-like cell lines.  (A) Conventional RT-PCR 
for osteoblast-specific gene expression in NIH3T3, C3H10T1/2, and MC3T3-E1 
cells transduced with Runx2 (+) and control (-) at various time points.  Runx2 and 
OCN transcripts were detected in all Runx2-infected cell types, indicating 
induction of osteoblast-specific gene expression in the fibroblasts and accelerated 
up-regulation in the immature osteoblast-like cells.  As detected by conventional 
PCR, BSP expression was only up-regulated in MC3T3-E1 cells overexpressing 
Runx2.  Samples were normalized to endogenous cytoskeletal β-actin expression.  
(B) Relative gene expression (mean, SEM) for Runx2, OCN, BSP, and COLα1(I) 
generated from real-time PCR of NIH3T3 (n=4), C3H10T1/2 (n=3), and MC3T3-
E1 (n=4) cells transduced with Runx2 and control virus.  Tabulated concentrations 
were normalized to β-actin expression and plotted on a log scale.  ANOVA 
showed significant differences between Runx2-modified and controls: NIH3T3, 
Runx2 (p<0.000001) and OCN (p<0.000001); C3H10T1/2, Runx2 (p<0.000001), 
OCN (p<0.0005), and BSP (p<0.0001); MC3T3-E1, Runx2 (p<0.0002) and OCN 
(p<0.03).  Pairwise comparisons:  * different from control (p<0.00001); ** 
different from control (p<0.001); † different from control (p<0.005); †† different 
from control (p<0.0001); ‡ different from control (p<0.05).  Dotted line represents 
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Runx2 expression enhances alkaline phosphatase activity 
ALP activity was examined at 3, 7, and 14 days post transduction (Figure 4-4).  
NIH3T3 cells expressing Runx2 demonstrated only moderate ALP activity at 7 and 14 
days.  However, Runx2-expressing C3H10T1/2 pluripotent fibroblasts demonstrated up-
regulated and sustained activity nearly equivalent to that seen in the immature osteoblast-
like cells, an observation consistent with previous work (Harada et al., 1999).  Forced 
expression of Runx2 in MC3T3-E1 cells resulted in a 4-fold higher activity at 3 and 7 
days and a 2-fold increase at 14 days compared to endogenous levels in control cultures.  
Consistent with osteoblast-specific gene expression results, ALP activity in Runx2-
treated and control cultures progressively increased over time up to 14 days. 
Figure 4-4.  Alkaline phosphatase activity of model fibroblastic and 
osteoblast-like cell lines transduced with Runx2 or control virus. Data are 
reported as [(mean, SEM), n=3].  ANOVA demonstrated significant differences 
between Runx2-transduced and controls (p<0.0001) and among time points 
(p<0.01).  Pairwise comparisons: * different from control (p<0.05); ** different 
from control (p<0.01); † different from 3 day Runx2-infected (p<0.01); ‡ different 










































































































Effects of forced expression of Runx2 on matrix mineralization 
NIH3T3 fibroblasts.  Matrix mineralization was examined by von Kossa staining at 14 
and 21 days.  Even though Runx2-transduced NIH3T3 fibroblasts expressed multiple 
osteoblast-specific genes, mineralization was completely absent in cultures maintained 
even to 28 days.  In order to ensure that this response was not specific to this established 
fibroblastic cell line, IMR-90 human lung fibroblasts (ATCC, CCL-186) were also 
examined for matrix mineralization following Runx2 overexpression.  eGFP expression 
was detected by fluorescence microscopy, indicating this human cell line was transduced 
by the amphotropic retrovirus (data not shown).  Although murine Runx2 was 
overexpressed in a human cell line, the MASNSLF Runx2-isoform contains high 
sequence homology in both exonic and intronic regions across mouse, rat, and human 
species (Xiao et al., 1998b).  Functionality was confirmed by detection of human OCN 
gene expression by conventional RT-PCR in Runx2-modified IMR-90 cultures (data not 
shown), yet Runx2-expressing IMR-90 fibroblasts also failed to mineralize in all 
experiments. 
 
C3H10T1/2 fibroblasts.  This pluripotent cell line displayed induction of several 
osteoblast-specific genes as well as dramatically enhanced ALP activity in response to 
Runx2 overexpression.  Interestingly, the capacity of C3H10T1/2 fibroblasts to 
mineralize in vitro revealed two responses.  In six of eight (75%) mineralization 
experiments, each conducted with independent Runx2 retroviral supernatants, the Runx2-
expressing C3H10T1/2 cells did not produce a mineralized matrix (data not shown).  
However, two of these eight supernatants resulted in mineralization (Figure 4-5A), 
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although significantly less than matched MC3T3-E1 control cultures.  In all cases, cells 
transduced with control virus did not mineralize.  Osteoblast-specific gene expression and 
ALP activity were examined in one of the two mineralizing cultures.  Conventional PCR 
revealed ubiquitous OCN gene expression in both mineralizing and non-mineralizing 
Runx2-modified C3H10T1/2 cultures at 7 days.  However, BSP transcripts were only 
detected in the mineralizing Runx2-expressing C3H10T1/2 culture (Figure 4-5B).  
Furthermore, quantification of Runx2 and OCN transcript levels in the mineralizing 
Runx2-transduced C3H10T1/2 culture at 1, 3, and 7 days indicated nearly equivalent 
expression levels of these two genes when compared to non-mineralizing Runx2-
expressing cultures at all time points (data not shown).  Additionally, 7 day ALP activity 
of the mineralizing Runx2-modified culture (4.9 nmol/min/mg protein) was 
approximately equal to that of non-mineralizing Runx2-expressing C3H10T1/2 cultures 
(6.9 nmol/min/mg protein).  In contrast, BSP gene expression in this mineralizing Runx2-
treated culture exhibited large differences when compared to those Runx2-expressing 
cultures which did not mineralize.  At 1 day, BSP expression levels in both cases were 
approximately equal to the assay detection limit.  However, the mineralizing Runx2-
modified C3H10T1/2 culture displayed 100-fold higher BSP transcript levels at 3 days 
and nearly 60-fold higher levels at 7 days compared to non-mineralizing Runx2-
transduced cultures (data not shown).  This expression level in the mineralizing Runx2-
expressing culture was nearly equivalent to Runx2-expressing MC3T3-E1 cells.  
Following these observations, parallel transductions were performed simultaneously on 
all target cells with retroviral supernatants which both had and had not previously 
resulted in C3H10T1/2 mineralization.  Viral supernatant-dependent expression of BSP 
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and mineralization in C3H10T1/2 cultures was again observed, i.e. the same two Runx2 
viral stocks resulted in high levels of BSP expression and mineralization in C3H10T1/2 
cultures, while remaining lots did not induce mineralization.  Matched NIH3T3 and IMR-
90 fibroblast cultures failed to mineralize in all cases, and Runx2-modified MC3T3-E1 
cells demonstrated indistinguishable up-regulated mineralization independent of the 
particular Runx2 viral stock.  These parallel analyses indicated that no significant 
differences in viral titer or transduction efficiency existed among various viral 
supernatants and showed that the stochastic response to different Runx2 viral supernatant 
stocks was unique to the C3H10T1/2 cell line and most likely attributable to secondary 
factors in the retroviral supernatant. 
Figure 4-5. Mineralization staining and gene expression of mineralizing and 
non-mineralizing Runx2-expressing C3H10T1/2 cells.  (A) Matrix 
mineralization (21 days) in Runx2-expressing C3H10T1/2 pluripotent fibroblasts.  
Overexpression of Runx2 in two of eight independent experiments each with 
unique retroviral supernatant lots resulted in mineralization, although much less 
than matched MC3T3-E1 controls.  (B) Conventional PCR for osteoblast-specific 
gene expression (7 days) from non-mineralizing (MIN-) and mineralizing (MIN+) 
Runx2-modified (+) and control (-) C3H10T1/2 fibroblasts.  OCN transcripts were 
detected in both cases; however, BSP expression was only detected in the culture 
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Subsequent experiments were performed to further examine this stochastic 
mineralization response in C3H10T1/2 fibroblasts.  Three independent, non-mineralizing 
Runx2 viral supernatants were used in combination with the osteoinductive factors 
rhBMP-2 and dexamethasone.  It was hypothesized that BMP-2 would complement the 
effects of Runx2 overexpression in C3H10T1/2 cells to direct osteoblastic differentiation 
and induce mineralization independent of Runx2 viral stock.  BMP-2 is a potent 
stimulator of osteoblastic differentiation both in vitro and in vivo and induces osteoblast-
specific gene expression in non-osteoblastic C3H10T1/2 cells (Katagiri et al., 1990) and 
the myoblastic C2C12 cell line (Lee et al., 1999).  Additionally, BMP-2 enhances 
expression of the Id (inhibitor of differentiation) family of transcription factors, which act 
to inhibit function of helix-loop-helix transcription factors of alternative differentiation 
pathways, such as MyoD (Ogata et al., 1993; Locklin et al., 2001).  Dexamethasone 
stimulates in vitro nodule formation in rat calvarial osteoblasts (Bellows et al., 1987) and 
osteoblastic gene expression in rat bone marrow stromal cells (Leboy et al., 1991).  The 
complete mechanism of action of dexamethasone in osteoblastic differentiation has not 
been elucidated; however, as in the case of BMP-2, it was hypothesized that these 
pathways may act synergistically with Runx2 to enhance osteoblastic differentiation and 
mineralization of C3H10T1/2 cells. 
Matrix mineralization was examined at 14 days by von Kossa staining (Figure 4-
6A).  As previously seen with the non-mineralizing Runx2 viral stocks, all Runx2-
expressing C3H10T1/2 cultures without BMP-2 or dexamethasone did not mineralize, 
and all control cultures failed to mineralize in the presence or absence of either BMP-2 or 
dexamethasone.  Small, sparsely stained regions, only detectable at high magnification, 
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were present in Runx2-expressing cultures supplemented with BMP-2 (Figure 4-6A3).  
Notably, dexamethasone-treated, Runx2-modified cultures mineralized to a greater extent 
(Figure 4-6A5).  Osteoblast-specific gene expression was also examined in these cultures 
at 7 days by real-time PCR.  Gene expression levels of the previously described 
mineralizing Runx2-expressing C3H10T1/2 culture (Min +) are presented for reference 
(Fig 4-6B).  Runx2 gene expression levels were approximately equal in all Runx2-treated 
cultures, independent of treatment with BMP-2 or dexamethasone.  OCN levels were 
significantly increased in all Runx2-expressing cultures, and these expression levels were 
comparable to the mineralizing Runx2-modified C3H10T1/2 culture.  BMP-2 treated, 
control C3H10T1/2 cultures showed significantly higher OCN expression compared to 
untreated control cultures, indicating bioactivity of the BMP-2 stock used in these 
experiments.  Interestingly, BSP transcript levels increased slightly (4-fold) in Runx2-
expressing cells supplemented with BMP-2 and significantly higher (25-fold) with 
exposure to dexamethasone.  Control Runx2-expressing NIH3T3 fibroblasts failed to 
mineralize in the absence or presence of BMP-2 or dexamethasone, and no 
distinguishable differences in mineralized surface area were detected between control 
Runx2-transduced MC3T3-E1 cultures and those supplemented with these osteoinductive 




Figure 4-6.  Mineralization and gene expression in Runx2-transduced and 
control C3H10T1/2 cultures co-treated with either BMP-2 or dexamethasone. 
(A) von Kossa stained (1) Runx2-transduced, (2) control, (3) Runx2 + BMP-2 
(small nodules indicated by arrows), (4) control + BMP-2, (5) Runx2 + 
dexamethasone, and (6) control + dexamethasone cultures at 14 days.  Bar 
represents 100 microns.  (B) Real-time PCR data [(mean, SEM), n=3] at 7 days for 
Runx2, OCN, and BSP.  For reference, expression levels from the 7 day 
mineralizing Runx2-expressing culture (MIN+) are included.  ANOVA showed 
significant differences (p<0.000001) between Runx2-modified and controls for all 
genes.  Pairwise comparisons:  * different from same treatment control (p<0.001); 
** different from same treatment control (p<0.01); † different from same 
treatment control (p<0.00001); †† different from control (p<0.01); ‡ different 
from Runx2-transduced, no treatment (p<0.002).  Dotted line represents the assay 




















































































































Primary skin fibroblasts.  In order to further characterize the effects of exogenous 
Runx2 expression in fibroblasts, primary mouse skin fibroblasts were harvested, 
expanded in culture, and transduced with Runx2.  Real-time PCR analysis at 7 days 
demonstrated significant up-regulation in OCN and BSP gene expression in Runx2-
expressing primary cells compared to controls (Figure 4-7).  Mineralization studies in 
Runx2-expressing primary skin fibroblasts at 14 days revealed minute, sparse nodule-like 
regions independent of Runx2 retroviral supernatant lot.  However, these areas covered 
less than 5% of the culture surface area and were only distinguishable at high 
magnification (data not shown).  The authors note that selection was not performed to 
establish a homogenous population of primary skin fibroblasts.  As a result, cell types of 
the dermal region which may be responsive to Runx2 overexpression, including 
adipogenic or vascular lineages, were potentially present in the cultures examined.  
Therefore, further studies are necessary to completely elucidate the Runx2-




























Figure 4-7. Osteoblast-specific gene expression at 7 days in Runx2-expressing 
and control murine primary skin fibroblasts. Data are reported as [(mean, 
SEM), n=3]. ANOVA showed significant differences between Runx2-transduced 
and controls for all genes:  * different from control (p<0.001); ** different from 
control (p<0.05); † significant over assay detection limit (p<0.002).  Line 




















MC3T3-E1 immature osteoblast-like cells.  This cell line was selected as a model of 
osteoblastic differentiation as it produces a mineralized matrix in vitro (Sudo et al., 
1983), indicating endogenous expression of all essential factors necessary for 
mineralization.  As expected, overexpression of Runx2 in MC3T3-E1 cells significantly 
up-regulated in vitro matrix mineralization at 14 and 21 days compared to controls 
(Figure 4-8A and B).  Quantification of mineralized surface area revealed a 4-fold 
increase at 14 days and a 2-fold increase at 21 days (Figure 4-8C).  This indicated that in 
vitro mineralization was up-regulated in Runx2-modified cultures, yet mineralized 
surface area, which was ultimately restricted by the culture dish surface area, eventually 
saturated as control cultures approached similar levels of total mineralized area at later 
time points.  Comparison of Runx2-treated cultures to controls revealed an increase in the 
number of mineralized foci, suggesting that forced-Runx2 expression in these osteogenic 
cells increased the number of clones capable of differentiating and ultimately producing a 
mineralized matrix.  No detectable differences in mineralized surface area existed 
between cultures transduced with control retrovirus and cultures undergoing no retroviral 
transduction, indicating that retroviruses did not adversely impact mineralization 
capacity.   
The detection of high OCN expression at one day and up-regulated ALP activity 
at early time points in Runx2-expressing MC3T3-E1 cells indicated the acceleration of 
osteoblast-specific gene and protein expression.  A calcium dissolution assay was 
performed to determine the extent to which Runx2 overexpression accelerated the onset 
of matrix mineralization.  Beginning 6 and continuing to 8 days post transduction, 
incorporated calcium levels in both Runx2-expressing and control cultures were 
 
 54
indistinguishable from background levels (Figure 4-8D).  At day 9, a significant increase 
in incorporated calcium was observed in Runx2-expressing MC3T3-E1 cultures 
compared to both control cultures at day 9 and Runx2-transduced cultures at day 8.  
However, an increase in calcium incorporation was not detected in control cultures until 
day 10, indicating that in addition to accelerating osteoblast-specific gene expression, 
Runx2 overexpression accelerated matrix mineralization in the MC3T3-E1 osteoblast-
like cell line.  In agreement with mineralized surface area quantification data, calcium 
incorporation in Runx2-expressing cultures was higher than controls over the time course 
of the study. 
Mineralized areas were examined by FT-IR spectroscopy to determine the 
chemical composition of the mineral phase, ensuring biological hydroxyapatite formation 
rather than ectopic precipitation of calcium phosphate potentially resulting from 
increased alkaline phosphatase activity.   Mineral phase from MC3T3-E1 and 
C3H10T1/2 cultures transduced with Runx2 were compared to cadaveric bone as a 
positive control (Figure 4-8E).  Peaks of interest include the phosphate stretching peak at 
1100 cm-1 and the doublet split at 560 cm-1 and 605 cm-1, which are representative of a 
bending mode of crystallized phosphate.  Finally, the presence of a carbonate peak at 
approximately 870 cm-1 is characteristic of the biological substitution of carbonate for 
hydroxide (type I) and/or carbonate for phosphate (type II) in the hydroxyapatite 




Figure 4-8. Mineralization of Runx2-transduced and control MC3T3-E1 
immature osteoblast-like cells.  Forced expression of Runx2 in MC3T3-E1 
immature osteoblast-like cells significantly enhanced matrix mineralization at (A) 
14 and (B) 21 days.  (C) Mineralized surface area of cultures transduced with 
Runx2 and control virus quantified by image analysis [(mean, SEM), n=3].  
ANOVA demonstrated significant differences between Runx2-modified and 
control cultures (p<0.002) and among time points (p<0.001).  Pairwise 
comparisons: * different from control (p<0.03); † different from 14 day control 
(p<0.05); ‡ different from 14 day Runx2-transduced (p<0.05).  (D) Onset of 
mineralization as detected by Ca2+ incorporation in Runx2-expressing and control 
MC3T3-E1 cultures [(mean, SEM), 3 independent experiments each in duplicate].  
ANOVA for days 8-12 showed significant differences between Runx2-transduced 
and controls (p<0.000001).  Pairwise comparisons: * different from control 
(p<0.0001); † different from 8 day Runx2-modified (p<0.0001); ** different from 
control (p<0.00001); ‡ different from 9 day control (p<0.001).  Dotted line 
represents the mean background cellular Ca2+ levels (0.003 mg/well) of NIH3T3 
cells.  (E) FT-IR spectra of mineralized nodules from 21 day Runx2-expressing 
MC3T3-E1 and mineralizing C3H10T1/2 cultures and a cadaveric bone positive 
control.  Spectra showed bands characteristic of biological hydroxyapatite 
formation, including phosphate- and carbonate-related vibrations.  st: stretching 






















































































































































































 The requirement of Runx2 for osteoblastic differentiation and in vivo bone 
formation and maintenance has been clearly shown (Otto et al., 1997; Komori et al., 
1997; Mundlos et al., 1997; Ducy et al., 1999).  Furthermore, Runx2 forced expression 
induced osteoblast-specific gene and protein expression in vitro as detailed here and 
elsewhere (Ducy et al., 1997; Xiao et al., 1998b; Xiao et al., 1999), yet the effects of 
Runx2 overexpression on in vitro matrix mineralization had not been demonstrated.  
Mineralized matrix formation is time-intensive, requiring nearly one to two weeks of in 
vitro culture prior to initial nodule formation in the MC3T3-E1 cell line (Marsh et al., 
1995; Choi et al., 1996).  Therefore, conventional in vitro transfection techniques provide 
insufficient efficiency and expression duration to examine the long term effect of Runx2 
overexpression on this complex differentiation cascade.  To address this complication, 
this study focused on exogenous expression of Runx2 in target cells using retroviral gene 
delivery, which provided highly efficient, constitutively active, and sustained gene 
expression. 
Runx2-expressing NIH3T3 fibroblasts did not form mineralized nodules in vitro, 
even though the presence of OCN transcripts in Runx2-expressing cultures demonstrated 
that the cell line was responsive to exogenous Runx2 expression (Figure 4-3).  The IMR-
90 fibroblastic cell line also failed to mineralize following Runx2 overexpression.  These 
results indicated that forced expression of Runx2 in these non-osteogenic cell lines was 
not sufficient for in vitro matrix mineralization, suggesting that additional cofactors 
which spatiotemporally interact either directly with Runx2 or its gene targets are 
required.  Lack of mineralization was consistent with the absence of BSP gene expression 
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and potentially insufficient ALP activity in these cell lines.  BSP has been shown to be an 
enhancer of in vitro hydroxyapatite nucleation even at low concentrations, suggesting it 
plays a critical role in the initiation of bone mineralization (Hunter et al., 1996).  
Furthermore, ALP activity in Runx2-expressing NIH3T3 fibroblasts was more than 30 
times less than in mineralizing MC3T3-E1 cultures, and it has been shown that isolated 
calvarial cells from ALP knockout mice fail to produce mineralized matrix in vitro 
(Wennberg et al., 2000). 
C3H10T1/2 fibroblasts overexpressing Runx2, although not ubiquitously, were 
capable of producing a biologically equivalent mineralized matrix (Figs. 4-5 and 4-8E), 
consistent with the pluripotent nature of this cell line.  However, this was a low-
frequency, stochastic response which occurred in a retroviral supernatant lot-dependent 
manner and was independent of viral titer and Runx2 transduction efficiency.  
Additionally, OCN gene expression and alkaline phosphatase activity were 
approximately equal in both non-mineralizing and mineralizing Runx2-modified 
C3H10T1/2 cultures.  Detection of 50 to 100-fold higher levels of BSP transcripts in 
mineralizing Runx2-expressing C3H10T1/2 cultures compared to Runx2-treated cultures 
which failed to mineralize, suggested that the variable response in matrix mineralization 
arises from the activation of additional pathways by secondary factors in the retroviral 
supernatant, possibly serum growth factors.  This stochastic behavior was cell type-
dependent, however, as simultaneously transduced Runx2-expressing NIH3T3 and IMR-
90 cultures failed to produce mineralized nodules, and MC3T3-E1 cells demonstrated 
equivalent up-regulated mineralization independent of viral supernatant.  Further 
substantiating the requirement of additional factors for mineralization in the C3H10T1/2 
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cell line, a synergistic induction of mineralization was observed in Runx2-treated cultures 
treated with dexamethasone, whereas control Runx2-modified and dexamethasone-
treated control cultures failed to mineralize in all cases (Figure 4-6A).   
When cultured under appropriate conditions, immature osteoblast-like MC3T3-E1 
cells endogenously express all factors necessary for in vitro mineralization, and it was 
expected that this cell line would therefore be highly responsive to Runx2 
overexpression.  In accordance with the observed up-regulation in osteoblast-specific 
gene and protein expression, enhanced mineralization capacity was observed in this 
osteogenic cell line following forced Runx2 expression (Figure 4-8).  Appearance of 
OCN transcripts in Runx2-transduced MC3T3-E1 cultures as early as one day post 
transduction indicated accelerated expression of this late marker of osteoblastic 
maturation, and examination of calcium incorporation revealed the onset of 
mineralization was also accelerated in Runx2-expressing cultures (Figure 4-8D).  
Furthermore, overexpression of Runx2 in this immature osteoblast-like cell line increased 
the population of fully differentiated, mineralized matrix-producing clones as a greater 
number of mineralizing foci were observed in Runx2-expressing cultures when compared 
to controls.  Interestingly, Liu et al. reported in vivo overexpression of Runx2 under 
control of the tissue-specific pro-α1(I) collagen promoter arrests osteoblast maturation 
and results in osteopenia and multiple fractures in transgenic mice (Liu et al., 2001).  
These results underscored the dynamic complexity of in vivo osteoblastic differentiation 
and emphasized the requirement of regulated, spatiotemporal expression of Runx2 for 
normal in vivo bone formation. 
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Transient transfection of Runx2 has been shown by other groups to enhance 
osteoblast-specific gene expression and increase osteoblast-specific promoter construct 
activities in NIH3T3, C3H10T1/2, and MC3T3-E1 cells (Ducy et al., 1997; Harada et al., 
1999; Xiao et al., 1999).  In agreement with these observations, this study demonstrated 
that forced expression of Runx2 induced or up-regulated OCN in non-osteoblastic and 
osteoblastic cell lines, respectively.  Temporal observation of osteoblast-specific gene 
expression showed BSP up-regulation in Runx2-treated MC3T3-E1 cells (Figure 4-3), 
although transcripts were not detected as early as OCN.  Additionally, BSP expression 
was not detected in Runx2-expressing NIH3T3 fibroblasts and at substantial levels in 
only a fraction of C3H10T1/2 cultures examined.  These results suggest that Runx2 
regulation of BSP is indirect and cell type-dependent, requiring additional factors.  For 
example, Enomoto et al. examined the forced expression of Runx2 in chick immature 
chondrocytes and showed an up-regulation of collagen type X and collagenase-3 protein 
expression, but did not detect OCN gene transcripts (Enomoto et al., 2000).  Benson et al. 
reported two putative Runx2 binding sites within a 2.5-kb fragment of the murine BSP 
promoter.  Neither exhibited significant enhancer activity, suggesting that other factors 
may bind to cis-acting elements in the BSP promoter and thereby induce transcription 
(Benson et al., 1999).  No significant differences were detected in COLα1(I) gene 
expression in any of the cell lines examined.  Kern et al. (Kern et al., 2001) reported that 
the Runx2 cis-acting element in the COLα1(I) promoter is only active in osteoblasts and 
not in cell lines of non-osteoblastic origin.  However, they demonstrated activation of a 
luciferase reporter construct containing four copies of the α1(I) OSE2 cis-acting elements 
fused to a minimal α1(I) collagen promoter that was co-transfected with Runx2 in COS-7 
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cells.  While these results confirm that an exogenous murine collagen promoter construct 
is responsive to Runx2 overexpression, the up-regulation of endogenous COLα1(I) gene 
expression following forced expression of Runx2 may not be observed in non-
osteoblastic cells, such as the NIH3T3 and C3H10T1/2 fibroblasts examined here, due to 
cell type-specific promoter inactivation.  Although COLα1(I) transcript levels trended 
higher at later time points in Runx2-expressing MC3T3-E1 cultures, a significant 
increase in expression was not observed.  Notably, endogenous COLα1(I) expression 
levels were orders of magnitude higher than other osteoblast-specific genes investigated 
(Figure 4-3B).  As a result, Runx2 overexpression may not have provided a detectable 
effect on COLα1(I) expression in this osteogenic cell line. 
Cell type-dependent induction/enhancement in expression of certain osteoblast-
specific genes, such as BSP, supported the hypothesis that Runx2 interacts with 
additional factors or other osteoblast-specific transcriptional pathways throughout the 
differentiation cascade.  For example, McLarren et al. suggested that TLE corepressors 
and HES-1 modulate Runx2 transcriptional activation (McLarren et al., 2000), and 
physical association of Runx2 with cofactors such as c-fos and c-jun of the AP-1 complex 
(Hess et al., 2001) or the CCAAT/enhancer binding proteins (Gutierrez et al., 2002) may 
be a mechanism for regulating tissue-specific gene expression.  Finally, the identification 
of Osterix (Osx) as an essential osteoblast-specific transcription factor acting downstream 
of Runx2 provides even more insight into the complexity of osteoblast differentiation 
(Nakashima et al., 2002).  Similar to Runx2 knockouts, Osx null mice lacked osteocalcin 
and BSP expression as well as differentiated osteoblasts.  Osterix expression was ablated 
in Runx2 knockouts, yet it has not been determined if Runx2 directly or cooperatively 
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regulates Osx expression.  These or other currently undefined transcriptional pathways 
support the cell-type dependent activity of Runx2 observed in the present study. 
In summary, this study demonstrated that forced expression of Runx2 via 
retroviral gene delivery induced or up-regulated several osteoblast-specific genes and 
proteins ubiquitously in non-osteoblastic and osteoblast-like cells, respectively, while 
expression of other osteoblast-specific genes (notably BSP) was enhanced in cell type-
dependent manner.  Furthermore, results indicated that sustained overexpression of 
Runx2 enhanced in vitro osteoblastic differentiation by up-regulating and accelerating 
mineralized matrix formation in an immature osteoblast-like cell line.  These results 
suggest that Runx2 is an essential but insufficient transactivating factor for complete in 




RUNX2-EXPRESSING PRIMARY BONE MARROW STROMAL CELLS 
 
INTRODUCTION 
Bone marrow stromal cells have been extensively examined as a candidate cell 
source for bone tissue engineering applications in both in vitro and in vivo model systems 
(Ohgushi et al., 1989; Ohgushi et al., 1993; Bruder et al., 1994; Ishaug et al., 1997; 
Kadiyala et al., 1997; Breitbart et al., 1999; Quarto et al., 2001; Horwitz et al., 2002; 
Holy et al., 2003), yet the effectiveness of these stromal/osteoprogenitor cell-based 
therapies is hampered by their initially low frequency in healthy marrow (0.001% of 
nucleated cells) (Bruder et al., 1997) and propensity for dedifferentiation in response to 
adhesion-dependent in vitro expansion (Ter Brugge and Jansen, 2002; Shi et al., 2002; 
Simonsen et al., 2002).    
Based on the Runx2-responsiveness of MC3T3-E1 osteoblast-like cells (Chapter 
4) (Byers et al., 2002), it was of particular interest to examine exogenous Runx2 
expression in bone marrow stromal cells.  Marrow-derived stromal cells, isolated from 
the marrow young adult rats, were subjected to Runx2 retroviral transduction and 
maintained under in vitro osteogenic culture conditions.  Runx2-modified stromal cells 
demonstrated increased osteoblastic gene and protein expression and produced 
significantly higher quantities of mineralized matrix compared to control cultures.  
Furthermore, subcultured stromal cells undergoing considerable in vitro expansion 




MATERIALS AND METHODS 
Reagents 
Fetal bovine serum (FBS) was obtained from Hyclone Laboratories (Logan, UT).  
Remaining cell culture supplies were purchased from Invitrogen (Carlsbad, CA), while 
chemical reagents were acquired from Sigma Chemical Co. (St. Louis, MO).  RNA 
isolation reagents were purchased from Qiagen (Valencia, CA).  Molecular biology 
reagents for reverse transcription (RT) were obtained from Invitrogen, reagents for real-
time PCR were acquired from Applied Biosystems (Foster City, CA), and PCR 
oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA). 
 
Cell Isolation and Culture 
Primary bone marrow stromal cells were harvested from the femora of young 
adult male Wistar rats as previously described (Maniatopoulos et al., 1988) in accordance 
to an IACUC-approved protocol.  Briefly, following excision, hindleg femora and tibia 
were cleared of soft tissue and processed through three consecutive 15 minute rinses in 
growth media (α-minimum essential medium supplemented with 10% FBS, 1% 
penicillin-streptomycin, 50 µg/ml gentamicin sulfate, and 0.3 µg/ml fungizone).  The 
ends of the long bones were then removed, and the marrow space was flushed with 
excess culture media (3 to 5 ml) using a syringe with an 18 gauge needle.  Marrow 
isolates were pooled (typically 6 to 8 rats per harvest), centrifuged, resuspended in 
growth media, and seeded for adhesion-dependent selection on tissue culture polystyrene 
dishes.  Nonadherent hematopoeitic cells were removed during subsequent media 
exchanges that occurred every other day.  Following 7 days of in vitro expansion, 
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adherent stromal cells were trypsinized, counted, plated on 0.1% type I collagen-coated 
(Vitrogen-100; Cohesion, Palo Alto, CA) 6-well dishes at a density of 1×104 cells/cm2, 
and incubated in growth media overnight at 37°C.  After two rounds of retroviral 
transduction, cultures were maintained in osteogenic media consisting of growth media 
supplemented with 50 µg/ml L-ascorbic acid, 3 mM sodium β-glycerophosphate, and 10 
nM dexamethasone (+Dex) (Bellows et al., 1987; Leboy et al., 1991).  To isolate the 
effect of Runx2 overexpression from the osteogenic influence of dexamethasone, some 
cultures were also maintained in the absence of dexamethasone (-Dex).  In all 
experiments, media was changed every second day.  Additional experiments were 
performed to examine the effect of Runx2 overexpression on serially passaged stromal 
cells.  At confluence, subcultured cells were trypsinized, counted, and reseeded for 
continued subculture at 5×103 cells/cm2 (Bruder et al., 1997) or seeded for retroviral 
transduction following passages 2, 4, and 8 as described.  During subculture, cells were 
maintained in growth media with exchanges every other day.      
 
Runx2 Retroviral Vector and Retroviral Transductions 
Cloning of the Runx2 retroviral expression vector containing the type II 
(MASNSLF) Runx2 isoform, packaging of Runx2 and control (no Runx2 insert) 
retroviruses, and retroviral transduction procedures were performed as described in 
Chapter 4 and Appendix A (Byers et al., 2002).  Retrovirally transduced cells were 
noninvasively analyzed for transduction efficiency by flow cytometric detection of eGFP 




Osteoblast-Specific Gene Expression 
Total RNA was isolated at 1, 3, and 7 days post transduction using the RNeasy 
RNA isolation kit and quantified by spectroscopy.  cDNA synthesis was performed on 
DNaseI-treated (27 Kunitz units/sample) total RNA (1 µg) by oligo(dT) priming using 
the Superscript II™ Preamplification System.  Real-time PCR was performed with the 
ABI Prism 7700 Sequence Detection System and Sybr Green intercalating dye (Applied 
Biosystems).  Generation of standard templates and quantification techniques were 
performed as previously described in Chapter 4 (Byers et al., 2002).  Real-time PCR 
oligonucleotide primers for rat osteoblast-specific genes (Table 5-1) were designed using 
Primer Express software (Applied Biosystems).   
 
Table 5-1. Real-time PCR oligonucleotides for rat osteoblastic genes
 Gene Forward Primer Reverse Primer Size (bp) 
 Runx2 
     AF010284¥ 
5'-AGCCTCTTCAGCGCAGTGAC-3' 5'-CTGGTGCTCGGATCCCAA-3' 59 
 OCN 
     X04141 5'-ACGAGCTAGCGGACCACATT-3' 5'-CCCTAAACGGTGGTGCCATA-3' 67 
 COL α1(I) 
     Z78279 
5'-TCGATTCACCTACAGCACGC-3' 5'-GACTGTCTTGCCCCAAGTTCC-3' 67 
 BSP 
     J04215 5'-TGACGCTGGAAAGTTGGAGTT-3' 5'-GCCTTGCCCTCTGCATGTC-3' 69 
 ALP 
     7106245 5'-CGTGGCCAAGAACATCATCA-3' 5'-GCGGGCAGCTGTCACTGT-3' 67 
 OPN 
     AB001382 5’-TGAGACTGGCAGTGGTTTGC-3’ 5’-CCACTTTCACCGGGAGACA-3’ 63 
¥: GenBank accession number 
NOTE:  Runx2 primer sequences reported were designed to detect murine type II isoform cloned into retroviral expression 
vector, but the sequences will detect endogenous rat Runx2 as they are conserved across both species.  
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Alkaline Phosphatase Biochemical Activity 
Alkaline phosphatase (ALP) activity was quantified at 7 days post transduction 
using 4-methyl-umbelliferyl-phosphate fluorescent substrate as detailed in Chapter 4 
(Byers et al., 2002) and normalized to total DNA, which was quantified with PicoGreen 
reagent according to the manufacturer’s instructions (Molecular Probes, Eugene, OR).  
 
Matrix Mineralization Quantification and Fourier-Transform Infrared Spectroscopy 
Following 7, 14, and 21 days, cultures were fixed in 70% ethanol and examined 
histochemically for mineralized matrix by von Kossa staining as detailed in Chapter 4 
(Byers et al., 2002).  Image Pro image analysis software (Media Cybernetics, Silver 
Springs, MD) was used to quantify low magnification light micrographs of von Kossa-
stained cultures.  FT-IR analyses were performed as described (Bonewald et al., 2003) on 
bulk ethanol-fixed cultures prepared in potassium bromide (KBr) pellets.  Spectra, 64 
scans acquired at 4 cm-1, were obtained on a Nexus 470 FT-IR spectrometer 
(ThermoNicolet, Madison, WI) under N2 purge.  A spectral range from 400-2000 cm-1 
was analyzed for mineral and matrix peaks characteristic of the mineral phase of bone.  
Rat calvarial bone, lyophilized, pulverized, and similarly prepared in KBr pellets, served 
as a positive control.    
 
Data Analysis 
All analyses were performed on assays conducted at least three times, each with 
unique Runx2 retroviral supernatant preparations.  Data are reported as mean ± SEM, and 
statistical comparisons using SYSTAT 8.0 were based on an analysis of variance 
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(ANOVA) and Tukey’s test for pairwise comparisons with a p-value < 0.05 considered 
significant.  In order to make the variance independent of the mean, statistical analysis of 




Transduction efficiency in  marrow stromal cells 
Flow cytometry analyses indicated transduction efficiencies of approximately 
50% in both Runx2-transduced and control cells (Figure 5-1).  Similar transduction 
efficiencies in rat bone marrow stromal cells have been reported for HA-LB MLV 
amphotropic retrovirus (Peng et al., 2001).  Cell selection procedures (e.g., eGFP/Runx2-
positive) were not performed to avoid removal of accessory cells which may support 
osteoblastic differentiation.  Aubin proposed a stimulatory heterotypic cell-cell 
interaction between non-adherent hematopoeitic cells and adherent cells (Aubin, 1999), 
and a similar complementary interaction may exist across heterogeneous adherent cell 
populations.  DAPI cell-cycle analyses revealed no significant differences in cell 
proliferation between Runx2-transduced and control cells (data not shown).  Finally, no 
differences were observed between unmodified stromal cells and those transduced with 




Figure 5-1.  Retroviral transduction efficiency of marrow stromal cells 
examined by flow cytometry and fluorescence microscopy.  (A) Flow 
cytometry histograms depicting eGFP co-selectable marker expression at 3 days in 
retrovirally transduced bone marrow stromal cells, including unmodified cell 
autofluorescence (top), control retrovirus (middle), and Runx2 retrovirus (bottom).  
Transduction efficiencies are reported as an average of the independent 
experiments each conducted with unique lots of retroviral supernatant [(mean, 
SEM), n=3].  (B) Phase contrast (left) and fluorescence (right) micrographs of 
control virus-transduced bone marrow stromal cells.  (C) Phase contrast (left) and 
fluorescence (right) micrographs of Runx2-expressing bone marrow stromal cells. 
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Runx2 enhances expression of osteoblastic genes 
Under standard osteogenic culture conditions (including 10 nM dexamethasone) 
for bone marrow stromal cells, Runx2-transduced cells demonstrated more than 10-fold 
higher Runx2 gene expression compared to endogenous levels in control cultures at each 
of the time points examined (Figure 5-2).  Up-regulated transcript levels were also 
observed for osteocalcin (OCN) and collagen α1 (I) (COLα1(I)) throughout culture time.  
In contrast, apart from the day 3 time point, bone sialoprotein (BSP) and osteopontin 
(OPN) gene expression levels were not different between Runx2-modified and control 
cultures.  ALP mRNA levels were higher in Runx2-engineered cells at 1 and 3 days, but 
equivalent expression levels were attained by day 7.  ALP biochemical activity, however, 
was nearly two-fold higher in Runx2-expressing stromal cells compared to control 
cultures at the same time point (Figure 5-3). 
Because dexamethasone is a potent stimulator of osteoblastic differentiation in 
bone marrow stromal cells (Bellows et al., 1987; Leboy et al., 1991), additional 
experiments were performed in the absence of dexamethasone.  No differences in Runx2 
transcript levels were observed between dexamethasone-treated and dexamethasone-free 
cultures for both Runx2-modified and control cells (Figure 5-2), indicating that 
dexamethasone does not alter Runx2 mRNA expression.  On the other hand, significantly 
higher expression levels were observed for all osteoblastic genes examined in Runx2-
transduced cultures compared to controls at 7 days in the absence of dexamethasone.  The 
increases were most significant in OCN (>50-fold) and BSP (>30-fold) and still 
pronounced for COLα1(I), OPN, and ALP (3 to 9-fold).  As expected, expression of all 
osteoblastic markers in dexamethasone-free control (no Runx2) cultures was lower than 
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that corresponding to dexamethasone-treated control cultures at 7 days.  These results 
demonstrate that exogenous Runx2 expression enhances osteoblastic gene expression in 
stromal cells, particularly in the absence of dexamethasone. 
Figure 5-2.  Relative gene expression in Runx2-transduced and control bone 
marrow stromal cells in the presence and absence of dexamethasone. Data are 
reported as [(mean, SEM), n=6] at 1, 3, and 7 days.  ANOVA showed a significant 
effect of genetic modification (control versus Runx2 overexpression) and time:  
Runx2, OCN, COLα1(I), BSP, and ALP (p<0.000001 for both) and OPN (p<0.025 
for treatment and p<0.000001 for time).  Pairwise comparisons for same time 
point: * (p<0.000001); ** (p<0.0005); † (p<0.00005); †† (p<0.04); ‡ (p<0.005); 
‡‡ (p<0.01); $ (p<0.03).  Gene expression was also quantified at 7 days for control 
and Runx2-modified cultures which had dexamethasone excluded from the culture 
media.  ANOVA for all 7 day cultures showed differences in genetic modification 
(control versus Runx2 overexpression) for Runx2 (p<0.000001) and genetic 
modification and culture media supplementation (+/- dexamethasone) for OCN, 
COLα1(I), BSP, ALP, and OPN (p<0.000001 for both).  Pairwise comparisons:  
Runx2-modified (-Dex) versus control (-Dex): * (p<0.000001); † (p<0.00005), 
Runx2-modified (-Dex) versus Runx2-modified (+Dex): § (p<0.01); # (p<0.005), 
























































































































































Runx2 up-regulates mineralization by marrow stromal cells  
Runx2 overexpression enhanced matrix mineralization in stromal cell cultures 
(Figure 5-4).  Mineralized areas were present at 7 days in Runx2-transduced cultures 
maintained either in the presence or absence of dexamethasone, whereas controls cultures 
lacked appreciable von Kossa-positive regions.  At 14 days, Runx2-engineered cultures 
supplemented with dexamethasone exhibited nearly 2-fold more mineralization than 
either Runx2-modified or dexamethasone-treated samples, whereas as dexamethasone-
free controls displayed minimal mineralization.  The additive effects of Runx2 expression 
and dexamethasone treatment on the mineralization capacity of stromal cells were also 
evident at 21 days.  Dexamethasone-free control cultures displayed punctate nodules at 
21 days, in agreement with the observation that a subpopulation of stromal cells is 
predisposed to osteoblastic differentiation even in the absence of dexamethasone (Aubin, 


























Figure 5-3. Alkaline phosphatase biochemical activity following 7 days of in 
vitro culture for control and Runx2-modified cells maintained in the presence 
of dexamethasone. Data are reported as [(mean, SEM), n=6].  Single factor 































FT-IR spectroscopy was used to examine the chemical composition of the mineral 
phase deposited by Runx2-transduced and control cultures (Figure 5-5).  This analysis is 
important because in vitro osteogenic culture conditions can lead to von Kossa-positive 
deposits that do not correspond to biological mineralization (Bonewald et al., 2003).  
Similar to the mature bone positive control, Runx2-modified and control stromal cell 
cultures displayed the amide I and II peaks indicative of protein, a broad phosphate 
stretching peak near 1100 cm-1, a phosphate bending doublet split at 560 cm-1 and 605 
cm-1, and a carbonate peak near 870 cm-1 which is characteristic of the biological 
substitution of carbonate for hydroxide (type I) and/or carbonate for phosphate (type II) 
in the hydroxyapatite crystalline structure (Mendelsohn et al., 1989; Boskey et al., 1996).  
These chemical moieties characteristic of the mineral phase are representative of a poorly 
crystalline apatite (Bonewald et al., 2003).  Taken together, these results demonstrate that 
exogenous Runx2 expression up-regulates formation of a biological mineralized matrix in 
primary bone marrow stromal cell cultures. 
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Figure 5-4.  Mineralized surface area for Runx2-transduced and unmodified 
stromal cells with and without dexamethasone treatment. (A) von Kossa-
stained control and Runx2-expressing cultures co-treated with dexamethasone at 
multiple time points.  (B) von Kossa-stained control and Runx2-modified cultures 
maintained in the absence of dexamethasone at multiple time points.  (C) 
Mineralized surface area quantification of control and Runx2-transduced marrow 
stromal cells in both the presence and absence of dexamethasone [(mean, SEM), 
n=6)].  ANOVA showed differences in genetic modification (control versus 
Runx2 overexpression), culture media supplementation (+/- dexamethasone), and 
time (p<0.000001 for all).  Pairwise comparisons for same time point: * greater 
than control (+Dex) (p<0.00005) and control (-Dex) (p<0.00001); # greater than 
control (+Dex) (p<0.005) and control (-Dex) (p<0.001); ** greater than Runx2 (-
Dex), control (+Dex), and control (-Dex) (p<0.000005); † both greater than 
control (+Dex) and control (-Dex) (p<0.000005);  ‡ greater than Runx2 (-Dex) 
(p<0.00005) and control (+Dex) and control (-Dex) (p<0.000005); § both greater 





















































































































Figure 5-5. Comparative FT-IR spectra of Runx2-modifed and control bone 
marrow stromal cells.  Adult rat cranial bone was included as a positive control.  
Transmission spectra, generated from bulk phase, ethanol fixed cultures in KBr 
pellets, showed bands characteristic of biological hydroxyapatite formation, 
























































Runx2 overexpression maintains mineralization capacity of subcultured stromal cells  
The effect of Runx2 overexpression on mineralization of bone marrow stromal 
cells expanded in culture was also examined.  Therapeutic applications involving 
marrow-derived cells require large numbers of phenotypically stable cells, but stromal 
cells often lose the ability to differentiate when expanded in vitro (Ter Brugge and 
Jansen, 2002; Shi et al., 2002; Simonsen et al., 2002).  Stromal cells expanded to 
passages 2, 4, and 8 without osteogenic stimulation were transduced with Runx2 or 
control retrovirus and subsequently cultured with or without dexamethasone (Figure 5-6).  
These passage numbers correspond to 2.5, 7, and 13 cumulative population doublings 
beyond passage 1 (Figure 5-6D).  Consistent with the response of passage 1 cultures, 
Runx2 overexpression and dexamethasone treatment enhanced matrix mineralization 
compared to Runx2 modification or dexamethasone stimulation alone (Figure 5-6C).  
More importantly, forced Runx2 expression in high-passage cells retained the capacity to 
mineralize, although at lower levels than earlier passages, while the endogenous 
mineralization capacity of subcultured control stromal cells ceased prior to passage 8 








































































































dexamethasone and transduced following passages 1, 2, 4, and 8 [(mean, SEM), 
n=6].  ANOVA demonstrated differences in genetic modification (control versus 
Runx2 overexpression), culture media supplementation (+/- dexamethasone), and 
time (p<0.000001 for all).  Pairwise comparisons between same passage 
treatments: * greater than Runx2 (-Dex), control (+Dex), and control (-Dex) 
(p<0.000005); # both greater than control (-Dex) (p<0.000005); ** greater than 
control (+Dex), and control (-Dex) (p<0.000005); ## greater than control (+Dex) 
(p<0.00001) and control (-Dex) (p<0.000005); † greater than control (-Dex) 
(p<0.01);  ‡ greater than Runx2 (-Dex) (p<0.001), control (+Dex) (p<0.0001), and 
control (-Dex) (p<0.000005); § both greater than control (-Dex) (p<0.00005); ‡‡ 
greater than control (+Dex) and control (-Dex) (p<0.005).  (D) Cumulative 
population doubling data for stromal cells subcultured up to 8 passages prior to 
transduction with Runx2 retrovirus.
Figure 5-6.  Mineralized surface area in 14 
day control and Runx2-expressing (+/-
dexamethasone) cultures transduced 
following in vitro subculture. von Kossa-
stained control and Runx2-expressing cells 
transduced after passage 1, 2, 4, and 8 
supplemented with (A) or without (B) 
dexamethasone.  (C)  Mineralized surface 
area quantification of control and Runx2-
transduced marrow stromal cells 






































































These results demonstrated that sustained and elevated Runx2 expression up-
regulates osteoblast-specific gene and protein expression as well as biological matrix 
mineralization in primary bone marrow stromal cells.  Consistent with observations that 
Runx2 overexpression accelerates and up-regulates the differentiation and mineralization 
capacity of immature MC3T3-E1 osteoblast-like cells (Chapter 4) (Byers et al., 2002).  
The up-regulated expression of osteoblastic markers in stromal cells in response to 
exogenous Runx2 most likely resulted from enhanced differentiation of osteoprogenitor 
cells present in the stromal compartment.  Additionally, forced Runx2 expression in the 
non-osteoblastic progenitor cell fraction of the stroma, such as adipocytes, myoblasts, and 
chondroblasts, could result in additional cells differentiating down the osteoblastic 
lineage. 
The effect of Runx2 overexpression on osteoblastic differentiation in the presence 
or absence of dexamethasone was also analyzed.  This synthetic glucocorticoid is a potent 
stimulator of ALP and OPN gene expression but only modestly affects OCN mRNA 
levels in rat marrow stromal cells (Leboy et al., 1991).  In the presence of 
dexamethasone, exogenous Runx2 expression up-regulated COLα1(I) and OCN mRNA 
transcripts, indicating induction of early and late osteoblastic markers.  These genes 
contain consensus Runx2 DNA binding elements which are positively regulated by 
Runx2 (Frendo et al., 1998; Kern et al., 2001).  Although ALP transcript levels were 
higher in Runx2-modified cells at early time points, they were equivalent to control levels 
at 7 days.  On the other hand, ALP activity at 7 days was 2-fold higher in Runx2-
modified cultures compared to controls.  This difference between ALP mRNA levels and 
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enzyme activity could arise from accumulation of ALP protein throughout the time 
course of the study.  Alternatively, Runx2 or a downstream target of Runx2 may exert 
post-transcriptional regulation on ALP, thereby enhancing production or activity of ALP 
protein from equivalent amounts of mRNA message.  No differences were observed in 
OPN or BSP gene expression between Runx2-treated and control cells, suggesting either 
lack of Runx2 involvement in the regulation of these genes or saturation of 
transcriptional activity in response to dexamethasone.  To separate the effects of Runx2 
overexpression from dexamethasone stimulation, additional experiments were performed 
in the absence of dexamethasone.  All genes, including BSP and OPN, exhibited 
significantly higher expression levels for Runx2-transduced cells compared to 
dexamethasone-free controls.  In fact, Runx2 overexpression alone was sufficient to 
attain gene expression levels similar to those observed in Runx2-modified cultures 
treated with dexamethasone.  Interestingly, the observation of elevated BSP transcript 
levels in Runx2-expressing cultures was unexpected.  Previous groups reported that the 
BSP promoter lacks Runx2 responsiveness and Runx2 expression suppressed BSP 
transcripts (Benson et al., 1999; Javed et al., 2001).  This inconsistency may be explained 
by cell type-dependent effects or differences in exogenous Runx2 expression levels or 
duration.  The mechanism by which this enhancement in BSP expression occurred in 
stromal cells, whether by direct Runx2 transactivation or secondary transcription 
pathways, remains unknown.   
Consistent with increased osteoblastic gene expression, Runx2 overexpression in 
combination with dexamethasone increased matrix mineralization compared to forced 
Runx2 expression or dexamethasone treatment alone, while dexamethasone-free control 
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cultures displayed minimal mineralization.  These results are in agreement with the 
combined effects of forced Runx2 expression and dexamethasone on the osteoblastic 
differentiation of C3H10T1/2 pluripotent cells (Chapter 4) (Byers et al., 2002).  The 
additive effects of Runx2 overexpression and dexamethasone supplementation on 
mineralization can be explained by (i) contributions from distinct subpopulations (i.e. 
Runx2-responsive and dexamethasone-responsive cells) in the heterogeneous stromal cell 
population or (ii) dexamethasone-mediated enhancement of Runx2 activity.  However, 
the results with expanded cell cultures (Figure 5-6) do not support a model with separate 
contributions to mineralization from distinct cell populations.  Dexamethasone-treated 
control cultures did not mineralize at passage 8, while both dexamethasone-free Runx2-
transduced and dexamethasone-treated, Runx2-engineered cells produced significant 
mineralization.  Moreover, dexamethasone-treated Runx2-modified cells still deposited 
higher levels of mineralized matrix than Runx2 overexpression alone, suggesting that 
dexamethasone enhances Runx2 activity.  Because it did not alter Runx2 gene 
expression, dexamethasone most likely enhances the effects of Runx2 by directly altering 
Runx2 functional activity or activating pathways complementary to Runx2.  Indeed, 
Prince et al. demonstrated higher Runx2 protein levels and DNA-binding activity in 
response to dexamethasone, even though dexamethasone supplementation did not alter 
Runx2 mRNA levels (Prince et al., 2001).  Interactions between Runx2 and 
dexamethasone may involve the CCAAT/enhancer-binding protein (C/EBP) transcription 
factor family.  C/EBPβ mRNA expression and DNA binding affinity are enhanced by 
dexamethasone (Gotoh et al., 1997).  Furthermore, Gutierrez et al. demonstrated 
C/EBPβ-mediated activation of the OCN promoter and direct interaction between Runx2 
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and C/EBPβ in the synergistic enhancement of OCN gene expression (Gutierrez et al., 
2002).  C/EBP factors have also been implicated in COLα1(I) expression (Attard et al., 
2000), which, in addition to OCN, was up-regulated by Runx2 overexpression in the 
present study.  These results suggest that complementary interactions between 
dexamethasone-responsive regulatory factors, such as C/EBP, and Runx2 may be 
responsible for the additive effects of Runx2 overexpression and dexamethasone on 
mineralization. 
Runx2 overexpression, but not dexamethasone treatment, maintained the 
mineralization capacity of expanded stromal cells.  In vitro serial expansion of bone 
marrow stromal cells results in a complete loss of osteoblastic differentiation and 
mineralization capacity as demonstrated in this and other studies (Ter Brugge and Jansen, 
2002; Shi et al., 2002; Simonsen et al., 2002).  In a heterogeneous cell population, such as 
bone marrow stromal cell cultures, several mechanisms could be responsible for the loss 
of osteoblastic differentiation capacity.  For instance, mitotically active cells lacking 
inherent osteoprogenitor characteristics (e.g., fibroblasts) may overtake osteoprogenitor 
cells, thereby reducing the frequency of osteogenic cells.  Alternatively, the 
osteoprogenitor subpopulation could become restricted in its differentiation capacity 
either due to lack of requisite external signals and/or cessation of internal pathways 
critical to the osteoblastic differentiation cascade.  Regardless of the underlying 
mechanism, these results demonstrate that serially expanded stromal cells lose their 
ability to produce a mineralized matrix, even in the presence of dexamethasone, but a 
fraction of this population remains responsive to Runx2 overexpression even after 13 
population doublings (>8000-fold expansion) beyond initial passage.  These findings are 
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particularly significant to cell-based strategies for therapeutic applications requiring large 
numbers of osteogenic cells to synthesize mineralized constructs for the treatment of 




IN VITRO AND SUBCUTANEOUS IN VIVO EVALUATION OF RUNX2-
MODIFIED CELLS IN 3-D PLGA SCAFFOLDS  
 
INTRODUCTION 
Tissue engineering to develop bone graft substitutes offers a promising alternative 
to address the clinical demand and limitations associated with conventional autologous 
and allogenic bone grafting substrates (Crane et al., 1995; Baum and Mooney, 2000).  
After demonstrating that Runx2 overexpression enhanced osteoblast phenotype 
expression of primary bone marrow stromal cells in monolayer culture (Chapter 5), 
specifically osteoblast-specific gene expression and mineralization, Runx2-modified cells 
were integrated into 3-D polymeric scaffolds to create tissue-engineered constructs.  
Compared to unmodified cells, Runx2 overexpression significantly up-regulated 
osteoblastic differentiation and mineralization of 3-D scaffolds in vitro and in vivo in an 
ectopic, nonosseous site.  Additionally, in vitro construct development to create a 
mineralized template prior to implantation dramatically enhanced in vivo mineralized 
tissue formation, suggesting a novel templating tissue engineering strategy to improve in 
vivo mineralization.  Finally, Runx2 overexpression and in vitro construct development 
synergistically enhanced in vivo mineralization compared to in vitro construct 
development or genetic engineering with Runx2 alone. 
 
MATERIALS AND METHODS 
Stromal cell isolation and retroviral transductions  
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Primary bone marrow stromal cells were isolated from the femora of 6-week-old 
young adult male Wistar rats (Maniatopoulos et al., 1988) and expanded in culture for 7 
days prior to retroviral transduction as described (Chapter 5).  Runx2-transducing and 
control (no Runx2 insert) retroviruses were produced using standard techniques and sub-
confluent cultures of target cells were transduced with retroviruses (1-2 x 105 cfu/ml viral 
titer) as described (Chapter 4). 
 
Cell culture and construct preparation   
Following transduction, cells were seeded 2 days post transduction into Innopol® 
75/25 PLGA scaffolds (Innotech Medical, Korea; 8 mm diameter × 5 mm thick, 100-200 
micron pore size, 85% porosity) (Nam et al., 2000) at 106 cells/scaffold, a seeding density 
consistent with previously published work (Ishaug et al., 1997; Holy et al., 2000).  To 
enhance initial cell adhesion, constructs were pre-coated in a solution of rat plasma 
fibronectin in PBS (20 µg/mL).  During in vitro culture, constructs were maintained 
statically in osteogenic media (α-minimum essential medium, 10% fetal bovine serum, 
1% penicillin-streptomycin, 50 µg/ml gentamicin sulfate, and 0.3 µg/ml fungizone, 50 
µg/ml L-ascorbic acid, 3 mM sodium β-glycerophosphate, and 10 nM dexamethasone), 
and media was exchanged every other day. 
 
Subcutaneous implantation surgeries   
Cell-seeded constructs were implanted into subcutaneous pockets made by blunt 
dissection in the backs of 7-week-old syngeneic rats in accordance to an IACUC-
approved protocol.  Each animal received two implants (one Runx2 and one unmodified 
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cell-seeded scaffold) (Figure 6-1) on opposite sides of a midline incision (n=5).  Some 
animals received cell-free scaffolds for comparative analysis to observe any abnormal 
inflammatory responses to the scaffold material or implanted cells.  Constructs were 
explanted after 4 weeks of implantation following euthanasia.    
 
Microcomputed tomography 
In vitro and in vivo mineralization of 3-D scaffolds was quantified by high 
resolution X-ray microcomputed tomography (micro-CT) using a Scanco Medical µCT 
40 imaging system (Bassersdorf, Switzerland).  Formalin-fixed specimens were scanned 
in 70% ethanol at 16 µm voxel resolution and evaluated at a threshold corresponding to a 
linear attenuation of 0.96 cm-1, filter width of 1.2, and filter support of 2.0.  The 
reconstructed and thresholded 3-D images were evaluated using direct distance 
Figure 6-1.  Image depicting the location of the subcutaneous site (arrows 
point to implanted constructs).
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transformation methods to calculate mineralized matrix volume within each construct or 
explant (Hildebrand et al., 1999).  
 
Histology 
Histological sections (5 µm) were prepared using the paraffin tape-transfer system 
(Instrumedics, Hackensack, NJ) to enhance adhesion and retention of the scaffold to the 
slide during deparaffinization and staining.  Sections were stained with hematoxylin-
eosin or von Kossa-nuclear fast red to observe cellular distribution and mineralization of 
the 3-D polymeric scaffolds. 
   
Data Analysis 
In vitro analyses were conducted at least three times, each with unique Runx2 
retroviral supernatant preparations and donor cell harvests.  Data are reported as mean ± 
SEM, and statistical comparisons were based on ANOVA and Tukey’s test for pair-wise 
comparisons with a p-value < 0.05 considered significant. 
 
RESULTS 
Runx2 expression increases 3-D construct in vitro mineralization 
Cells were cultured within porous PLGA scaffolds to examine the kinetics of in 
vitro construct mineralization.  This formulation of biodegradable scaffold is extensively 
used in bone tissue engineering applications and supports in vitro mineralization by 
stromal cells (Ishaug et al., 1997; Holy et al., 2000; Murphy et al., 2000).  DNA 
measurements verified equivalent cell seeding between Runx2-modified and control 
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constructs (data not shown).  Micro-CT revealed significantly higher levels of 
mineralization at 21 (8-fold), 28 (3-fold), 42 (2-fold), and 56 (2-fold) days in culture on 




Figure 6-2.  Mineralization of 3-D PLGA scaffolds seeded with Runx2-
transduced or control cells following various in vitro culture times.  (A) micro-
CT images of control and Runx2-expressing cell-seeded PLGA constructs at 28 
days (A) and 56 days (B) of in vitro culture.  (C) Quantification of total mineral 
volume following static in vitro culture for various time periods [(mean, SEM), 
n=9].  ANOVA showed differences in treatment (p<0.000001).  Pairwise 
comparisons: † (p<0.05); †† (p<0.005); * (p<0.00001).  (D) Photograph of Runx2-
expressing and control cell-seeded PLGA scaffolds following various durations of 






































































Interestingly, a definitive macroscopic difference existed between scaffolds 
seeded with Runx2-modified and control cells.  Specifically, a time-dependent, cell-
mediated contraction was consistently observed, and this artifact appeared to be more 
prevalent in control cell than Runx2-transduced cell-seeded scaffolds (Figure 6-2D).  
Although the precise origin of this difference was not determined, it suggests that in the 
absence of Runx2 overexpression, a greater number of stromal cells retained a more 
fibroblastic, contractile phenotype even in the presence of osteogenic differentiation 
medium.   
Histological analyses confirmed the presence of mineralized regions in pore 
spaces adjacent to the polymer scaffold (Figure 6-3A).  Although cells were present 
throughout the constructs, metabolically active cells, those producing significant 
quantities of mineralized matrix, were primarily confined to the outer 100-250 µm of the 
scaffold periphery (Figure 6-3B), an artifact commonly observed for statically-cultured 3-
D constructs (Ishaug et al., 1997).  This phenomenon was consistent for both Runx2-
transduced and control cell-seeded scaffolds and confirmed by cross-sectional analysis of 
micro-CT micrographs (Figure 6-3C).          
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Figure 6-3.  Histological sections of an in vitro cultured Runx2-transduced 
cell-seeded PLGA scaffold at 56 days.  (A) Full cross-section of a hematoxylin-
eosin-stained Runx2-modified stromal cell-seeded scaffold at 56 days (bar = 1 
mm).  (B) High magnification histological micrograph of region shown in A (bar 
= 100 µm). (C) Cross-section of a reconstructed micro-CT image of a Runx2 cell-
seeded scaffold following 56 days of static in vitro culture demonstrating 





In vitro construct development and Runx2 expression synergistically enhance in vivo 
mineralized tissue formation 
The ability of these tissue-engineered constructs to promote in vivo mineralization 
was evaluated in a heterotopic, subcutaneous site.  This is a stringent implantation model 
to examine the in vivo mineralization capacity of an osteogenic cell source due to the 
absence of regenerative and osteoinductive cues typically present in orthotopic defects.  
In addition to investigating the effects of Runx2 overexpression, the contributions of in 
vitro construct development to in vivo mineralization were analyzed.  The rationale for 
these studies was that in vitro mineralization prior to implantation may provide a 
template for subsequent in vivo mineralization.  Three stages of in vitro construct 
maturity were examined:  (i) cell-scaffold constructs with minimal cell-mediated matrix 
(1 day post-seeding, cultured in growth media lacking osteogenic supplements), (ii) 
constructs containing more significant quantities of organic matrix prior to mineralization 
(7 days of pre-culture in osteogenic media), and (iii) constructs having significant 
amounts of mineralized matrix (21 days of in vitro culture in osteogenic media).   
Following 28 days of subcutaneous implantation, relatively insignificant amounts 
of in vivo mineral formation (<0.1 mm3 mineral volume, Figure 6-4A) were observed by 
micro-CT for both Runx2-expressing and control cell-seeded constructs cultured for 
either 1 or 7 days prior to implantation.  In contrast, constructs pre-cultured for 21 days 
prior to implantation exhibited a dramatic increase in mineral volume (Fig. 6-4A-C), 
indicating that in vitro construct development enhances in vivo mineralization in this 
subcutaneous model.  More importantly, following 21 days of pre-culture, constructs 
containing Runx2-modified cells displayed 10-fold more mineral volume than control 
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scaffolds after 28 days of subcutaneous implantation (Figure 6-4A-C).  This 10-fold 
enhancement of in vivo mineralization was significantly higher than the 2.5-fold increase 
observed between parallel Runx2-modified cell-seeded constructs maintained for similar 
durations in vitro (Figure 6-2B).  In vivo mineralization enhancement was not a simple 
consequence of the presence of more in vitro mineral prior to implantation, but instead, 
was synergistically up-regulated by Runx2 overexpression in the implanted cells.  
Specifically, comparative analysis between total mineral volume present on in vitro 
constructs following 21 days of pre-culture (Figure 6-4C, left bars) and 28 day in vivo 
explant constructs (Figure 6-4C, right bars) revealed a greater than 5-fold faster average 
daily mineral deposition rate for Runx2-modified constructs (0.32 mm3/day) compared to 
controls (0.06 mm3/day).  Collectively, these results indicate an interaction between in 
vitro culture duration and Runx2 overexpression which acted synergistically to up-
regulate the in vivo mineralization of tissue-engineered constructs. 





Figure 6-4.  Mineralization of 3-D PLGA scaffolds seeded with Runx2-
expressing or control cells and implanted subcutaneously for 28 days 
following various in vitro pre-culture conditions.  (A) Total mineralized matrix 
volume quantified by micro-CT following various in vitro pre-culture durations 
and subsequent 28 day subcutaneous implantation [(mean,SEM), n=5].  ANOVA 
showed significance in treatment and in vitro culture time (p<0.000001).  Pairwise 
comparison: ** greater than 21 day control and 1 and 7 day pre-cultured, both 
treatments (p<0.00001).  (B) micro-CT images of control (top) and Runx2-
transduced (bottom) cell-seeded scaffolds subcutaneously implanted for 4 weeks 
following 21 days of in vitro development. (C) Total mineral volume quantified 
by micro-CT for (i) 21 day in vitro pre-cultured constructs (0 days in vivo) (n=3) 
and (ii) 28 day explant constructs pre-cultured for 21 days (28 days in vivo) (n=5) 
for Runx2-modified and control cell-seeded constructs.  One-way ANOVA was 
performed on each group, i.e. input constructs (0 days) and explant constructs (28 











































In vitro development 
time (days) Treatment
Control 0.003 ± 0.002
Runx2 0.004 ± 0.002
Control 0.010 ± 0.008
Runx2 0.022 ± 0.009
Control 0.98 ± 0.22





























Histological analyses showed equivalent host tissue responses among cell-free 
scaffolds and cell-seeded constructs, indicating minimal inflammatory/immune response 
to Runx2-modified and control cells (data not shown).  Uniform distribution of 
infiltrating host cells was characteristically observed throughout construct explants which 
had been pre-cultured for either 1, 7, or 21 days prior to implantation (Figure 6-5).  In 
agreement with micro-CT analyses, mineralized regions were not observed in histological 
micrographs (Figure 6-5A and B).  However, significant mineralized regions were 
observed in close association with the scaffold periphery for those constructs pre-cultured 
for 21 days prior to implantation (Figures 6-5C and 6-6).  Furthermore, much higher 
levels of mineralized tissue were observed for constructs containing Runx2-modified 
cells compared to controls.  The peripheral localization of these mineralized areas is 
likely explained by the observation that at the time of implant, matrix and cellular 
distribution were already primarily confined to the outer 100-200 µm of the scaffold 
following only 21 days of in vitro pre-culture (data not shown).  As a result, subsequent 
in vivo mineralization was also confirmed to be peripherally located at the interface of the 




   
Figure 6-5. Histological micrographs of Runx2-modified cell-seeded scaffolds  
implanted subcutaneously for 28 days following 1, 7, and 21 days of in vitro
pre-culture. (A) Hematoxylin-eosin stained Runx2-modified cell-seeded 
scaffolds following 1 day of in vitro maturation and 28 days of subcutaneous 
implantation.  (B) Hematoxylin-eosin stained Runx2-modified cell-seeded 
scaffolds following 7 days of in vitro maturation and 28 days of subcutaneous 
implantation.  (C) Hematoxylin-eosin stained Runx2-modified cell-seeded 
scaffolds following 21 days of in vitro maturation and 28 days of subcutaneous 









Figure 6-6. Histological micrographs of control and Runx2-modified cell-
seeded scaffolds implanted subcutaneously for 28 days following 21 days of in 
vitro pre-culture. von Kossa-nuclear fast red stained (A) Control and (B) Runx2-
modified cell-seeded scaffolds following 21 days of in vitro maturation and 28 
days of subcutaneous implantation (bar = 1 mm).  (C) High magnificatio n 
micrograph of inset in A (bar = 100 µm).  (D) High magnification micrograph o f 
inset in B (bar = 100 microns). 
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DISCUSSION 
Isolation, expansion, and controlled phenotypic maturation of cells capable of 
robust osteoblastic differentiation and matrix deposition represent critical steps in the 
successful clinical application of bone tissue engineering approaches.  To date, several 
groups have demonstrated the potential of bone marrow-derived progenitors as candidate 
osteogenic cells in model systems (Ohgushi et al., 1993; Ishaug-Riley et al., 1997; 
Kadiyala et al., 1997), yet the ultimate application of this cell type to tissue engineering is 
limited by the ability to harvest sufficient cell numbers and maintain their osteogenic 
differentiation capacity in ex vivo culture environments.  To address these cell sourcing 
limitations, retroviral gene delivery to constitutively overexpress the osteoblast-specific 
transcriptional activator Runx2 was examined in this study.   The evaluation of Runx2-
modifed stromal cells incorporated into 3-D scaffolds builds upon the rigorous in vitro 
analyses of monolayer cultures as described in Chapter 5, in which it was demonstrated 
that Runx2 overexpression in stromal cells significantly increased osteoblast-specific 
gene and protein expression and matrix mineralization.  Notably, Runx2-transduced 
stromal cells produced a robust mineralized matrix compared to controls following 3-D in 
vitro culture (Figure 6-2A-C), indicating their responsiveness to Runx2 overexpression 
throughout the duration of the complex, time-dependent osteoblastic differentiation 
cascade. 
Runx2-expressing bone marrow stromal cells also up-regulated in vivo 
mineralization compared to control cells (Figure 6-4 and 6-5).  These results contrast 
recent reports of Runx2 overexpression in other cell types using adenoviral gene delivery.  
Yang et al. implanted Runx2-expressing pluripotent C3H10T1/2 cells subcutaneously and 
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showed sparse bone and cartilage-like tissue formation at levels considerably lower than 
BMP-2-expressing cells (Yang et al., 2003).  Hirata and colleagues implanted scaffolds 
seeded with primary skin fibroblasts overexpressing Runx2 into craniotomy defects and 
observed negligible bone-like tissue formation by Runx2-modified cells in vivo (Hirata et 
al., 2003).  Several factors, such as cell type, transgene expression duration, and in vitro 
construct development, could be responsible for these contradictory observations.  For 
instance, as observed in Chapter 4, exogenous Runx2 expression was not sufficient to 
promote significant in vitro mineralization in either primary fibroblasts or C3H10T1/2 
cells (Byers et al., 2002).  Furthermore, dexamethasone supplementation up-regulated in 
vitro mineralization by Runx2-modified stromal cells (Chapter 5).  Taken together, these 
results suggest the existence of additional pathways or factors which act either in series to 
complement Runx2 activity or in parallel cascades to supplement the physiologic role of 
Runx2 in directing terminal differentiation of osteoblasts.  Currently, the complex 
interactions of these pathways and factors in the complete osteoblastic differentiation 
process and specifically in Runx2 transactivation/repression are not well understood.  As 
a result, significant attention must be directed toward target cell selection and gene 
delivery approaches for bone tissue engineering applications. 
It was demonstrated that in vitro construct development to create mineralized 
templates, especially when combined with Runx2 overexpression, enhances in vivo 
mineralization in an ectopic implantation site (Fig. 6-4A-C).  These results provide a 
promising templating tissue engineering strategy to develop bone grafting substrates, in 
which osteogenic cell-scaffold constructs are matured under osteogenic culture 
conditions to create mineralized templates, and then implanted into a defect site to 
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facilitate healing.  This approach is fundamentally different from typical in vivo models 
for tissue-engineered bone substitutes, which focus on direct implantation of scaffolds 
immediately following cell seeding and/or ex vivo genetic modification of target cells 
(Ishaug-Riley et al., 1997; Kadiyala et al., 1997; Lieberman et al., 1999; Krebsbach et al., 
2000).  These techniques, while successful in model systems, result in the implantation of 
a relatively undeveloped construct.  Consequently, the active contribution of the 
implanted cells to the healing process may actually be limited due to the infiltration of 
high quantities of host cells into the defect site.  This scenario provides a likely 
explanation for the current results, in which immature, non-mineralized constructs (1 or 7 
days of in vitro pre-culture) failed to produce significant quantities of mineralized tissue 
in vivo compared to more mature, mineralized constructs which had been pre-cultured in 
vitro for 21 days prior to implantation.     
Finally, Runx2 overexpression and in vitro construct development synergistically 
enhanced in vivo mineralization compared to in vitro construct development or genetic 
engineering alone.  This interaction presents further evidence that construct 
mineralization prior to implantation enhances subsequent in vivo mineralization and 
construct performance in this subcutaneous model by providing a mature, mineralized 
template prior to implantation.  These results suggest this novel integrated genetic and 
tissue engineering strategy to create mineralized bone grafting templates may overcome 
limitations associated with conventional genetic and tissue engineering approaches, 





EVALUATION OF RUNX2-TRANSDUCED CELLS SEEDED IN FUSED 
DEPOSITION-MODELED POLYCAPROLACTONE SCAFFOLDS BOTH IN 
VITRO AND IN A CRANIOTOMOY DEFECT MODEL  
 
INTRODUCTION 
Runx2 overexpression in bone marrow-derived stromal cells significantly 
enhanced 2-D and 3-D in vitro osteoblastic phenotype expression (Chapters 5 and 6), 
specifically through increases in osteoblastic gene expression, alkaline phosphatase 
activity, and matrix mineralization.  Additionally, Runx2-expressing stromal cells and in 
vitro pre-culture synergistically enhanced in vivo mineralization of 3-D polymeric 
scaffolds in a subcutaneous implantation model.  These initial studies were of significant 
scientific interest toward validating this genetic and tissue engineering methodology; 
however, the ultimate effectiveness and potential of this strategy will be validated 
through examination of the ability of Runx2-modified stromal cells to facilitate healing of 
critical size bone defects. 
Craniotomy defect studies are a common, non-loaded critical size defect (CSD) 
model, in which an osseous defect of sufficient size is created to prohibit spontaneous 
healing during the lifetime of the animal (Schmitz and Hollinger, 1986).  The rat CSD 
model has been commonly used in characterizing a broad range of therapeutic healing 
mechanisms including recombinant BMP delivery and gene delivery techniques to 
deliver a variety of soluble osteoinductive and mitogenic agents which facilitate defect 
healing (Kenley et al., 1994; Hollinger et al., 1998; Krebsbach et al., 2000; Gysin et al., 
2002; Hirata et al., 2003).  The accepted defect size in rat craniotomy studies is 8 mm in 
diameter, which has been characterized as non-healing beyond three months (Schmitz 
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and Hollinger, 1986; Schmitz et al., 1990).  Additionally, the healing response 
demonstrated in these models has been largely attributed to progenitor cells in the dura as 
opposed to ingrowth of cranial bone from the periphery of the defect (Wang and 
Glimcher, 1999).  Although sensitive in nature due to the proximity of the defect to the 
brain, the craniotomy defect model was in principle a logical selection for an initial 
characterization of Runx2-modified cells.  Other bone defect models, such as the femoral 
segmental defect model, require accessory fixation devices which definitively complicate 
surgical techniques and may potentially introduce even greater variability amongst 
subjects.  Furthermore, the current work involved genetic manipulation of rat primary 
bone marrow stromal cells; however, an autologous implantation model was impractical 
based on the study parameters.  Therefore, a rat syngeneic implantation study was 
selected as an alternative strategy in order to minimize experimental complications 
arising from immuno-rejection of the implanted cells.   
The evaluation of Runx2-modified stromal cells in any bone defect model 
requires the identification of a suitable scaffold carrier for cellular delivery and 
implantation.  Based on the outcomes of the subcutaneous implantation model (Chapter 
6), it was of particular interest to further examine the role the interactive role of Runx2 
overexpression and in vitro construct maturation on subsequent healing in a bone defect 
model.  Based on the previous study, the pre-culture conditions selected for the 
craniotomy model would play a significant role toward identifying characteristic 
requirements, specifically the mechanical integrity, of a candidate carrier matrix/scaffold 
for the delivery of Runx2-modified cells.  Although a modest increase in in vivo 
mineralization occurred by extending in vitro pre-culture time from 1 to 7 days, the most 
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significant enhancement in subsequent in vivo performance was observed in constructs 
matured for 21 days prior to implantation.  Therefore, two construct development 
conditions were selected for the craniotomy defect model: (i) 1 day of in vitro culture 
following cell seeding, a condition which reflects the typical protocol for implantation of 
genetically modified osteogenic/osteoinductive cells and further represents a relatively 
immature construct and (ii) constructs pre-cultured for 21 days, a time point beyond the 
onset of in vitro mineralization which therefore provides a more mature, mineralized 
template in the defect site.  Previous 3-D in vitro culture studies involving Runx2-
modified and especially control cell-seeded PLGA scaffolds demonstrated a pronounced 
cell-mediated scaffold contraction following extended in vitro culture, even in as little as 
21 days (Figure 6-2D).  Therefore, to ensure the implantation of constructs of similar size 
and pore architecture independent of in vitro culture parameters, it was necessary to 
identify a scaffold material possessing sufficient mechanical integrity to resist cell-
mediated contraction.  Furthermore, similar to previous subcutaneous studies, it was of 
interest to evaluate the performance of Runx2-modified cells on a polymeric scaffold 
which was deficient in osteoconductive properties characteristic of bioceramics.  Poly(ε-
caprolactone) (PCL) fused deposition-modeled scaffolds (Hutmacher et al., 2001; Zein et 
al., 2002) were selected as an appropriate biodegradable, polymeric scaffold.  PCL is an 
FDA-approved bioresorbable polymer which provided suitable mechanical integrity to 
resist previously observed cell-mediated contraction artifacts.  Additionally, the fused 
deposition manufacturing technique provided a completely interconnected honeycomb-
like architecture at a prescribed pore size (300-500 µm). 
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Prior to in vivo implantation, an in vitro characterization scheme similar to that 
performed for PLGA cell-seeded scaffolds (Chapter 6) was instituted for Runx2-modified 
and control cells seeded on PCL scaffolds.  Runx2-modified stromal cells significantly 
enhanced matrix mineralization in 3-D in vitro culture.  Furthermore, Runx2-modified 
and control cell-seeded PCL scaffolds were implanted into critical size craniotomy 
defects (CSD) in syngeneic rats.  Consistent with the subcutaneous results, defects 
receiving 21 day in vitro pre-cultured constructs seeded with Runx2-modified cells 
demonstrated greater amounts of new bone formation than similarly pre-cultured control 
stromal cell-seeded scaffolds.  However, scaffolds implanted immediately upon cell-
seeding demonstrated greater amounts of new bone formation than constructs pre-
cultured for 21 days independent of cell treatment, suggesting that the architecture and 
physical nature of these PCL scaffolds was conducive to bone formation and promoting 
defect healing in the absence of cell loading in this particular critical size defect model. 
              
MATERIALS AND METHODS 
Stromal cell isolation and retroviral transductions  
Primary bone marrow stromal cells were isolated from the femora of 6-week-old 
young adult male Wistar rats (Maniatopoulos et al., 1988) and expanded in culture for 7 
days prior to retroviral transduction as described (Chapter 5).  Runx2-transducing and 
control (no Runx2 insert) retroviruses were produced using standard techniques and sub-
confluent cultures of target cells were transduced with retroviruses (1-2 x 105 cfu/ml viral 

















Cell culture and construct preparation   
Following transduction, cells were seeded 2 days post-transduction at 5×105 
cells/scaffold onto fused deposition-modeled PCL scaffolds (8.1 mm diameter × 2.4 mm 
thick, 300-500 micron pore size, 66% porosity) (Zein et al., 2002).  To enhance initial 
cell adhesion, constructs were pre-coated in a solution of rat plasma fibronectin in PBS 
(20 µg/mL).  During in vitro culture, constructs were maintained statically in osteogenic 
media (α-minimum essential medium, 10% fetal bovine serum, 1% penicillin-
streptomycin, 50 µg/ml gentamicin sulfate, and 0.3 µg/ml fungizone, 50 µg/ml L-ascorbic 
Figure 7-1.  Micro-CT and SEM micrographs of fused deposition-modeled 
polycaprolactone scaffolds. (A) Top-down (left) and angled profile (right) 
micro-CT images of 8.1 mm × 2.4 mm polycaprolactone disks.  (B) Top-down 




acid, 3 mM sodium β-glycerophosphate, and 10 nM dexamethasone).  Media was 
changed every other day. 
 
Confocal microscopy 
 Viability staining was performed on cell-seeded constructs using a calcein-
AM/ethidium homodimer Live/Dead assay kit (Molecular Probes, Eugene, OR) 
according to the manufacturer’s instructions, and specimens were viewed on a Zeiss 
LSM/NLO 510 Confocal/Multi-Photon microscope. 
 
Fourier Transform Infrared Spectroscopy (FT-IR) 
FT-IR analyses were performed as described (Bonewald et al., 2003) on bulk 
phase ethanol-fixed, oven-dried constructs, in which mineralized cultures were gently 
scraped from the underlying PCL substrate using a small blade and stereomicroscope, 
and prepared in potassium bromide (KBr) pellets.  Spectra, 64 scans acquired at 4 cm-1, 
were obtained on a Nexus 470 FT-IR spectrometer (ThermoNicolet, Madison, WI) under 
N2 purge.  A spectral range from 400-2000 cm-1 was analyzed for mineral and matrix 
peaks characteristic of the mineral phase of bone.  The bands of interest were those of 
mineral phosphate (900-1200 cm-1), matrix amide I (1585-1720 cm-1), and carbonate 
(855-890 cm-1).  The mineral to matrix and carbonate to phosphate ratios were computed 
from the integrated areas of baseline-corrected peaks.  Rat calvarial bone, lyophilized, 
pulverized, and similarly prepared in KBr pellets, served as a positive control. 
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Scanning Electron Microscopy (SEM) 
Following overnight fixation in Karnovsky’s fixative (2.0% paraformaldehyde, 
2.5% glutaraldehyde, and 0.1 M sodium cacodylate buffer, pH 7.2-7.4), mineralized  
constructs were rinsed two times in 0.1 M sodium cacodylate buffer and dehydrated in a 
series of graded alcohol (70%, 80%, 90%, 95%, 100%) for 2×5 min and slowly dried in 
and hexamethyldisilazane (EM Sciences, Hatfield, PA).  Samples were then sputter-
coated with gold and visualized using a Hitachi S800 FEG scanning electron microscope. 
    
Craniotomy defect surgeries   
Adult male Wistar rats (~250 g, Charles Rivers Laboratories) served as syngeneic 
recipients of tissue-engineered constructs.  All surgical and implantation procedures were 
performed in accordance to an IACUC-approved protocol.  Briefly, animals were 
anesthetically induced with 4% isoflurane/O2 gas mixture, and the incision site and 
surrounding area were shaved and cleaned with chlorhexidine.  During surgery, 
anesthesia was reduced to 2% isoflurane/O2 or lower as necessary.  A midline incision in 
the skin was made over the cranium from the middle of the nasal bones to the posterior 
nuchal line.  The periosteum was then dissected from the site, and the critical size 
craniotomy defect was made using a slow speed (500 rpm) Osada Electric Co. dental tool 
and trephine (8.95 mm O.D.) (Ace Surgical Supply Co., Brockton, MA).  The calvarial 
disks were carefully removed to avoid dural perforation.  The implementation of a 
consistent surgical technique resulted in a high success rate with minimal compromise of 
dural integrity.  The trephine was used to completely perforate the periphery of the defect 
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in all locations except the rostral and caudal (anterior and posterior) midline sagittal 
sutures areas.  A thin connection of bone remained attached at each of these two 
locations.  A forked periosteal elevator and thin periosteal elevator were then used in 
tandem to gently pry up the caudal sagittal suture region.  Next, the thin elevator was 
gently slid under the cranial disk and moved slowly toward the rostral sagittal area while 
downward pressure was applied to the caudal half of the detached cranial disk.  After 
positioning the thin elevator near the only remaining site of attachment, continued 
downward pressure was applied to the caudal half of the disk while an upward prying 
motion at the rostral side was used to completely detach the disk.  It was consistently 
observed that progression from the caudal location to the rostral location was the most 
effective technique to avoid dural perforation.   
Residual peripheral bony regions around the periphery were carefully excised 
with either scissors or forceps, and the defect site was then flushed with saline prior to 
insertion of the scaffold implant.  PCL scaffolds were press-fit into the defect.  The 
subcutaneous tissue was sutured to cover the defect site, and the incision was closed with 
surgical staples.  The relative position and size of the defect as well as the placement of 
the scaffold within the defect are detailed in Figure 7-2.  After 28 days of implantation, 
animals were euthanized by CO2 asphyxiation, and defect regions were dissected from 
the cranium with bone cutters and fixed in 10% phosphate-buffered formalin. 
In this study, a total of 6 experimental groups were examined.  The first group, 
termed empty defect, consisted of defects receiving no implanted scaffold.  The second 
group received cell-free PCL scaffold implants.  The third and fourth groups were control 
and Runx2-transduced cell-seeded scaffolds pre-cultured for 1 day, while the fifth and 
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sixth groups consisted of control and Runx2-modified cell-seeded scaffolds developed in 
vitro for 21 days prior to implantation.  The final two sets of experimental groups 
represent two distinct approaches toward the development of tissue-engineered solutions 
for bone repair.  The first set was designed to evaluate a relatively immature scaffold, 
similar to the common approach of implanting scaffolds almost immediately after 
seeding with cells.  The second implant time point, occurring after the onset of in vitro 
mineralization at 21 days, was selected to evaluate a more mature construct 
















Figure 7-2. Photographs and accompanying micro-CT scans of a craniotomy 
defect and implanted scaffold at day 0. (A) Photograph detailing a complete 
defect just prior to implantation.  (B) Photograph of a defect containing a PCL 





In vitro and in vivo mineralization of 3-D scaffolds was quantified by high 
resolution X-ray microcomputed tomography (micro-CT) using a Scanco Medical µCT 
40 imaging system (Bassersdorf, Switzerland).  Formalin-fixed specimens were scanned 
in 70% ethanol at 16 µm voxel resolution.  In vitro cultured constructs were evaluated at 
a threshold corresponding to a linear attenuation of 0.96 cm-1.  Craniotomy explants, 
however, were evaluated at a threshold corresponding to a linear attenuation of 1.68 cm-1, 
a threshold selected to evaluate the average attenuation of slightly less mature, new bone 
formed in healing defect.  Evaluation of in vitro and in vivo specimens used identical 
filter width (1.2) and filter support (2.0) settings.  As a result, of the differences in 
thresholding, the mineral and bone volume data determined for in vitro and in vivo 
constructs, respectively, could not be directly compared.  The reconstructed and 
thresholded 3-D images were evaluated using direct distance transformation methods to 
calculate mineral volume within each construct (Hildebrand et al., 1999).  Data are 
reported as total mineral volume or total bone volume for in vitro and in vivo specimens, 
respectively.  Additionally, bone volume fraction data was tabulated for in vivo 
specimens by dividing the new total bone volume detected within the defect by a total 
average void volume (total pore volume) of 82.1 ± 0.8 mm3.  The individual void volume 
data set used to calculate the total average void volume was generated from parallel 
scaffolds (n=12) having an average total volume of 125.7 ± 0.6 mm3 and a an average 
PCL polymer volume of 42.6 7 ± 0.3 mm3 as determined by micro-CT analysis using an 




Craniotomy defects were bisected along the coronal plane, and one half was 
decalcified in Surgipath (Surgipath Medical Industries, Richmond, IL), dehydrated in a 
graded series of alcohol, and embedded in paraffin using standard techniques.  Serial 
sections were stained with either Masson’s trichrome or hematoxylin and eosin.  Sections 
were examined to assess host immune and inflammatory response to the implanted cells 
and polymer scaffold, respectively.       
 
Histomorphometry 
 Midline sections were examined to assess total new bone formation within the 
defect area.  Quantitative analyses were performed using Image Pro image analysis 
software to determine the total new bone area and the bone area fraction within the 
defects.  The architecture of the PCL enabled straightforward determination of the 
polymer area per section, so in order to normalize for any variability associated with 
scaffold orientation in the defect site, the area devoid of polymer was used to calculate 
the bone area fraction.  Full description and graphic representation of the 








NEW BONE FORMATION AREA
Figure 7-3.  Description of methodology for determination of total bone area 
and bone area fraction from histomorphometrical analyses.  (A) Masson’s 
trichrome stain from PCL scaffold implanted into an 8 mm critical size 
craniotomy defect.  (B)  Contours were drawn around (i) the total cross-sectional 
area of the construct, (ii) the areas of polymer present within the cross-section, and 
(iii) the areas of new bone formation present within the cross-section as indicated 
by the blue staining component of the trichrome stain.  (C) Equations representing 
the calculations for void area and bone area fraction in the defects.









Data are reported as mean ± SEM, and statistical comparisons were based on 





Runx2 expression increases 3-D construct in vitro mineralization 
Based on previous 3-D culture experiments (Chapter 6), it was anticipated that 
Runx2-modified stromal cells would significantly enhance in vitro mineralization of PCL 
scaffolds.  As previously described, transduction efficiencies were determined by flow 
cytometry at the time of scaffold seeding, and levels were equivalent to previous 
observations (~50%) for both Runx2-transduced and control cells.  Quantification of 
DNA 24 hours after cell seeding demonstrated equal numbers of Runx2-modified or 
control cells were seeded onto the constructs (data not shown).  Scaffold colonization and 
cellular longevity was examined by a cell viability assay and confocal microscopy at 1, 7, 
21, and 56 days post-seeding (Figure 7-3).  Observations at 1 day post-seeding indicated 
cells were sparsely covering the scaffold, yet they attained a rather spread morphology 
and were fairly well distributed.  The scaffolds were typically confluent by 7 days, and 
cells began bridging struts and in some cases filling large pore voids by 21 days.  
Demonstrating their ability to be maintained under long term in vitro culture conditions, 
both Runx2-modified and control stromal cells remained viable and had undergone 
extensive proliferation by 56 days as observed by confocal microscopy.  Specifically, a 
high percentage of the pore structures were occupied by a circular ring of cells which 
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bridged struts running in multiple directions.  Relatively few dead cells were observed at 
any of the time points examined, and both Runx2-modified and control cells followed 
similar trends toward scaffold colonization.   
 
Figure 7-4.  Confocal micrographs of Runx2-modified cell-seeded PCL 
scaffolds at multiple time points. Cell-seeded scaffolds following (A) 1 day, (B) 
7 days, (C) 21 days, and (D) 56 days of in vitro culture [bar in (A) = 250 µm, bar 
in (B, C, D) = 500 µm].  Control cell-seeded scaffolds demonstrated similar levels 






 Mineralization was quantified weekly by micro-CT beginning at 21 days post-
seeding (Figure 7-4).  Large quantities of mineralized matrix were already present at 21 
days, especially on Runx2-modified cell-seeded PCL scaffolds.  In agreement with the 
cell viability study and the presence of living cells, a steady, linearly increasing amount 
of mineralization was observed in both Runx2-transduced and control cell-seeded 
scaffolds.  However, the average rate of mineral deposition was significantly higher in 
Runx2-modified cells compared to control cells (p<0.02).  Specifically, Runx2-modified 
cells deposited 1.4 ± 0.1 mm3 of mineral per week, whereas control stromal cells added 
on average only 0.9 ± 0.1 mm3 of mineral per week.  This nearly 60% difference in 
mineral deposition rate indicated that the observed differences in the quantity of 
mineralized tissue at specific time points was not attributable merely to an acceleration in 
mineral deposition by Runx2-modified cells.  Rather Runx2 overexpression enhanced the 
overall mineralized matrix-producing potential of stromal cells maintained in the 
described 3-D environment. 
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Figure 7-5.  Mineralization of 3-D fused deposition-modeled PCL scaffolds by 
Runx2-transduced and control cells at various time points. (A) micro-CT 
images of control and Runx2-expressing cell-seeded PCL scaffolds following 21 
days (A) and 56 days (B) of in vitro culture. (C) Quantification of mineral 
deposition my micro-CT at various time points [(mean, SEM), n=6].  ANOVA 
showed differences between treatment and time (p<0.000001).  Pairwise 












21 28 35 42 49 56



































Examination of micro-CT micrographs confirmed the presence of significantly more 
mineral present on Runx2-modified cell-seeded scaffolds compared to controls.  By 56 
days, mineralized regions were clearly visible on all struts of Runx2-modified cell-seeded 
scaffolds, including those on the periphery and on either face of the construct.  In 
contrast, mineralization on control scaffolds remained primarily confined to peripheral 
locations.  Somewhat surprisingly based on the open architecture of the scaffold and even 
though ample cell colonization was observed throughout all regions of the scaffold by 
confocal microscopy, mineralized regions were primarily confined to the outer surfaces 
of the scaffold.  At the outset of the study, it was anticipated that the open macrostructure 
of the fused deposition-modeled scaffolds would facilitate more homogeneous 
mineralization due to an anticipated enhancement of localized nutrient transport in the 
larger pore structures.  This response was not observed, however, suggesting the 
continued persistence of local mass transfer barriers which limit the ability of centralized 
cells to fully differentiate.  Histological analyses confirmed the presence of mineralized 
regions in peripheral locations similar to those observed my micro-CT, yet the extremely 
open architecture and in vitro culture system resulted in the presence of only small 
quantities of tissue (data not shown).         
 
Runx2-modified and control cell-seeded scaffolds produce a biologically equivalent, 
collagen-associated  mineralized matrix 
 FT-IR analysis performed on 56 day in vitro constructs revealed Runx2-modified 
and control stromal cell cultures displayed the amide I and II peaks indicative of protein, 
a broad phosphate stretching peak near 1100 cm-1, a phosphate bending doublet split at 
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560 cm-1 and 605 cm-1, and a carbonate peak near 870 cm-1 (Figure 7-7A).  These 
chemical moieties are representative of a poorly crystalline apatite (Bonewald et al., 
2003) and were similar to that observed for a native cranial bone specimen.  To further 
analyze the relative maturity of the matrix, the mineral to matrix and carbonate to 
phosphate ratios were determined, and no significant differences existed between the 
treatments or compared to the cranial bone positive control (Figure 7-7B).  Taken 
together, these results demonstrate that exogenous Runx2 expression up-regulates 
formation of a biologically equivalent mineralized matrix.  Examination of cultures by 
SEM revealed the presence of freshly deposited fibrillar collagen (Figure 7-6A) as well 
as collagenous meshes containing significant quantities of mineral (Figure 7-6B). 
 
 
Figure 7-6.  SEM micrographs of 56 day Runx2-modified cell-seeded 
constructs. (A) SEM micrograph detailing a representative region of 
unmineralized fibrillar collagen, which is actually overlaying mineralized collagen 
beneath.  (B) SEM micrograph showing a region of mineralized collagen, 




Figure 7-7. Comparative FT-IR spectra of Runx2-modifed and control bone 
marrow stromal cells on PCL scaffolds following 56 days of in vitro culture.  
Adult rat cranial bone was included as a positive control.  (A) Transmission 
spectra, generated from bulk phase, ethanol fixed cultures carefully extracted from 
the underlying PCL scaffold and pressed into KBr pellets, showed bands 
characteristic of biological hydroxyapatite formation, including phosphate- and 
carbonate-related vibrations.  st: stretching vibrations, bd: bending vibrations.  (B) 
Comparative ratios, including the mineral to matrix (900-1200 cm-1 to 1585-1720 
cm-1) and carbonate to phosphate (855-890 cm-1 to 900-1200 cm-1 ), were 
calculated from baseline-corrected, integrated peak areas [(mean,SEM), n=6].  No 
statistical differences were observed between Runx2 and control specimens 
compared to that observed in native cranial bone.
A
B
Cranial Bone 5.3 ± 0.1 0.015 ± 0.001
Control 4.9 ± 0.6 0.013 ± 0.001
Runx2 6.3 ± 0.4 0.013 ± 0.001


































Histological evaluation of experimental groups 
 No severe immune or inflammatory responses were observed in any of the cell-
containing groups examined, suggesting that minimal adverse reaction to the implanted 
cells or PCL scaffold material had occurred (Figure 7-8).  Formation of new bone 
appeared normal, resulting in embedded osteocytes and marrow ossicles, and none of the 
groups revealed abnormal osteoclastogenesis.  Void spaces not filled with new bone were 
filled with soft connective tissue which lacked any detectable inflammatory cells, 
including macrophages.  As a result of the decalcification, mineralized tissue resident 
near the scaffold surface/interface of experimental groups containing implanted cells, 
especially those pre-cultured in vitro for 21 days, could not be distinguished from other 
soft connective tissue present in the void spaces of the PCL scaffold. 
   
Micro-computed tomography and histomorphometric analyses of in vivo scaffolds 
 Based on the results of in vitro studies and the subcutaneous implantation model 
which revealed a synergistic interaction between Runx2 overexpression and in vitro 
construct development, it was of particular interest to examine similar parameters in an in 
vivo bone healing environment.  Following 28 days of in vivo implantation, explant 
constructs were evaluated by micro-CT to determine new bone volume and bone volume 
fraction data and by histomorphometry to quantify new bone area and bone area fraction 
data.  All experimental groups demonstrated a healing response as determined by both 
characterization methods (Figures 7-9 through 7-12).   
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Figure 7-8.  Hematoxylin-eosin staining of cell seeded scaffolds following 28 
days in vivo implantation. (A) Control cell-seeded scaffold pre-cultured for 1 
day prior to implantation. (B) Runx2-modified cell-seeded scaffold pre-cultured 
for 1 day prior to implantation. (C) Control cell-seeded scaffold pre-cultured for 
21 days prior to implantation. (D) Runx2-modified cell-seeded scaffold pre-
cultured for 21 days prior to implantation.  Similar morphologies were detected in 






Figure 7-9.  Micro-CT and radiograph images of complete skulls and 
contoured craniotomy defect areas for experimental groups.  Contoured 
regions of the defects from each group were used for quantification of new bone 
formation by micro-CT.  Images shown are representative complete skulls (micro-
CT top left, radiographs bottom left) and 0.545 cm2 (8.3 mm diameter) contoured 
defects (right), providing an approximate tolerance of 0.2 mm to the diameter o f 
the implanted construct.  Groups shown are PCL scaffolds seeded with control (A) 
or Runx2-transduced (B) stromal cells pre-cultured for 1 day, PCL scaffold seeded 
with control (C) or Runx2-modified (D) stromal cells pre-cultured for 21 days, or 




Control, 1 day in vitro Runx2, 1 day in vitro
Control, 21 days in vitro
Empty defect Cell-free scaffold








Figure 7-10.  Histological micrographs from midline sections of craniotomy 
defects stained with Masson’s modified trichrome.  Representative sections 
from each group were used for histomorphometric analysis, including PCL 
scaffolds seeded with control (A) or Runx2-transduced (B) stromal cells pre-
cultured for 1 day, PCL scaffold seeded with control (C) or Runx2-modified (D) 
stromal cells pre-cultured for 21 days, empty defect (E), and PCL scaffold with no
cells (F) (bar = 1 mm).
Control, 1 day in vitro
Runx2, 1 day in vitro
Control, 21 days in vitro
Empty defect
Cell-free scaffold
Runx2, 21 days in vitro
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Figure 7-11.  Micro-CT total bone volume and bone volume fraction data and 
histomorphometric total bone area and bone area fraction data from 28 day 
craniotomy defect explants, including control and Runx2-modified cell-seeded 
PCL scaffolds pre-cultured for either 1 or 21 days. (A) Total bone volume 
from micro-CT data (mean, SEM).  One-way ANOVA showed differences in 
groups (p<0.001).  Pairwise comparisons: greater than control cell, 21 day pre-
cultured constructs, * (p<0.005); ** (p<0.05).  (B) Bone volume fraction data 
determined by normalizing the total bone volume by the average void volume o f 
PCL scaffolds (mean, SEM). One-way ANOVA showed differences in groups 
(p<0.001).  Pairwise comparisons: greater than control cell, 21 day pre-cultured 
constructs, * (p<0.005); ** (p<0.05).  (C) Total bone area from histomorphometry 
data (mean, SEM).  One-way ANOVA showed differences in groups (p<0.01).  
Pairwise comparisons: greater than control cell, 21 day pre-cultured constructs, * 
(p<0.03); ** (p<0.01).  (D) Bone area fraction data determined by normalizing the 
total bone area by the void area for each section (mean, SEM).  One-way ANOVA 
showed differences in groups (p<0.001).  Pairwise comparisons: greater than 













Control, 21 days in vitro; n=8
Runx2, 21 days in vitro, n=7
Control, 1 day in vitro; n=5






































































Figure 7-12.  Micro-CT total bone volume and bone volume fraction data and 
histomorphometric total bone area and bone area fraction data from 28 day 
craniotomy defect explants, including empty defects, PCL scaffolds with no 
cells, and control and Runx2-modified cell-seeded PCL scaffolds pre-cultured 
for 21 days. (A) Total bone volume from micro-CT data (mean, SEM).  One-way 
ANOVA showed differences in groups (p<0.00002).  Pairwise comparisons : 
greater than empty defect, * (p<0.0001), ** (p<0.005); greater than control cell, 
21 day pre-cultured constructs, † (p<0.0005); †† (p<0.02).  (B) Bone volume 
fraction data determined by normalizing the total bone volume by the average 
void volume of PCL scaffolds (mean, SEM). One-way ANOVA showed 
differences in groups (p<0.0005).  Pairwise comparisons: greater than control cell, 
21 day pre-cultured constructs, † (p<0.0005); †† (p<0.01).  (C) Total bone area 
from histomorphometry data (mean, SEM).  One-way ANOVA showed 
differences in groups (p<0.01).  Pairwise comparisons: greater than empty defect, 
* (p<0.02); greater than control cell, 21 day pre-cultured constructs, † (p<0.05).  
(D) Bone area fraction data determined by normalizing the total bone area by the 
void area for each section (mean, SEM).  One-way ANOVA showed differences in 
groups (p<0.01).  Pairwise comparisons: greater than control cell, 21 day pre-
cultured constructs, † (p<0.01); †† (p<0.05).
Empty defect; n=7
Cell-free scaffold; n=7
Control, 21 days in vitro; n=8














































































Examination of the effects of in vitro pre-culture revealed a quite different result 
than that observed in the subcutaneous implantation study previously described (Chapter 
6).  Specifically, defects containing constructs pre-cultured for only 1 day demonstrated 
the highest total bone volume and bone area independent of cell treatment (Figure 7-11).  
Furthermore, defects treated with cell-free PCL scaffolds exhibited comparable degrees 
of healing (Figure 7-12), suggesting that in this particular bone defect model, the open 
architecture and interconnected structural network of the fused deposition-modeled 
scaffolds provided a suitable osteoconductive scaffold capable of supporting significant 
new bone formation by infiltrating host cells.  Interestingly, extended in vitro pre-culture 
appeared to have a negative effect on new bone formation in defects treated with 
constructs containing control stromal cells pre-cultured for 21 days prior to implantation, 
as this group contained significantly less new bone formation than all other treatments 
evaluated (Figures 7-11 and 7-12).  However, Runx2-modified cell-seeded scaffolds pre-
cultured for 21 days contained significantly more new bone volume, nearly 2-fold 
greater, than similarly pre-cultured control cell-seeded scaffolds.  Furthermore, no 
differences in bone volume or area existed between Runx2-transduced cell-seeded 
scaffolds pre-cultured for 21 days and the 1 day pre-culture and cell-free groups (Figures 
7-11 and 7-12).  Although the relative differences in histomorphometric data persisted 
between the 21 day pre-cultured groups, statistically significant differences in bone area 
or bone area fraction were not observed.  This observation is not entirely unexpected 
based on the non-uniform distribution of new bone formation as revealed by micro-CT or 
the potential for slightly offset micro-CT threshold values.  These findings suggest that 
Runx2 overexpression in bone marrow stromal cells is capable of overcoming the 
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observed inhibitory effect on new bone formation observed in response to in vitro pre-
culture of constructs containing unmodified stromal cells.  The parameters of the current 
study did not allow for determination of the method by which Runx2-modified cells 
induced higher levels of new bone formation.  The two most likely mechanisms are (i) 
through cell-mediated secretion of soluble osteoinductive factors subsequent to 
implantation or (ii) through the development of a more robust osteoinductive, 
osteoconductive, and biologically active matrix synthesized ex vivo prior to implantation.   
Finally, the implantation of unmodified 21 day pre-cultured stromal cell-seeded 
scaffolds, containing cells not exposed to viral treatment, demonstrated levels of new 
bone formation equivalent to control cell-seeded scaffolds, suggesting a muted immune 
response to any residual viral particles and proteins (data not shown). 
As stated, new bone formation was quite prevalent in defects receiving cell-free 
PCL scaffolds (Figure 7-12).  The mean bone volume and bone area were comparable to 
that observed in the 1 day pre-cultured cell-seeded experimental groups and significantly 
higher than that observed in 21 day pre-cultured control cell-seeded scaffolds.  Some of 
the cell-free scaffold implants were pre-cultured for 21 days in vitro in parallel with cell-
seeded scaffolds, while the remainder were implanted following only 1 day of in vitro 
pre-culture.  Importantly, no differences existed in new bone volume between 1 and 21 
day pre-cultured cell-free scaffolds, suggesting that in vitro pre-culture does not alter the 
scaffold properties in a manner which impacts its function in this craniotomy defect 
model.  Although none of the empty defects healed completely, a significant amount of 
new bone formation was formed along the dura in this experimental group (Figures 7-6, 
7-7 and 7-9).  For reference, total new bone volume in the empty defects was nearly 
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equivalent to that observed in 21 day pre-cultured control stromal cell-seeded scaffolds.  
However, direct comparison of total new bone formation in the empty defect group to 
any of the scaffold containing groups proved inappropriate due to the presence of 
significant quantities of PCL scaffold material in the dural plane, which greatly reduced 
the volume/area available for new bone formation.      
 
DISCUSSION 
Runx2 overexpression significantly increased mineralization of 3-D constructs 
following in vitro culture.  A time series quantitative analysis of matrix mineralization 
demonstrated more than a 1.5-fold increase in the average mineral deposition rate by 
Runx2-modified cells.  These results indicate that the observed increase in mineral 
volume at a particular time point is not attributable solely to an acceleration of 
mineralization by Runx2-modified cells, but rather occurs due to an increase in the 
mineralized matrix-producing capacity of a stromal cell population undergoing 
osteoblastic differentiation. 
Subcutaneous implantation of Runx2-expressing stromal cells seeded in PLGA 
scaffolds and pre-cultured in vitro for 21 days resulted in a greater than 10-fold increase 
in mineralization and a 5-fold increase in the average daily rate of mineral deposition 
compared to controls.  However, insignificant quantities of mineral were detected on 
either Runx2-modified or control cell-seeded constructs implanted following 1 day of 
pre-culture (Chapter 6).   These results indicated a synergistic interaction between Runx2 
overexpression and in vitro construct development in the subcutaneous environment.  It 
was, therefore, hypothesized that a similar interaction would facilitate healing of a critical 
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size bone defect.  Evaluation of these parameters in a syngeneic craniotomy defect model 
demonstrated different results than the subcutaneous study, however.  Specifically, 
constructs implanted following 1 day demonstrated the highest levels of new bone 
formation independent of cell treatment, while defects receiving constructs maintained 
under in vitro culture conditions for 21 days contained less and in the case of control 
cells, significantly less, new bone formation.  These results suggest that in this model, a 
defect created by the extraction of bone from a site capable of reasonable spontaneous 
regeneration, in vitro pre-culture of stromal cell-seeded constructs is inhibitory to 
subsequent bone formation.  However, as observed in the subcutaneous model, Runx2-
transduced stromal cells pre-cultured for 21 days elicited significantly more bone 
formation compared to these control cell-seeded scaffolds.  There are several factors and 
differences which potentially address the observed disparity in these experimental 
models. 
The first and potentially most pronounced difference exists at the physiologic 
level of the two models.  Bone defect models in general introduce a significant 
complexity resulting from the presence of endogenous osteoinductive and osteogenic 
factors present in the defect site.  Based on its heterotopic location, these factors are 
notably absent from a subcutaneous implantation site.  As a result, a significant amount 
of endogenous healing is possible in a bone defect model, and factors such as scaffold 
selection and species selection can have a profound impact on the clarity of the model 
and the ability to detect differences among experimental groups.  For example, although 
the rat cranial defect model has been shown to be non-healing out to at least 3 months 
(Schmitz et al., 1990) and the empty defects in the current study remained nonunions at 
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28 days, a significant amount of new bone formation was quantified by both micro-CT 
and histomorphometry.  This suggests limited or at least variable functionality of this 
particular critical size defect model to evaluate the effectiveness of Runx2-transduced 
stromal cells to facilitate defect healing. 
Additionally, the scaffolds used in the two studies were markedly different in 
physical structure and composition.  PLGA is highly porous, possesses minimal 
mechanical integrity, low interconnectivity, and a relatively high surface area to volume 
ratio.  The fused deposition-modeled scaffolds used in the cranial defect study, on the 
other hand, contained fewer but larger pores, were mechanically sound and completely 
interconnected, and had a low surface area to volume ratio.  By virtue of the pores being 
sufficiently large, an exceptional quantity of endogenous signal, in the form of blood 
born cells and soluble factors, was able to infiltrate the scaffold and potentially initiate 
substantial localized bone formation in conjunction with progenitor cells present in the 
dura.  This property, coupled with the interconnected architecture of the scaffold and the 
relatively high rate of spontaneous healing observed in empty defect group, may explain 
the elevated levels of new bone formation observed in cell-free scaffolds.  Furthermore, 
the comparatively low surface area to volume ratio and large pore structure of the PCL 
scaffold resulted in a relatively low therapeutic load factor.  Specifically, the number of 
cells, whether Runx2-modified or control, which were introduced into the defect was 
relatively low compared to alternative scaffolds with higher surface area to volume ratios.  
This artifact was especially significant for the 1 day pre-cultured scaffolds, in which no 
differences existed between Runx2-modified and control cell-seeded scaffolds. 
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A crucial consideration is to clearly identify the attenuating components in the 
two models.  In the subcutaneous explants, the mineral component requires thresholding 
at a much lower level due to its relative low density compared to that necessary to 
accurately detect the opaque structure of native bone, specifically, at threshold of 0.96 
cm-1, the same threshold used to quantify in vitro mineralization of both 3-D PLGA and 
PCL constructs.  Alternatively, the attenuating bone detected in the craniotomy defect 
was thresholded at 1.68 cm-1, a level above the detection limit of in vitro cell-mediated 
mineralization.   As a result, any mineralization present on the PCL constructs prior to 
implantation or deposited subsequently in the defect following implantation would not 
have been detected using the selected threshold.  Therefore, it is important to maintain the 
perspective that different physical structures were being quantified by the two different 
models. 
Nonetheless, extended in vitro pre-culture reduced the amount of new bone 
formation observed in control cell-seeded scaffolds pre-cultured for 21 days prior to 
implantation compared to constructs pre-cultured for 1 day.  It is possible that the 
relatively low therapeutic loading present on 1 day pre-cultured scaffolds actually results 
in minimal signal from the cellular component, and the observed new bone formation 
results from the scaffolds closely approximating the cell-free scaffold group, which 
demonstrated similar levels of new bone formation.  Sikavitsas et al. observed a similar 
trend in response to pre-cultured, stromal cell-seeded titanium meshes (Sikavitsas et al., 
2003).  Constructs pre-cultured under fluid flow conditions for 1 day demonstrated 
enhanced defect healing compared to those pre-cultured for 4 or 8 days (Sikavitsas et al., 
2003).  In the present study, however, scaffold implants containing Runx2-modified cell-
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seeded scaffolds pre-cultured for 21 days enhanced new bone formation compared to 
similarly cultured controls.  Taken together, the results of these two studies underscore 
the importance of matrix maturity and the relative degree of osteoblastic differentiation 
toward enhancing in vivo osteoinductivity of a tissue-engineered matrix.      
Examination of bone volume fraction and bone area fraction data (Figures 7-11 
and 7-12) revealed a fairly consistent offset between the values, as bone area fraction data 
was approximately 10% higher for each of the experimental groups.  While these 
differences could be explained by variability in scaffold orientation and section location 
or the observed non-homogeneity in new bone distribution, an additionally plausible 
explanation involves the threshold selection for micro-CT evaluation.  The value 
selected, corresponding to a linear attenuation of 1.68 cm-1, although justified in 
magnitude based on its correlation to the attenuation of the newly formed native bone, 
may be sufficiently high to exclude less dense or somewhat less mature woven bone that 
is present in the defect.  As histomorphometric analysis was based on visual inspection of 
histological cross-sections, these subtle differences could be more easily taken into 
account.  Other factors which may contribute slightly to the offset include (i) 
overestimating the total bone area due to the inability to distinguish osteoid, or the 
unmineralized portion of the matrix, from that collagenous matrix which was previously 
mineralized due to the fact that these analyses were performed on decalcified sections, 
(ii) failing to subtract large marrow cavities from the total bone area, or (iii) conducting 
the histomorphometric analysis at only one location, in this case the center of the defect 
rather than doing multiple averaging analysis at several locations.  Furthermore, the 
threshold used was nearly double that selected to evaluate in vitro specimens, and 
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evaluation of in vitro scaffolds at this elevated threshold essentially excludes all signal 
detected under the typical attenuation of 0.96 cm-1 used in quantifying mineralization of 
in vitro cultured scaffolds (data not shown).  Therefore, in addition to the exclusion of 
less radio-dense woven bone present in the defect, this threshold restricts the ability to 
quantify the amount of mineralized tissue deposited by Runx2-expressing or control 
stromal cells. 
Several groups have recently examined the Runx2-responsiveness of selected 
target cells for bone tissue engineering applications.  To date, these reports have provided 
mixed indications as to the effectiveness of Runx2 overexpression, largely explained by 
the target cell source or method of Runx2 transduction.  Yang et al. examined adenoviral 
Runx2-expressing pluripotent C3H10T1/2 cells subcutaneously and showed sparse bone 
and cartilage-like tissue formation at levels considerably lower than BMP-2-expressing 
cells (Yang et al., 2003).  Further supporting this observation that exogenous BMP-2 
expression is more effective at promoting bone repair than Runx2, Hirata and colleagues 
implanted scaffolds seeded with primary skin fibroblasts overexpressing either BMP-2 or 
Runx2 into craniotomy defects and observed negligible bone-like tissue formation by 
Runx2-modified cells in vivo, whereas BMP-2-expressing fibroblasts demonstrated 
effective defect healing (Hirata et al., 2003).  Both of these studies examined adenoviral 
gene therapy which admittedly resulted in a rapid decay in transgene expression.  It has 
been proposed that constitutive expression of Runx2 may be required to sustain the 
osteoblastic phenotype (Prince et al., 2001) and data described herein indicates that 
sustained Runx2 overexpression enhances differentiation of osteoblastic cells (Chapter 4 
and 5) (Byers et al., 2002).  As a result, transgene expression duration may have a 
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profound impact on the overall effectiveness of a genetic engineering strategy involving 
Runx2 overexpression.  Furthermore, it has been clearly shown that Runx2 
overexpression alone is not sufficient to direct mineralization of non-osteoblastic target 
cells (Chapter 4) (Byers et al., 2002) and that supplementation with additional 
osteoinductive agents, such as dexamethasone, enhances the activity of exogenous Runx2 
expression.  These results underscore the essential role of Runx2 in osteoblastic 
differentiation, yet clearly demonstrate the requirement of additional factors which act 
either in series or in parallel to potentiate Runx2 overexpression.  Therefore, an 
additional underlying limitation associated with the studies of Yang et al. and Hirata et al. 
in the context of a Runx2 overexpression genetic engineering strategy relates to target 
cell selection. 
The prominence of endogenous healing capacity even in the defects which 
received no implants suggests that this model may not have been sufficiently rigorous to 
adequately evaluate the added benefit of incorporating pre-cultured Runx2-modified cell-
seeded constructs into the defect site.  Alternatively, more challenging models such as a 
segmental defect study, or perhaps even more appropriately, a spine fusion model, which 
was initially completely devoid of bone at the site of the fusion may provide even greater 
insight as to the significance and potential of Runx2-overexpressing stromal cells as a 









Collectively, these in vitro and in vivo studies have provided a thorough 
characterization regimen to observe the in vitro and in vivo performance of Runx2-
expressing marrow-derived stromal cells and evaluated their potential as a candidate cell 
source for bone tissue engineering applications.  Furthermore, these analyses provided a 
novel combination of tissue and genetic engineering techniques toward the development 
of a Runx2-modified stromal cell/polymeric scaffold composite tissue-engineered bone 
graft substitutes.  There are several key areas to address in order to further develop this 
technology and these integrated approaches toward the development of mature, 
biologically active tissue-engineered substitutes. 
Based on recent evidence suggesting that constitutive Runx2 expression may 
actually sustain the differentiated osteoblast phenotype phenotype (Prince et al., 2001), 
the long term expression duration provided by retroviral systems may be invaluable.  
However, perhaps the greatest barrier to clinical acceptance of this genetic and tissue 
engineering strategy is directly associated with the risks of gene therapy techniques, 
especially retroviral gene delivery.  Although insertional mutagenesis is in principle a 
rare occurrence, inappropriate integration near a proto-oncogene can activate it or 
integration within a tumor suppressor gene can inactivate it.  Short term objectives of this 
work should likely be the completion of in vitro tumorogenicity assays, such as growth 
on agarose, in order to determine how many if any tumorogenic cells result from this 
retroviral transduction system.  The insertion pattern of a number of retroposons indicate 
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that these elements are capable of inserting with a high degree of sequence specificity.  
Long term implications for the gene therapy field and specifically this work might be to 
identify more advanced retroviral delivery vehicles which have the capacity to 
preferentially target a safe/dead zones in DNA to even further reduce the risks associated 
with conventional retroviral mediated gene delivery. 
Retroviral gene therapy is only effective in transducing dividing cells, which in 
principle is acceptable for ex vivo genetic modification of stromal cells.  However, 
transduction efficiency and yield of Runx2-expressing cells may be enhanced by the 
implementation of alternative viral transduction techniques which may offer greater 
flexibility in target cell identity or stage of mitotic progression, including adeno-
associated viruses, lentiviruses, or even adeno-retroviral chimeras (Zheng et al., 2000).  
Additional areas for improvement include the optimization of transduction efficiency in 
bone marrow stromal cells.  For this particular retroviral packing system, i.e. the ΦNX 
amphotropic producer line, our results consistently demonstrate transduction efficiencies 
in the range of 50% for rat bone marrow stromal cells.  While our results in 
demonstrating the effectiveness of Runx2 overexpression in stromal cells are promising 
even at this level of transduction efficiency, enhancing the transduction efficiency or 
even the purity of the Runx2-expressing cell population through selection methods may 
potentiate the osteoblastic phenotypic enhancement capacity of this strategy.  This is 
especially true when examining the transition from a rodent model to the human stromal 
cells, as the mitogenic properties may vary significantly between species, donor age, etc.  
Increasing transduction efficiency is the most desirable and perhaps the most practical 
solution to addressing this issue.  Cell sorting/selection techniques while effective in 
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concept and function are both time consuming and technically demanding.  Furthermore, 
the resulting challenges introduced into cellular system make this a less than optimal 
solution.  Any selection process which reduces the number of viable cells for inclusion in 
cell-intensive therapeutic applications such as large tissue-engineered bone grafts 
logistically complicates cell expansion protocols necessary to obtain significant cell 
numbers.  Additionally, the removal of Runx2-negative stromal cells from the population 
could potentially negatively impact the resulting differentiation capacity of the 
transduced cell population if requisite support cells are inadvertently removed during the 
selection process.  As suggested by our data examining the Runx2-responsiveness of 
subcultured stromal cells, a subpopulation of stromal cells remained capable of in vitro 
nodule formation beyond 15 population doublings, suggesting that dramatic cellular 
expansion and retention of Runx2-responsiveness to generate significant quantities of 
cells for tissue-engineered strategies is quite feasible.  However, it has been shown that 
extensive in vitro subculture reduces the transducibility of human stromal cells (Bulabois 
et al., 1998).  This observation further underscores the need to optimize transduction 
efficiency so that the maximum number of potentially Runx2-responsive target cells 
receive the target gene and are thereby induced toward a more pronounced state of 
osteoblastic differentiation. 
A related concern is the longevity and temporal optimization of exogenous Runx2 
gene expression.  The requisite expression duration of exogenous Runx2 necessary to 
maximize the effect of the transgene in vitro but more specifically in vivo has yet to be 
determined.  Studies have indicated that retroviral promoter silencing/inactivation does 
occur in stromal cells following extended in vivo implantation (Allay et al., 1997).  
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Further transduction optimization studies would then ideally incorporate long term in 
vivo implantations to observe the efficacy and longevity of the transduced cells and 
transgene expression.  Based on the results of long term in vivo studies, further attention 
could be given to the examination of alternative promoters, including other viral 
promoters, tissue-specific promoters, or even inducible systems which would allow for 
enhanced regulatory of Runx2 transgene expression.   As reported by several researchers, 
Runx2 mRNA transcripts have been detected at nearly constant levels throughout the 
maturation of osteoblasts, in fully mature osteoblasts, and even in nonosseous cells 
(Prince et al., 2001; Xiao et al., 2001; Shui et al., 2003).  The posttranscriptional activity  
leading to increased Runx2 protein expression observed in these studies has yet to be 
completely elucidated, but Xiao et al. demonstrate an ablation of an immature splice 
variant Runx2 transcript and concomitant appearance of the fully mature Runx2 mRNA 
in C2C12 cells following BMP-2 treatment (Xiao et al., 2001).  These results indicate the 
existence of biological cues and pathways to facilitate Runx2 protein expression and 
activity independent of Runx2 mRNA transcript levels.  As these pathways are 
determined and the physiologic roadmap of Runx2 expression and activity become 
evident and more accurately understood, the incorporation of alternative signals or 
additional inductive mechanisms to facilitate Runx2 activity could be incorporated into 
this tissue engineering strategy. 
 From a clinical and biotechnological perspective, the development of a tissue-
engineered mineralized bone repair template requires the generation of abundant 
quantities of biologically-equivalent matrix ideally possessing the osteogenic, 
osteoconductive, osteoinductive, and osteointegrative capacity of autologous bone grafts.  
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The studies detailed in the current research form the foundation of a combinatorial 
genetic and tissue engineering strategy, which may provide a conceivable approach to the 
creation of a mineralized bone repair template.   Specifically, target cells are genetically 
modified to overexpress an osteoblast-specific transcriptional activator which facilitates 
their osteoblastic differentiation toward the production of a more robust mineralized 
matrix ex vivo.  However, when examining the end result of marrow-derived stromal cells 
overexpressing Runx2, a product development engineer may not necessarily be 
concerned with the precise mechanism by which this process occurred, i.e. (i) Runx2 
overexpression forces a greater number of stem cells/osteoprogenitors toward 
osteoblastic differentiation and the concomitant production of tightly regulated quantities 
of bone-like matrix, (ii) forced Runx2 expression enhances the total average mineralized 
matrix producing capacity at the level of individual stem/osteoprogenitor cells, or (iii) a 
combination of these two equally plausible and perhaps equally desirable mechanisms.  
To this point, the effect of Runx2 overexpression on osteoblastic gene expression and 
matrix mineralization of stromal cells in both monolayer culture and on 3-D scaffolds has 
been accessed through quantitative analyses examining the bulk response of a population 
of Runx2-transduced cells, i.e. quantitative PCR, micro-computed tomography, and 
histology.  As a result, a clear determination of frequency versus total average osteogenic 
capacity per unit cell has not been determined.  Although cell selection protocols and/or 
limited dilution studies are tedious and time consuming, it would be of significant 
biological importance to more completely understand the mechanisms by which this 
genetic engineering technique is functioning in order to so markedly up-regulate the 
osteoblastic differentiation of target stromal cells.   
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The transition away from poorly interconnected scaffolds with exceedingly small 
pores, such as PLGA, to a more macroporous architecture like that of PCL was expected 
to facilitate a more pronounced and homogenous differentiation of scaffold-seeded cells.  
It was anticipated that the open architecture of the scaffold would more readily facilitate 
nutrient transport, waste removal, and soluble growth factor delivery to enhance 
differentiation and mineralization by cells throughout all of the interstitial regions of the 
construct.  Micro-CT and histological analyses indicated, however, that mineralization 
persisted at the periphery, and negligible mineralization occurred in the central pore 
regions, even in the presence of viable cells as indicated by cell viability assays.  To 
address this issue and establish a more homogeneously mature construct would be the 
implementation of a dynamic culture system to enhance in vitro culture parameters of 
Runx2-modified cell-seeded constructs.  A perfusion flow system would likely enhance 
scaffold colonization and matrix synthesis throughout all regions of the scaffold by 
reducing the mass transfer limitations associated with conventional static culture.   
Based on the outcomes of the present work, the flexibility and robust nature of 
this genetic engineering strategy to overexpress an osteoblast-specific transcription factor 
should be implemented in more stringent, higher order animal models and even 
preliminary in vitro analyses of Runx2-tranduced human bone marrow stromal cells or 
cells of non-osteogenic origin to examine the Runx2-responsiveness of a variety of target 
tissues, primarily those mesenchymal in origin.  The identification of factors such as 
dexamethasone which potentiate the effects of Runx2 in stromal cell cultures and even 
seemingly cooperatively enhance its activity suggests in principle that primary cells of 
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non-osteogenic origin may be capable of forming a bioactive mineralized matrix similar 
to that deposited by bone marrow stromal cells or other osteoblastic cells. 
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APPENDIX A 
CLONING OF THE RUNX2 RETROVIRAL EXPRESSION VECTOR 
The Runx2 sequence was acquired from the pCMV-Osf2 (Runx2) plasmid, a 
generous gift of Dr. Gerard Karsenty of the Baylor College of Medicine.  The focus of 
this phase of the project was to isolate the Runx2 sequence from the pCMV-Runx2 
plasmid and insert into the pTJ66 retroviral plasmid backbone.  Initial efforts focused on 
the restriction endonuclease digestion of the pCMV-Runx2 plasmid using enzymes 
located at the 5’ and 3’ ends of the sequence.  The Runx2 sequence was inserted into the 
pCMV5 backbone using the EcoRI/XbaI cloning site.  The presence of an internal EcoRI 
site within the Runx2 required a sequential enzymatic digestion of the plasmid, and 
ultimately, these efforts proved inefficient.  As a result, polymerase chain reaction (PCR) 
techniques were utilized.  Initially, the pCMV-Runx2 plasmid was sequenced in order to 
design the most efficient primers for amplification of the sequence.  The primers used in 
the sequencing of the pCMV-Runx2 plasmid were optimally designed using Primer 
Premier, a nucleotide analysis software package.  The primers were designed to be 
approximately 400 base pairs apart in order to ensure sufficient overlap during 
sequencing.  The 1791 base Runx2 sequence (Accession Number: AF010284) described 
by Karsenty et al. was used in the design of the following primers. 
  
 Primer Name Primer Sequence 
1 mRunx2-334.R 5'- GGC TCA CGT CGC TCA TCT TGC 
2 mRunx2-209.F 5'- CGT CAA ACA GCC TCT TCA GCG 
3 mRunx2-624.F 5'- CAA GAC CCT GCC CGT GGC 
4 mRunx2-1021.F 5'- CCA CGG CCC TCC CTG AAC 
5 mRunx2-1412.F 5'- CCA CCT TTA CCT ACA CCC CGC 
  Note: R=reverse, F=forward 
  
 Primers two through five provided sequences corresponding precisely to those 
reported through base 1791 by Ducy et al. in AF010284.  Primer one, mRunx2-334.R, 
was designed to provide the sequence at the 5’ end from base 334 backward as well as 
the sequence of the plasmid backbone directly proceeding the Runx2 gene.  The sequence 
was identical to AF010284 from base 334 to 81, however, at that point, the sequence 
diverged.  As a result of this sequence divergence, the ATG start codon present at base 
205 (corresponding to the methionine at amino acid position 69 of AF010284) was used 
in the pCMV-Runx2 plasmid rather than the ATG at base 1.  This in addition to literature 
further suggests the amino terminus (amino acids 1-68) are not necessary for a functional 
protein.   
 
Note:  Close observation of the Runx2 sequence indicates that elimination of the first 80 
bases of the sequence results in the presence of an ATG start codon (base 90) which 
would code for a protein that is out of frame; however, a TAA stop codon (base 141) 
which is in frame with this start codon ensures that the Runx2 protein is translated from 
the ATG start codon at base 205. 
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 Now that the pCMV-Runx2 sequence including additional bases on the 5’ and 3’ 
ends had been determined, primers were designed using Primer Premier in order to 
amplify the sequence by high fidelity polymerase chain reaction (PCR).  The optimized 
primers selected are indicated in the following table.    
 
 Primer Name Primer Sequence 
1 pCMV-Runx2-197.F 5'- CGA GGG CGT TTA AAT GGT TAA 
2 pCMV-Runx2-1928.R 5'- GCC ATG GTT GAC GAA TTT CAA 
 
The pCMV-Runx2-197.F primer included bases 81-97 of the Ducy sequence and four 
additional nucleotides upstream of that sequence.  The pCMV-Runx2-1928.R included 
bases 1788-1791 of the Ducy sequence and seventeen nucleotides downstream of the 
Runx2 sequence.  As a result of the high GC content in the region from base 300 to 500, 
the Advantage® -GC 2 PCR system marketed by Clontech Laboratories, Inc.  The 
Advantage-GC 2 enzyme mix contains AdvanTaq™ DNA polymerase as the primary 
polymerase in addition to a minor amount of proofreading polymerase and the TaqStart™ 
antibody to the provide the automatic hot start.  Additionally, the system utilizes an 
optimized buffer containing DMSO and GC-Melt that has been shown to improve the 
amplification of GC-rich sequences [Advantage® -GC 2 PCR User Manual 02/99, p. 3].  
The following table indicates the composition of the reaction mixture as well as the run 
conditions for the thirty-five cycle PCR reaction. 
 
Reagent Volume per Reaction 
(µl) 
5X GC-2 PCR Buffer (17.5 mM Mg2+) 10.0 
10 mM dNTP Mix (50 X dNTP Mix) 1.0 
100 µM Primer pCMV-Runx2-197.F 5' 0.5 
100 µM Primer pCMV-Runx2-1928.R 3' 0.5 
50X Advantage-GC 2 Polymerase Mix 1.0 
10X GC Melt (5.0 M) 5.0 
ddH2O 31.0 
pCMV-Runx2 plasmid DNA (0.250 µg/µl) 1.0 
Total 50.0 
  
Event Temperature (°C) Time (min) 
Initial Activation 94 3.0 
Cycle Temperature 1 94 0.5 
Cycle Temperature 2 55 0.5 
Cycle Temperature 3 68 3.0 
Final Extension 68 3.0 
 
 A small aliquot of the PCR product was ran on an agarose gel in order to 
determine purity and relative effectiveness of the PCR reaction, which resulted in a single 
band present at approximately 1700 base pairs (actual product 1731 base pairs).  The 
PCR product was then purified using a Qiagen QIAquick PCR Purification Kit.  The 
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QIAquick system utilizes special buffers which are optimized for efficient recovery of 
DNA and removal of contaminants using spin-column technology with selective binding 
properties of a uniquely-designed silica-gel membrane [QIAquick Spin Handbook 07/97, 
p.11]. The PCR product was eluted from the column in 50 µl of 10 mM Tris·Cl, pH 8.5. 
 Isolation of the Runx2 sequence from the pCMV-Runx2 plasmid allowed for 
cloning of this sequence into a retroviral expression vector.  This pTJ66 vector utilizes a 
retroviral long terminal repeat promoter to express a single, bicistronic mRNA that can 
produce a therapeutic protein through cap-dependent translation and a zeocin resistance-
eGFP fusion protein by translation from an internal ribosomal entry site (IRES).  The 
fusion protein can be used as a selection marker or a monitor of retroviral production and 
infection efficiency.  The plasmid backbone additionally expresses Ampicillin resistance 
for selection of positively transformed bacteria during culture.  The development of the 
pTJ66 vector is explained in more detail by Abbott and Murphy in a future publication, 
NFATc1 expression augments cyclosporin-sensitive interleukin-6 gene expression in 
vascular smooth muscle cells.  The therapeutic gene, Runx2 was cloned into the SfiI 
universal cloning site present in the backbone of the pTJ66 vector, an SfiI site exists at 
base 1639 and base 1661. 
 The first step of the cloning process was to blunt end the purified Runx2 PCR 
product using the Klenow enzyme.  The Klenow enzyme (New England Biolabs) 
functions to fill in 5’ overhangs while chewing back 3’ overhangs, which are 
characteristic of PCR.  The enzyme was used at a concentration of 1 U/µg DNA, and the 
following table indicates the other components of the reaction.          
      
Reagent Volume per Reaction (µl) 
Runx2 fragment (0.26 µg/µl) 36.0 
2 mM dNTPs 2.0 
10X EcoPoI Buffer 5.0 




 The reaction mixture was incubated at room temperature for fifteen minutes, and 
the enzyme was heat inactivated by incubating at 65°C for twenty minutes.  The Klenow 
product was then purified using a Qiagen QIAquick PCR Purification Kit, and the PCR 
product was eluted from the column in 50 µl of 10 mM Tris·Cl, pH 8.5. 
 In order to enhance the ligation of the Runx2 fragment into the pTJ66 vector, the 
blunt-ended Runx2 fragment was kinased, which resulted in the transfer of the γ-
phosphate of ATP to the 5’ hydroxyl terminus of the DNA.  The reaction composition is 
detailed below: 
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Reagent Volume per Reaction 
(µl) 
Blunt-ended Runx2 fragment 50.0 
10 mM ATP 10.0 
5X Kinase Buffer (Forward Reaction) 20.0 




The reaction mixture was incubated at 37°C for thirty minutes, and the enzyme 
was heat inactivated by incubating at 75°C for fifteen minutes.  The Kinased product was 
then purified using a Qiagen QIAquick PCR Purification Kit, and the PCR product was 
eluted from the column in 50 µl of 10 mM Tris·Cl, pH 8.5. 
In order to clone the Runx2 sequence into the SfiI site of the pTJ66 vector SfiI 
adapters were ligated to the kinased Runx2 fragment.  The SfiI adapters were made from 
the two oligos having the following sequence:  ACE 258 -> 3’-GATCCGGA and ACE 
259-> 5’-CTAGGCCTACA, which when kinased together result in an ACA 3’ overhang.  
The reagents necessary to make a 30 µM stock of SfiI adapters are detailed in the 
following table. 
   
Reagent Volume per Reaction (µl) 
ACE258 (9-30-99) 111 µM stock 27.0 
ACE259 (9-30-99) 104 µM stock 28.8 
5X Kinase Buffer (Forward Reaction) 20.0 
10 mM ATP 10.0 






The reaction mixture was incubated at 37°C for thirty minutes, and the enzyme 
was heat inactivated by incubating at 75°C for fifteen minutes.  The reaction was allowed 
to slow cool to room temperature, and the adapters were then ligated to the kinased, 
blunt-ended Runx2 fragment in the following reaction. 
 
Reagent Volume per Reaction (µl) 
Kinased, blunt-ended Runx2 fragment 20.0 
30 µM SfiI Adapters 20.0 
10X T4 Ligase Buffer 5.0 
10 mM ATP 2.0 





The reaction mixture was incubated overnight at 16°C.  This reaction results in 
the addition of approximately a 100 molar excess of adapters, which if left in the reaction 
mixture would significantly impede the ligation of the Runx2 fragment into the pTJ66 
vector.  As a result, the excess adapters were removed from the solution using a Biospin 
P30 Column (Bio-Rad).  The top and bottom of the column were removed and allowed to 
empty by gravity flow.  The column was then centrifuged at approximately 200 g for 1.5 
minutes.  The reaction mixture was then added to the column which was centrifuged at 
200 g for 5 minutes.  The small oligonucleotide adapters are adsorbed by the column 
while the larger Runx2 fragment containing SfiI adapters is eluted from it.  6X loading 
buffer was then added to the eluent and it was loaded into multiple lanes of 1% agarose 
gel in order to further purify the Runx2 fragment and ensure that all of the excess 
adapters were removed. SfiI digested pTJ66 vector was loaded onto another gel.  The 
presence of two SfiI sites on the pTJ66 backbone separated by only 22 bases complicates 
the digestion process, so in order to ensure that the pTJ66 vector was completely 
digested, a series of two separate digestions using the SfiIase were conducted.  Initially, 
the 6817 base pair pTJ66 vector was purified from bacterial culture using a Qiagen 
Plasmid Purification Maxi Kit and resuspended in ddH2O.  The resulting linearized DNA 
would consist of 6795 bases, as the 22 bases between the two SfiI sites would be 
removed.          
  
Reagent Volume per Reaction (µl) 
Uncut pTJ66 (0.75 µg/µl) 6.7 
10X BSA (1.0 µg/µl) 2.0 
10X Buffer 2 2.0 




 The reaction mixture was overlayed with 30 µl of mineral oil and incubated at 
50°C for one hour.  After one hour, additional SfiIase was added (1.0 µl), and the 
reaction was allowed to proceed overnight at 50°C.  Following gel purification to remove 
uncut plasmid and the 22 base fragment resulting from the digestion using a Qiagen 
QIAquick Gel Extraction Kit, a second digestion was conducted.  The second digestion 
occurred after some time had passed and all of the initial SfiIase from NEB had been 
used, so new enzyme from Life Technologies was used in the second digestion.   
 
Reagent Volume per Reaction (µl) 
pTJ66 cut 1 time with SfiIase (0.1 µg/µl) 17.0 
10X Buffer 2 2.0 
SfiIase (Life Technologies) 1.0 
Total 20.0 
 
The reaction mixture was overlayed with 30 µl of mineral oil and incubated 
overnight at 50°C. Additional SfiIase was added (1.0 µl) the next day, and the reaction 
was allowed to proceed for an additional hour at 50°C.  This SfiI digested pTJ66 vector 
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was loaded onto a second gel as previously mentioned and both it and the Runx2 
fragment containing SfiI adapters were purified using a Qiagen QIAquick Gel Extraction 
Kit.  Each DNA fragment was eluted from the QIAquick spin column with 50 µl of 10 
mM Tris·Cl, pH 8.5. 
 The two key reagents, Runx2 with SfiI adapters and SfiI digested pTJ66, were 
then available for ligation.  Following previous experimental results by others, the Runx2 
insert was added to the reaction mixture in approximately 3M excess to the cut pTJ66 
vector.  This ensured that the Runx2 fragment was not the limiting reagent in the reaction 
mixture.  As previously mentioned, the complete digestion of pTJ66 with SfiIase results 
in a 6795 base fragment.  The addition of the SfiI adapters (8 bases on the 5’ end and 11 
bases on 3’ end) to the Runx2 fragment results in a combined insert approximately 1750 
bases in length.  Assuming equivalent distributions of nucleotides, the molecular weight 
of the insert is approximately one-fourth that of the pTJ66 backbone.  As a result, it was 
determined to add equal masses of the two reagents to the ligation reaction, which would 
provide slightly greater than a 3M excess of the insert.   
In addition to the primary ligation reaction necessary to complete the pTJ66-
Runx2 vector, a negative and a positive control reaction were conducted.  The negative 
control reaction was conducted in the presence of cut pTJ66 vector with no ligase or 
insert in the reaction mixture.  This would provide insight as to the completeness of the 
digestion process.  If many colonies were present on a plate streaked with bacteria that 
had been transformed with DNA from this reaction, it would therefore be likely that 
neither of the SfiI sites had been digested on a large fraction of the pTJ66 vector used in 
the reaction.  Although this was highly unlikely, as the cut plasmid was purified using 
agarose gel electrophoresis, and supercoiled plasmid DNA will migrate faster in the gel 
than linearized DNA of the same molecular weight.  As a control to monitor this 
progression, uncut pTJ66 was loaded into the same gels as the digested samples, and in 
the cases investigated, no uncut pTJ66 remained in the reaction mixture.  The positive 
control reaction was conducted in the presence of ligase and cut pTJ66 vector with no 
insert in the reaction mixture.  This would also provide insight as to the completeness of 
the digestion process.  If many colonies were present on a plate streaked with bacteria 
that had been transformed with DNA from this reaction, it would therefore be likely that 
only one of the two SfiI sites had been digested on a large fraction of the pTJ66 vector 
used in the reaction and it was therefore capable of ligating back together.  It should be 
noted that pTJ66 completely digested with SfiIase is incapable of ligating back onto 
itself, as this digestion results in the creation of 5’-TGT overhangs at both digestion sites.  
The following tables indicate the reagents used in the three reactions. 
 
Primary Reaction 
Reagent Volume per Reaction (µl) 
Runx2 with SfiI adapters (0.024 µg/µl) 20.0 
pTJ66 digested two times with SfiIase (0.030 µg/µl) 16.0 
10X T4 Ligase Buffer 5.0 
10 mM ATP 2.0 




Negative Control Reaction 
Reagent Volume per Reaction (µl) 
Runx2 with SfiI adapters (0.024 µg/µl) 0.0 
pTJ66 digested two times with SfiIase (0.030 µg/µl) 16.0 
10X T4 Ligase Buffer 5.0 
10 mM ATP 2.0 




Positive Control Reaction 
Reagent Volume per Reaction (µl) 
Runx2 with SfiI adapters (0.024 µg/µl) 0.0 
pTJ66 digested two times with SfiIase (0.030 µg/µl) 16.0 
10X T4 Ligase Buffer 5.0 
10 mM ATP 2.0 




All three reactions were incubated overnight at 16°C. 
 
The ligation products were then used to transform Top 10 F’ bacteria using the 
following protocol. Bacterial cells were thawed on ice until liquid, and an appropriate 
number of 14 ml culture tubes were simultaneously chilled.  200 µl of bacterial cells and 
50 µl of each respective ligation reaction were added to the chilled tubes.  The tubes were 
then incubated on ice for 30 minutes.  They tubes were then transferred to a 37°C water 
bath for 2 minutes and replaced back on ice for 2 minutes.  800 µl of LB was then added 
to the cell/DNA mixture and the tubes were incubated in a 37°C bacterial incubator for 1 
hour.  While the bacteria were incubating, LB agar plates containing the appropriate 
antibiotics were prepared.  In addition to the ampicillin resistance present for bacteria 
which have been successfully transformed with the pTJ66-Runx2 or a pTJ66 backbone 
plasmid, the Top 10 F’ bacteria are equipped with resistance to tetracycline.  As a result, 
the plates in this study contained both ampicillin (100 µg/ml) and tetracycline (10 µg/ml).  
After 1 hour, cells were added to the LB agar plates in a series of dilutions in order to 
simplify the isolation of one colony.  The following table details the dilutions prepared 
for each of the transformations. 
 
 1 2 3 
Bacterial Culture 200 20 5 
LB 0 180 195 
Total 200 200 200 
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Following addition of the cell solutions, the plates were streaked, and incubated 
overnight in a 37°C incubator.   
The next day, the plates were investigated and individual colonies were isolated in 
order to obtain one containing the pTJ66-Runx2 plasmid.  Both dilution 1 and 2 from the 
table above were nearly confluent with colonies, while dilution 3 provided distinct 
colonies which could be easily selected.  The negative and positive control samples 
yielded very little background, indicating that the cloning had likely yielded the 
appropriate vector.  Ten colonies were selected from dilution 3 of the pTJ66-Runx2 plate, 
and one colony was selected from the dilution 1 plates of both the negative and positive 
controls.  The selected colonies were used to innoculate cultures consisting of 3 ml of LB 
medium, 3 µl ampicillin (100 µg/µl stock -> 100 µg/ml working), and 12.5 µl 
tetracycline (5 µg/µl stock -> 20.83 µg/ml working), and the cultures were incubated 
overnight at 37°C.  The following day, the plasmid DNA from each of the colonies was 
purified using a QIAprep Miniprep Kit.  The plasmid DNA was eluted from the column 
with 50 µl of 10 mM Tris·Cl, pH 8.5.   
In order to determine if a pTJ66-Runx2 had been successfully isolated, a 
diagnostic restriction enzyme digestion was performed on each of the purified samples.  
As was previously explained, the SfiI digested pTJ66 contains 5’-TGT overhangs, while 
the Runx2 fragment with ligated SfiI adapters contains 3’-ACA overhangs.  This 
introduces the possibility of the insert being ligated into the pTJ66 cloning in the reverse 
orientation.  The appropriate diagnostic will, therefore, identify whether the insert was 
ligated into the cloning site and if so was it ligated in the correct orientation.  The enzyme 
selected for the diagnostic was BamHI.  A restriction site exists within the Runx2 insert 
at base 193 and within the pTJ66 backbone at base 3057.  As a result, if the insert is 
ligated in the correct orientation, complete digestion with BamHI would result in two 
bands, one 5592 bases and the other 2954 bases in length.  If the insert was ligated in the 
reverse direction, one of the bands would be 6957 bases and the other 1589 bases.   These 
two possibilities could be easily distinguished using agarose gel electrophoresis.  The 
following table indicates the reaction components of the diagnostic digestion. 
 
      
Reagent Volume per Reaction (µl) 
10X BamHI NEB Buffer 2.0 
10X BSA (1.0 µg/µl) 2.0 
Miniprep purified plasmid DNA 5.0 




The reaction mixture was incubated at 37°C for 2 hours, loaded with 6X loading 
buffer, and ran on a 1% agarose gel.  As expected from the previous description, 50% of 
the colonies provided plasmid in which the Runx2 insert had been correctly ligated, while 
the other 50% were in the reverse orientation.  The colonies isolated from the negative 
and positive control plates were run in conjunction with a positive control BamHI 
digestion of uncut pTJ66.  The results indicated that both colonies provided bands on the 
gel that corresponded to linear pTJ66 (6817 bases).   
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Glycerol stocks (50%) were prepared for the five colonies which appeared to be 
pTJ66-Runx2, and one was selected to be grown up and harvested for sequencing and 
any other further diagnostic work.  In this innoculation, 0.5 ml of the colony was added to 
500 ml of LB containing 500 µl ampicillin (100 µg/µl stock -> 100 µg/ml working), and 
1250 µl tetracycline (5 µg/µl stock -> 12.5 µg/ml working), which was cultured overnight 
at 37°C. 
The plasmid DNA was then harvested using the Very Low Copy Protocol 
contained in the Qiagen Plasmid Maxi Kit.  The purified plasmid was verified for 
correctness and purity by conducting a BamHI diagnostic digest and running the uncut 
stock and digest samples on a 1% agarose gel.   
A portion of the stock plasmid was diluted to a working concentration of 0.2 
µg/µl for sequencing, and the same sequencing primers introduced previously were used 
to determine the sequence of the insert and the regions immediately preceding and 
following the insert.  Following analysis of the sequence chromatograms, it was 
determined that all of the functional areas of the Runx2 sequence had been correctly 
polymerized and the sequence appeared to be correct.  Two minor variations from the 
predicted sequence did exist, however.  One base on each end of the Runx2 sequence just 
inside the SfiI adapters was not present, likely indicating they were cleaved during the 
Klenow blunt-end step of the cloning protocol.  The resulting pTJ66-Runx2 plasmid is 
8544 bases, consisting of 1587 functional bases (1775-3361 in pTJ66-Runx2) of the 
Runx2 sequence (205-1791 in AF010284), 127 nonfunctional bases on the 5’ end of the 
Runx2 sequence and 16 nonfunctional bases on the 3’ end of the Runx2 sequence, 8 
bases on the 5’ end and 11 bases on the 3’ end of the Runx2 sequence (functional and 
nonfunctional) resulting from the SfiI adapters, and 6795 bases of the pTJ66 backbone 
(22 bases were removed by the digestion with SfiIase).   
 After successfully cloning the pTJ66-Runx2 expression vector, the focus shifted 
to the packaging of functional retrovirus.  A second generation packaging cell line known 
as the φNX helper-free producer line, which function to produce the gag-pol and 
envelope proteins necessary for encapsulation of the retroviral plasmid, has been 
developed for the production of retroviruses.  The cell line is based on the human 
embryonic kidney 293T cell line.  As is desirable for transient transfection, this cell line 
is highly transfectable, up to 50% using calcium-based or liposome-mediated transfection 
protocols.  Improvements introduced by this cell line in comparison to previous 
packaging lines include the ability to monitor gag-pol production through the 
incorporation of an IRES-CD8 surface marker downstream of the reading frame of the 
gag-pol construct and the minimization of recombination potential through the use of 
unique, non-moloney promoters for the gag-pol and envelope constructs.  The gag-pol 
construct was introduced into the cell line with hygromycin as the co-selectable marker 
while the envelope proteins were introduced with diptheria as the co-selectable marker.  
The specific φNX cell line used in this research is one capable of producing amphotropic 
retrovirus, and the protocol previously described by Pear et al. for production of 
amphotropic retrovirus will now be introduced. 
φNX-ampho cells were plated in 150 mm plates the day prior to transfection at a 
density of approximately 9.0 x 104 cells/cm2 and incubated for about 24 hours at 37°C in 
order to establish approximately 80% confluence immediately prior to transfection (2.5 x 
106 cells per 60 mm plate, 7.0 x 106 cells per 100 mm plate, 1.6 x 107 cells per 150 mm 
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plate etc.).  The growth media for the φNX cells consists of high glucose DMEM 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin.  After 24 
hours, the cells were refed with 18 ml of growth media + 1/1000 chloroquine (22.5 µl of 
25 mM chloroquine stock solution in PBS) and returned to 37°C.  The plasmid DNA 
solution was then prepared.  For each plate infected, 90 µg of plasmid DNA (from pTJ66-
Runx2 stock solution) was added to sterile ddH2O to reach a final working volume of 
1969 µl.  Next, 281 µl of 2 M CaCl2 was added to the DNA solution.  Finally, 2.25 ml of 
37°C 2X BES solution (50 mM BES, 280 mM NaCl, 1.5 mM Na2HPO4) was added to the 
DNA while vortexing in order to minimize salt precipitation.  This transfection solution 
was then added to the φNX cell plates and gently mixed.  The plates were incubated at 
37°C for 6 hours, the transfection medium was removed, and the cells were refed with 40 
ml of fresh growth media and returned to 37°C overnight.  The following day, 24 hours 
after the start of the transfection, the plates were refed with 20 ml of fresh growth media 
and placed at 32°C.  (Note: Kotani et. al. conducted studies using 22 different retroviral 
vector packaging cell lines in which they discovered a 5- to 15-fold increase in functional 
vector production at 32°C rather than at 37°C).  The media was then collected after 24 
hours (48 hours after the start of the transfection), filtered using a 0.45 µm cellulose 
acetate membrane bottle filter, aliquoted at 6.5 ml per 14 ml Falcon polypropylene test 
tubes, snap frozen in liquid N2, and placed in a       -80°C freezer for long term storage.  
Following refeeding with growth media, the plates were replaced at 32°C and two 
additional harvests occurred in twelve hour increments (60 and 72 hours after the start of 
the transfection, respectively). 
Acquisition of pTJ66-Runx2 retrovirus allowed for the infection of mammalian 
cells for verification of functionality, while the native pTJ66 retrovirus was used as a 
negative control.  Cell lines investigated include NIH3T3 murine fibroblasts, MC3T3-E1 
murine calvarial cells, and primary rat bone marrow stromal cells.  On the afternoon prior 
to the infection, cells were plated in a 6 well plate at a density of approximately 1 x 104 
cells/cm2 (1 x 105 cells per well) and incubated overnight at 37°C.  (Note: any size plate 
can be used depending upon the application).  It should be noted that in order for 
retroviral infection to be successful, the cells being infected must be replicating, and, as a 
result, seeding density for infection is cell-specific, i.e. large cells or cells displaying a 
larger surface area resulting from greater spreading should be seeded at lower densities.  
For the infection the following day, the growth media was aspirated and 2 ml of retroviral 
media which had just been thawed from storage in a -80°C freezer was added.  Note: do 
not warm the retroviral media to 37°C, leave it the bath only until it melts.  The infection 
cocktail was completed by adding 20 µl of 100X polybrene (0.8 mg/ml hexadimethrine 
bromide) directly to the cells, which was followed by incubation at 32 °C for 15 minutes 
in order to stabilize the pH of the infection medium.  (Note:  it may be necessary to 
supplement the infection cocktail with serum or other growth factors depending upon the 
growth medium required by the cells being infected, as the retroviral infection media is 
high glucose DMEM supplemented with 10% fetal bovine serum and 1% penicillin-
streptomycin.)  After 15 minutes, the plates were wrapped with parafilm and centrifuged 
in a swinging-bucket rotor at approximately 1200 g for 30 minutes at 32 °C.  After 
centrifuging, the retroviral media was aspirated, the appropriate growth media was 
reapplied, and the cells were returned to incubation at 37 °C.  An additional infection was 
completed 6-12 hours later in order to increase infection efficiency. 
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